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1. Glossary 
5-FU 5-Fluorouracil 
APC Activated Protein C 
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2. Abstract 
This thesis focuses on a nurse-led trial assessing the thromboprophylactic utility of 
warfarin in cancer patients (n=1590) with central venous catheters and designed 
following a UK survey of practice.    
 
Clinicians who were „uncertain‟ of the benefits of warfarin, randomised patients to no 
warfarin vs fixed dose warfarin of 1mg (FDW) vs dose adjusted warfarin (DAW) to 
maintain the international normalised ratio (INR) between 1.5 and 2.0.   Clinicians, 
who were „certain‟, randomised patients between FDW and DAW.  The primary 
endpoint was the number of symptomatic catheter-related thrombotic events (CRT). 
 
Compared to no warfarin, warfarin (79% FDW; 21% DAW) did not reduce CRT [5.9% 
vs 5.9%; relative risk (RR) 0.99, (95% Confidence Interval (CI) 0.57-1.72), p=0.98]. 
However, compared to FDW, DAW was superior in preventing CRT [2.8% vs 7.2%; 
RR 0.38, (95%CI 0.20-0.71), p=0.002].  Major bleeding events were rare; an excess 
was observed with warfarin compared to no warfarin (7 vs 1, p=0.07) and with DAW 
compared to FDW (16 vs 7, p=0.09).  
 
There is no benefit in using low dose warfarin in CRT prophylaxis. DAW shows 
benefit over FDW but at a cost of major bleeding events.  Subsequent meta-analysis 
confirmed the primary finding.  This research has changed clinical practice 
internationally. 
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3. Introduction and Background 
3.1 Introduction 
Venous thromboembolism (VTE) is well recognised as a complication of cancer.   In 
comparison with other patient groups, the cancer population is distinctive because the 
pathogenesis of cancer-related VTE differs, the frequency and risk of recurrent of 
VTE is increased and the clinical management of prophylaxis and treatment is more 
complex.  
 
There are three clinical goals for anticoagulation of cancer patients: primary 
prophylaxis, optimal management of VTE and to alter the natural history of the cancer 
by reducing the potential for metastasis, all of which pose difficult therapeutic 
challenges to the clinician.  This thesis focuses on the first objective: the prophylaxis 
of thrombosis with warfarin in cancer patients receiving chemotherapy via central 
venous catheters ( CVCs), in a clinical trial setting.  This nurse-led clinical trial, WARP 
(acronym for WARfarin Prophylaxis) stemmed from empirical observations recording 
the increased frequency of VTE and wide variation in thromboprophylactic measures 
whilst nursing patients receiving chemotherapy via CVCs.  A national pre-trial survey, 
based on this experience gathered in a single large cancer centre, was then 
undertaken to garner clinical views on thromboprophylaxis and whether a multicentre 
trial to address this problem was rational and timely. This resulted in WARP, a 
randomised, phase III trial assessing the utility of warfarin in this patient group.   The 
study design, based on the uncertainty principle, was structured to encompass 
contemporary clinical opinion.  Oncology nurses and physicians who were „uncertain‟ 
22 
of the benefits of warfarin in thromboprophylaxis, could randomise patients to control 
(no warfarin) vs fixed dose warfarin of 1mg (FDW) vs dose adjusted warfarin (DAW) 
to maintain the international normalised ratio (INR) between 1.5 and 2.0.   Clinicians, 
who were „certain‟ of the indication for warfarin, and who did not support the need for 
a control arm, randomised patients between FDW and DAW.   This pragmatic trial 
design united the entire clinical community and enabled two linked hypotheses to be 
tested: (i) whether warfarin (any dose) reduces catheter-related thrombosis (CRT) 
relative to no warfarin (warfarin evaluation) and (ii) whether DAW is superior to FDW 
(dose evaluation).  The primary endpoint of the trial was the number of catheter-
related thrombotic events with the secondary endpoints including the number of non-
catheter-related thrombotic events, duration of catheter patency, trial-related adverse 
events, trial-related costs and patient mortality. 
 
Although WARP was designed as the largest and therefore likely to be the most 
informative trial in the field, it was important to contextualise it relative to other trials 
evaluating the efficacy of pharmacologic thromboprophylaxis in patients with cancer; 
therefore meta-analyses of relevant trials were undertaken.    
 
 Increasingly, funding bodies are demanding that careful plans for dissemination of 
research findings are included with the primary trial proposal as part of a wider drive 
to accelerate conversion of research findings into practice. Following on from 
publication of this work, an invitation was received to contribute to the first UK 
thromboprophylaxis guidelines, „Reducing the risk of venous thromboembolism (deep 
vein thrombosis and pulmonary embolism) in patients admitted to hospital, thus 
23 
incorporating the results of this research into national guidelines and greatly 
increasing its visibility to frontline multidisciplinary teams. 
3.2 Aims and Objectives of Thesis 
There are three stepped aims of this thesis with linked objectives: 
Aim 1:  Conduct a national survey to identify: 
 current clinical practices for prophylaxis of thrombosis in patients with CVCs 
 ascertain if CRT was deemed an important clinical problem  
 establish the interest in participation in a 3-arm clinical trial of no warfarin vs 
1mg warfarin/day vs warfarin to maintain the INR between 1.5 and 2.0.  This 
range was taken from earlier trials in which it was found to be safe.  The initial 
trial design had been prepared in consultation with key opinion leaders in the 
field. 
Aim 2:  Design and deliver WARP, a pragmatic trial with the following objectives: 
 determine the utility of any warfarin in reducing CVC-related thrombosis rates in 
cancer patients 
 determine whether variable dose warfarin was superior to fixed dose warfarin in 
reducing CVC thrombosis rates 
 assess warfarin-related toxicity and monitor the trial-related adverse events 
 determine the effect of warfarin (fixed and variable dose) on overall thrombosis 
rates 
 compare survival of patients in the warfarin and no warfarin arms 
Aim 3:  Conduct meta-analyses of published studies in this field: 
 to provide a context for the results of WARP relative to other trials in the area 
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3.3 Background 
3.3.1 Venous Thromboembolism 
Venous thromboembolism (VTE) includes thrombosis of the deep veins (usually of 
the leg, thigh and pelvis), pulmonary embolus, thrombosis associated with central 
venous catheters (generally in the arm or veins draining the site of the catheter) and 
related sequelae of post-thrombotic syndrome and pulmonary hypertension.  VTE is a 
condition in which a thrombus (blood clot) forms in a vein through which blood flow 
may be limited by the thrombus, causing swelling and pain.  An embolism is created if 
all or part of the thrombus breaks off from the site of formation and travels through the 
venous system.  An embolus blocking the pulmonary arteries (pulmonary embolism 
[PE]), arising from a deep vein thrombosis (DVT), causes most deaths. Untreated PE 
has a mortality rate of around 30%; treated, this mortality reduces to 2% (Douketis et 
al, 2007). 
3.3.2 The Clotting Process 
3.3.2.1 Introduction 
The normal clotting process is discussed in detail as it is core to the understanding of 
the pathophysiology of catheter-related thrombosis (CRT) in cancer patients.   
A vein consists of three layers: tunica intima, the innermost and in direct contact with 
venous flow, formed of a single layer of endothelial cells (the endothelium) to provide 
a smooth surface that is normally non-thrombogenic; tunica media, composed of 
connective tissue with muscular and elastic fibres to allow changes in pressure and 
flow and the tunica adventitia, the outer layer, composed of longitudinal elastic fibres 
and loose connective tissue (Egan Sansivero, 1998).    Blood coagulation and 
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platelet-mediated primary haemostasis have evolved as important defence 
mechanisms against bleeding and are a dynamic, highly interwoven array of multiple 
processes (Furie and Furie, 2008). The coagulation system is usually triggered 
almost immediately in response to rupture of the endothelium, which allows exposure 
of blood to the extravascular tissue.  The responses of the coagulation system are 
coordinated and, for ease, are outlined in four phases:   
 Initiation and formation of the platelet plug (primary haemostasis) 
 Cascade response of the coagulation factors (secondary haemostasis) which 
occurs simultaneously  
 Termination by antithrombotic control mechanisms  
 Removal of the clot by fibrinolysis 
 
3.3.2.2 Primary Haemostasis 
Platelets are activated at the site of vascular injury to form a plug that provides the 
initial haemostatic response to stop bleeding.   
3.3.2.2.1 Platelet Activation 
The functional response of activated platelets involves four processes:  adhesion [the 
deposition of platelets on the subendothelial matrix]; aggregation [platelet-platelet 
cohesion]; secretion [the release of platelet granule proteins and procoagulant activity 
(the enhancement of thrombin generation] (Brass, 2003).  Collagen and thrombin are 
the most potent platelet activators.  The intact endothelium prevents adherence of 
platelets by the production of nitric oxide and prostacyclin.  Intimal injury impairs the 
flow of platelets and exposes subendothelial elements e.g. collagen, microfibrils and 
laminin which lead to platelet adherence, activation and secretion. The two most 
important platelet collagen receptors are Glycoprotein (GP)Ia/IIa and GPIV, playing 
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critical roles in platelet adhesion and activation respectively.  Platelet activation by 
thrombin (section 3.3.2.3.2) is mediated by a family of G-protein coupled protease-
activated receptors (PARs) using dual platelet receptors, PAR1 and PAR4 (Brass, 
2003) .  
3.3.2.2.1.1 Platelet Adhesion  
Following activation, platelets undergo significant shape changes, producing 
elongated pseudopods that make platelets extremely adhesive. Platelet adhesion is 
mediated by the large multimeric circulating protein von Willebrand factor (vWF) 
which forms links between the platelet GPIb,IX,V complex and collagen fibrils,  further 
strengthened by the binding of collagen–specific GPIa/IIa receptor to collagen fibrils 
(Sixma et al, 1997).   
3.3.2.2.1.2 Platelet Aggregation 
Platelet activation results in exposure of and conformational changes in the GPIIb/IIIa 
receptor (an adhesive protein receptor of the integrin family), binding fibrinogen and 
immobolised vWF.  The cytosolic portion of activated GPIIb/IIIa complex binds to the 
platelet cytoskeleton and can mediate platelet spreading and clot retraction, thus 
integrating receptor-ligand interactions with events inside the cell in a bidirectional 
fashion (Savage et al, 1992). 
3.3.2.2.1.3 Platelet Secretion 
The activated platelets then release the contents of their granules into the plasma: 
adenosine diphosphate (ADP) and serotonin stimulate and recruit other platelets 
(ADP activated platelets increase the surface expression of intercellular adhesion 
molecule (ICAM)-1 on endothelial cells); fibronectin and thrombospondin to reinforce 
and stabilise platelet aggregates; fibrinogen, providing a local source;  thromboxane 
A2, a prostaglandin metabolite, causing activation of new platelets and further 
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aggregation (Wu and Thiagarajan, 1996) and growth factors e.g. platelet derived 
growth factor which has potent mitogenic activity on smooth muscles cells as well as 
mediating tissue repair.    
3.3.2.2.1.4 Platelet Procoagulant Activity 
Platelet procoagulant activity is an important aspect of platelet activation and involves 
exposure of procoagulant phospholipids (section 3.3.2.3.3), primarily 
phosphatidylserine and the subsequent assembly of the clotting cascade (section 
3.3.2.3) on the platelet surface.  These complexes are an example of the close 
interrelationship between platelet activation and activation of the clotting cascade 
(Furie and Furie, 2008) which is examined in the next section. 
 
3.3.2.3 Thrombotic Cascade  
Thrombin (section 3.3.2.3.2) is the key effector enzyme of the coagulation system, 
having many biologically important functions such as the conversion of fibrinogen to a 
fibrin network, amplification of the feedback of coagulation and as discussed in 
section 3.3.2.2.1, activation of platelets. For review of thrombotic cascade, see 
(Provan D et al, 2009).  The exact and balanced generation of thrombin is the result 
of an ordered series of reactions collectively referred to as the „blood coagulation‟ 
(Figure 3.3.2.1).  At each stage, a precursor protein (zymogen) and its glycoprotein 
co-factor are converted to an active protease by cleavage of one or more peptide 
bonds in the precursor molecule and then catalyse the next reaction in the cascade, 
ultimately resulting in cross-linked fibrin.   Coagulation factors are indicated by 
Roman numerals, with „a‟ indicating the active form.  
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Figure 3.3.2.1 Blood Coagulation and Fibrinolytic Pathway 
Source: www.ganfyd.org (ganfyd, 2010) 
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3.3.2.3.1 Tissue Factor 
Tissue factor is the physiological initiator of coagulation (Figure 3.3.2.1).  It is a 
membrane protein abundantly present in cells surrounding the vascular bed.  It binds 
both zymogen and activated forms of factor VII (factor VIIa).   A fraction of factor VII 
in blood circulates as active enzyme and the binding of this form to tissue factor 
triggers coagulation by converting factors IX and X to their active forms, IXa and Xa.    
Feedback amplification is achieved when factor VII bound to tissue factor is activated 
by factors VIIa, IXa and Xa.   Factors IXa and Xa remain associated with the tissue-
factor-bearing cell or diffuse into the blood and bind to the surface or nearby activated 
platelets which have formed the platelet plug.    The activation of platelets (section 
3.3.2.2.1), is associated with the exposure of negatively charged phospholipids which 
Figure 3.3.2.1 Tissue factor binds to Factor VIIa and activates factors IX 
and X.  Factors IXa and Xa, together with factors VIIIa and Va 
respectively, form the tenase and prothrombinase complexes that 
activate factor X and prothrombin respectively.    Thrombin-mediated 
activation of factor XI, factor V and factor VIII gives positive feedback 
amplification of the system.   Thrombomodulin is present on endothelial 
cells.  Thrombin generated in the vicinity of intact endothelial cells binds 
to thrombomodulin and efficiently activates protein C.  Activated protein 
C (APC) and protein S form a complex on the plasma membrane of 
endothelial cells which inactivates factors Va and VIIIa, which results in 
downregulation of the coagulation system.  The degradation of factor 
VIIIa by APC is stimulated by protein S and by factor V. 
XL – cross-linked;  GLA - -carboxyglutamic acid; 
TPA – Tissue Plasminogen Activator 
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have high potential to bind coagulation factors and assemble enzyme-cofactor 
complexes that are crucially important for efficient propagation of the system.   
 
Prothrombin is activated to thrombin by the prothrombinase complex, which consists 
of the phospholipid-bound complex between the enzyme, factor Xa and its cofactor, 
activated factor V (Va).  The substances that activate factor V are Xa (on the 
phospholipid surface) and thrombi (in solution and on the surface).  Thrombin 
feedback amplifies the system by activating not only factor V, but also factors VIII and 
XI.   Factor VIII circulates bound to vWF, the adhesive protein important for the 
generation of the initial platelet plug.   After activation, factor VIIIa dissociates from 
vWf and forms a complex on the platelet surface with factor IXa; this complex 
(denoted the tenase complex) then activates factor X.  Activation of factor XI by 
thrombin in the amplification loop, results in the generation of factor IXa, which in 
turn, activates factor X (Furie and Furie, 2008) (Figure 3.3.2.1).  
 
The initiation of coagulation via the exposure of tissue factor as described above is 
referred to as the tissue factor (extrinsic) pathway, the mechanism by which 
coagulation is initiated in vivo in response to trauma, including chemotherapy and 
central venous catheters.   The contact activation (intrinsic) pathway is an alternative 
mechanism by which the coagulation can be initiated.  It involves factors VIII, IX, X, XI 
and XII, high-molecular-weight kininogen (HK), prekallikrein (PK) and factor XI and 
results in the conversion of factor X to factor Xa (Figure 3.3.2.1).   
 
Although the concept of intrinsic and extrinsic pathways served for many years as a 
useful model for coagulation, more recent evidence has shown that the pathways are 
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not, in fact, redundant but are highly interconnected, converging on a common 
pathway leading to clot formation.  For example, the tissue factor/VIIa complex 
activates not only factor X but also factor IX of the intrinsic pathway.  In addition, 
patients with severe factor VII deficiency may bleed even though the intrinsic pathway 
is intact (Kroll, 2001). Figure 3.3.2.2 shows the interrelationship between both 
pathways.  The common part in both pathways is the activation of factor X to factor 
Xa.  Factor Xa activates prothrombin (Factor II) to thrombin (Factor IIa) (Dahlback, 
2000).  
 
Figure 3.3.2.2 Schematic of extrinsic and intrinsic coagulation pathways 
Source: Adapted from Ferguson et al, Eur Heart J, 1998; Suppl 19:8 
 
Interrelationship between Intrinsic and Extrinsic Coagulation Pathways 
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3.3.2.3.2 Thrombin 
Thrombin, in turn, converts fibrinogen to fibrin.  Maximum thrombin generation occurs 
after the formation of the fibrin clot – for review of thrombotic cascade, see (Provan D 
et al, 2009).  This thrombin is important for additional fibrin generation as well as for 
activation of factor XIII and the thrombin-activatable fibrinolysis inhibitor (TAFI).  
Activated factor XIII (XIIIa) is a transglutaminase that stabilises the clot by covalent 
cross-linking of fibrin.   TAFI is a carboxypeptidase that releases carboxy-terminal 
lysines from fibrin and as these lysines are important for the binding of fibrinolytic 
enzymes to fibrin, activation of the inhibitor prevents fibrinolytic attack (Dahlback, 
2000).   Thrombin also binds to and leads to the release of G-protein-coupled PARs.  
The release of these proteins leads to the activation of numerous signalling cascades 
that, in turn, increases the release of the interleukins, IL-1 and IL-6.  IL-6 releases 
secretion of the ICAM-1 and vascular cell adhesion molecule, vascular cell adhesion 
molecule (V-CAM)-1.  ICAM-1 binds to three proteins (one of which is fibrinogen) and 
facilitates transmigration of leucocytes across vascular endothelia e.g. in 
extravasation.  As well as adhesion of proteins to the vascular endothelium, V-CAM-1 
is also involved in endothelial cell signalling transduction (Dugina et al, 2002).  
3.3.2.3.3 Phospholipid Membrane 
Early components of the clotting pathway circulate at lower concentrations than the 
factors that act at later stages.  The assembly of enzyme-cofactor complexes on 
negatively charged phospholipid surfaces increases the local concentration of the 
coagulation components and counteracts regulation by anticoagulant mechanisms. 
Phosphatidylserine is a negatively charged phospholipid required for the assembly of 
the tenase and prothrombinase complexes (Figure 3.3.2.1).  Under normal 
conditions, phosphatidylserine is present in the inner layer of the plasma cell 
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membrane.  During platelet activation, it is translocated from the inner to the outer 
layer of the membrane.  In the tenase and prothrombinase complexes, all 
participating proteins (the enzymes - factor IXa and Xa, the cofactors VIII and Va, and 
the substrates factor X and prothrombin), have affinity for the negatively charged 
phospholipid surface.  The enzymes and the substrates are vitamin-K dependant 
proteins that interact with the phospholipid membrane via their amino-terminal 
domains, which contain -carboxylation acid residues.  The post-translationally 
modified glutamic acid residue is present only in the vitamin-K-dependent proteins.  
The residues are involved in calcium binding, important for the correct folding of the 
-carboxyglutamin acid domain.  Inhibition of the -carboxylation reaction by 
antagonists of vitamin K results in defective calcium binding of the -carboxyglutamic 
acid domains and loss of ability to interact with the phospholipid membrane.  This is 
the molecular basis for anticoagulant therapy with warfarin and other vitamin K 
antagonists (Provan D et al, 2009) – see warfarin section 3.3.3.1.   
 
3.3.2.4 Regulation of blood coagulation by anticoagulant factors 
Regulation of coagulation is exerted at each level of the pathway, either by enzyme 
inhibition or by modulation of the activity of the cofactors.  The tissue-factor-pathway-
inhibitor (TFPI) inhibits the reactions involving tissue factor and factor VIIa.  This 
inhibitor is mostly bound to low density lipoprotein (LDL) in plasma or to haparan 
sulphate when associated with endothelial cells.   
 
Most of the enzymes generated during activation of coagulation are inhibited by the 
serine-protease inhibitor, antithrombin [AT] (also called Antithrombin III).   
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AT preferentially inhibits free enzymes, whereas enzymes that are part of the tenase 
or prothrombinase complexes are less accessible for inhibition.  The physiological 
role of AT is to limit the coagulation process to sites of vascular injury and to protect 
the circulation from liberated enzymes.  AT is the most important thrombin inhibitor 
since it can also inhibit the activities of factors IXa, Xa, XIa and XIIa. Heparin and the 
heparin-like molecules that are present on the surface of endothelial cells stimulate its 
activity by the following means:  heparin binds to the AT causing a conformational 
change which results in its active site being exposed. The activated AT then 
inactivates thrombin and other proteases involved in blood clotting, most notably 
factor Xa.  The rate of inactivation of these proteases by AT increases 1000-fold due 
to the binding of heparin.  AT binds to a specific pentasaccharide sulphation 
sequence contained within the heparin polymer.  The conformational change in AT on 
heparin binding mediates its inhibition of factor Xa but for thrombin inhibition, 
thrombin must also bind to the heparin polymer at a site proximal to the 
pentasaccharide (Perry, 1994). The highly negative charge density of heparin 
contributes to its very strong interaction with thrombin. The formation of a ternary 
complex between AT, thrombin and heparin results in the inactivation of thrombin. For 
this reason, heparin's activity against thrombin is size dependent, the ternary complex 
requiring at least 18 saccharide units for efficient formation.  In contrast, anti factor Xa 
activity only requires the pentasaccharide binding site (Dahlback, 2000). 
 
The protein C anticoagulant system regulates coagulation by modulation of the 
activity of the two cofactors, VIIIa and Va.  Protein C, the key component of the 
system, is a vitamin-K dependent zymogen to an anticoagulant protease.  It is 
activated on the surface of intact endothelial cells by thrombin that has bound to the 
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membrane protein thrombomodulin.  Thus thrombin has the capacity to express both 
procoagulant and anticoagulant functions depending on the context under which it is 
generated.   At sites of vascular disruption, the procoagulant effects of thrombin are 
fully expressed.  In contrast, in an intact vascular system, thrombin has anticoagulant 
function since it binds to thrombomodulin and activates protein C.  Activated protein C 
(APC) can cleave the phospholipid-membrane-bound cofactors factors Va and VIIIa 
which results in inhibition of the coagulation system.  A vitamin-K-dependent cofactor 
protein, protein S, supports the anticoagulant activity of APC.  APC and free protein S 
form a membrane-bound complex, which can cleave factors VIIIa and Va, even when 
they are part or fully assembled tenase and prothrombinase complexes.   
 
APC does not cleave intact factor VII because the binding of factor VII to vWF 
prevents it from interacting with the phospholipid membranes.  In contrast, factor V 
binds phospholipids as well as factor Va does, and APC is able to cleave the intact 
form of factor V.  The consequence of APC-mediated cleavage of factor V is the 
generation of anticoagulant factor V that functions in synergy with protein S and an 
APC cofactor in the degradation of factor VIIIa.  Thus, factor V can function as a 
procoagulant and anticoagulant cofactor.  The regulation of coagulation by 
anticoagulant factors is illustrated in Figure 3.3.2.1 as part of the whole cascade.  
 
3.3.2.5 Removal of clot by fibrinolysis 
Lastly, the degradation of fibrin clots is the function of plasmin, a serine protease that 
circulated as the inactive proenzyme, plasminogen.  Plasminogen binds to both fibrin 
and fibrinogen, thereby, getting incorporated into the clot.   Tissue plasminogen 
activator (tPA) and urokinase are serine proteases which convert plasminogen to 
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plasmin.  Inactive tPA is released from vascular endothelial cells following injury, 
binding to fibrin and then activated.  The inhibition of tPA activity results from binding 
to specific inhibitory proteins including plasminogen activator-inhibitors type 1 (PAI-1) 
and type 2 (PAI-2) (Dahlback, 2000).    This process is seen in Figures 3.3.2.3. 
 
Figure 3.3.2.3  The Fibrinolytic Pathway 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, prostacyclin and thromboxane are released from injured endothelial cells 
and modulate platelet adhesion and aggregation.  Injured endothelial cells also 
express TF on their membrane, a receptor for the circulating coagulation factor VII, a 
serine protease that initiates the blood coagulation cascade, unleashing sequential 
activation of other serine proteases: coagulation factors X, IX, VIII, V and thrombin.  
The latter promotes conversion of circulating fibrinogen into fibrin monomer which 
polymerises and is then cross-linked to for the fibrin-gel matrix.  This matrix acts as a 
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net, trapping platelets and various other cells into a clot that seals the wound and 
provides a scaffold for tissue repair (Mann KG, 1999).  Finally, the clot is removed by 
fibrinolytic enzymes, mostly plasmin, which derives from plasminogen through action 
of uPA or tPA.  Fibrinolysis is counteracted, among others, by PAI 1 and PAI 2. 
 
Having explored the coagulation cascade, the mechanism of action and effects of the 
anticoagulant drugs, warfarin and low molecular weight heparin, trialled in the 
prophylaxis of catheter-related thrombosis in cancer patients, will be considered. 
 
3.3.3  Anticoagulant Drugs 
3.3.3.1 Warfarin 
Warfarin, an oral anticoagulant, is still one of the most widely used drugs worldwide 
and is the most commonly prescribed anticoagulant in the UK (Sanger Institute, 
2009). 
3.3.3.1.1 Mechanism of action of warfarin 
Warfarin occurs as a pair of enantiomers that are differently metabolised by human 
cytochrome P450 (CYP) isozymes.  The dose-response relationship is influenced by 
genetic and environmental factors including a common mutation in the gene for a 
P450 enzyme (2C9), the hepatic enzyme responsible for oxidative metabolism of the 
warfarin S-isomer, and VKORC1, the gene for the enzyme Vitamin K epoxide 
reductase complex subunit 1 (see Figure 3.3.3.1) (Klein et al, 2009).   Warfarin exerts 
its anticoagulant action by inhibiting the vitamin K-dependent post- translational 
modification of the coagulation proteins II, VII, IX, X and also regulatory proteins C & 
S that serve as natural inhibitors of coagulation.   Before being released into the 
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circulation, these proteins undergo carboxylation, converting approximately 10 
glutamic acid (Glu) residues in their N-terminal regions to gamma-carboxy glutamates 
(Gla).  This process is catalysed by a carboxylase that requires molecular oxygen, 
carbon dioxide, and the reduced form of vitamin K (vitamin KH2).  During this reaction 
vitamin KH2 is oxidised to vitamin K epoxide, which is recycled back to vitamin KH2 by 
the actions of two reductases, vitamin K epoxide reductase and vitamin K reductase 
(Figure 3.3.3.1).  Warfarin inhibits the former and probably also the latter reductase, 
resulting in depletion of vitamin KH2 and thereby limiting the degree of carboxylation 
of the coagulation proteins.  These under or non-carboxylated proteins are released 
from their site of production in the liver into the circulation and are inactive. 
Conversely, the presence of Gla residues allows the coagulation proteins to bind 
calcium, which in turn allows these proteins to undergo a conformational change 
essential for their ability to complex with their respective cofactors on phospholipid 
surfaces.  The biological activity of these proteins is thus dependent upon the Gla 
residues (Ansell et al, 2008). 
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Figure 3.3.3.1 The Vitamin K cycle 
Source:  Hirsh J in Oral anticoagulants (Hirsh et al, 2001a) 
 
 
 
 
 
 
 
 
3.3.3.1.2 Pharmacokinetics of warfarin 
 
Warfarin is readily absorbed from the gastrointestinal tract, has a predictable onset 
and duration of action, is extensively bound to plasma proteins and has a plasma 
half-life of 36 to 48 hours for the unaltered compound.  It is metabolised in the liver 
and metabolites with negligible or no anticoagulation activity are excreted in the urine 
following reabsorption from bile.  The pharmacological response to warfarin varies 
between individuals.  Warfarin disposition (i.e. plasma concentration-time profiles) 
Figure 3.3.3.1 In the presence of calcium ions, carboxylation causes a 
conformational change in coagulation proteins that promotes binding to cofactors 
on phospholipid surfaces (section 3.2.3.3). The carboxylation reaction requires 
the reduced form of vitamin K (Vit KH2), oxygen and carbon dioxide and is linked 
to the oxidation of Vit KH2 to Vitamin K epoxide (VitKO). Vit KO is then recycled 
to to Vit KH2 through two reductase steps. The first, which is sensitive to warfarin, 
reduces Vit KO to Vit K1, while the second, which is relatively insensitive to 
warfarin, reduces the VitK1 (the natural food form of vitamin K), to Vit KH2. 
 
 
The major site of warfarin action (see „blocks‟) is the vitamin K epoxide 
reductase. 
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and the effect of warfarin on vitamin K–dependent clotting factor production have 
been shown to be altered in cancer patients (Mousa, 2006; Hutten et al, 2000).  The 
mechanisms for this alteration are complex and largely unknown.   
 
Warfarin action occurs within 24 hours, peaks at 2-3 days and can last for up to 5 
days.  The anticoagulant effect of warfarin is delayed until all the clotting factors 
already in circulation are cleared:  After achieving steady-state levels of warfarin, the 
anticoagulant effect overwhelms any potential hypercoagulability induced by 
decreasing protein C and/or protein S activity, although this may not be so in the first 
days following initiation of warfarin therapy.  In addition, factors II, IX and X levels 
decline more slowly (48-72 hours) than factor VII and adequate degree of 
anticoagulation is only evident after this time (Hirsh et al, 2008).  Given this 
pharmacokinetic profile, starting warfarin (where appropriate) three days prior to the 
insertion of a central venous catheter (CVC) allows time for exposure to warfarin prior 
to catheter insertion and the start of chemotherapy (Boraks et al, 1998).   
 
Fixed dose warfarin (FDW) [1mg daily] probably affects the in-vivo function of the 
vitamin K-dependent proteins in ways as yet not always detectable by current ex-vivo 
assays (Magagnoli et al, 2005; Bern et al, 1990) and so monitoring FDW as well as 
higher doses is prudent.   
3.3.3.1.3 Laboratory investigation for warfarin:  International 
Normalised Ratio (INR) 
Oral anticoagulant therapy is most commonly monitored by the prothrombin time 
(PT), a coagulation-based assay that is sensitive to depression of three of the four 
vitamin K-dependent procoagulants reduced in patients on warfarin therapy (factors 
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II, VII and X).  The test is performed by adding a mixture of tissue factor and calcium 
to citrated plasma and measuring the time to fibrin formation.  Tissue factor (section 
3.3.2.3.1) is a protein-phospholipid tissue extract, derived typically from lung, brain or 
placenta.  The responsiveness of tissue factors varies according to their source and 
method of preparation and determines the extent of PT prolongation.  PT ratios 
derived from an individual on warfarin will vary, therefore, according to the particular 
tissue factor used to perform the test.  Because of this unavoidable variability, the 
international normalised ratio (INR) is used.  The INR incorporates a correction factor 
(international sensitivity index, ISI) into the PT ratio to account for the reactivity of the 
particular tissue factor used to perform the PT (Horsti, 2000).    
3.3.3.1.4 Complications of warfarin therapy 
Bleeding is the most common side-effect of warfarin therapy.  Although the most 
common sites of bleeding from warfarin are the gastrointestinal and genitourinary 
systems, bleeding may occur at unusual sites and become manifest with atypical 
clinical presentations.  Both major and minor bleeding rates are much lower with „low-
intensity‟ dose of warfarin than „standard intensity‟ (target INR>2.0).  Additionally, the 
risk of major and minor bleeding for an individual patient rises with the INR.  Patient 
characteristics, e.g. dietary changes and cachexia, the use of interaction medications 
and non-compliance with warfarin also dictate bleeding risk to a large extent.   
Other complications including warfarin–induced skin necrosis, alterations in calcium 
metabolism, rebound hypercoagulability, cholesterol embolisation, fever, nausea, 
vomiting, anorexia, abdominal cramp, diarrhoea, dermatitis, urticaria, alopecia and 
mouth ulcers have also been reported infrequently but must be considered alongside 
the side effects of concomitant medication, in particular, chemotherapy (British 
National Formulary, 2010).  
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3.3.3.1.5 INR variations in cancer patients 
Given that the majority of patients in the WARP trial were on fluoropyrimidine-based 
chemotherapy, the following observation is of interest and strengthens the case for 
the recommendation in the protocol that regular INR monitoring in patients on both 
warfarin arms of WARP was undertaken.  Masci et al (2003) analysed the incidence 
of alterations in INR and bleeding episodes in cancer patients receiving warfarin (1mg 
daily) during treatment with continuous infusional 5-Fluorouracil (5-FU).  They 
evaluated 95 patients and found that 31 subjects (33%) had an INR>1.5, 18 of whom 
(19%) having an INR of >3.0.  Twelve of the patients (12/31, 39%) had liver 
metastases and the incidence of distorted INR was more common in patients 
receiving the combination of infusional 5-FU, folinic acid and oxaliplatin (FOLFOX) 
(Masci et al, 2003).  These authors concluded that a high incidence of INR 
abnormalities was observed in patients treated with infusional 5-FU and that regular 
measurement of INR should be undertaken.   Following this, patients on WARP, 
receiving all chemotherapies, had their INRs closely monitored and warfarin doses 
adjusted according to written guidelines provided in the protocol (item 4.6).  The 
protocol recommended monitoring patients more closely when they were taking, 
adding, stopping and changing dose of any medication known to interact with 
warfarin.   
3.3.3.1.6 Interaction between warfarin and other drugs  
3.3.3.1.6.1 Anticancer Drugs 
There are frequent case reports, retrospective and prospective analyses on the 
interaction between warfarin and cytotoxic therapies, most recently with the oral 
fluoropyrimidine, 5-FU prodrug, capecitabine (Shah et al, 2006; Camidge et al, 2005).  
The summary of product characteristics for capecitabine has this year (2010) been 
43 
amended by the drug manufacturers, Roche, to include a warning and description of 
an interaction with warfarin (Roche, 2010).  Altered coagulation parameters and/or 
bleeding have been reported in patients taking concomitant capecitabine and 
warfarin.  These events occurred within several days and up to several months after 
initiating capecitabine therapy and, in a few cases, within one month of it‟s cessation.  
In a clinical interaction study, after a single dose of 20mg warfarin, capecitabine 
treatment increased the area under the curve (AUC) of S-Warfarin by 57% with a 
91% increase in international normalised ratio (INR) value.    The manufacturers of 
capecitabine therefore recommend that patients on warfarin should be monitored 
regularly by INR test and careful consideration given to adjusting the anticoagulant 
dose accordingly (Roche, 2010).  This is the consistent theme on the warfarin-
cytotoxic drug interaction reports.   
3.3.3.1.6.2 Non-anticancer drugs 
Numerous drugs have been reported to potentiate or oppose the action of warfarin.   
Particularly relevant to cancer patients is the interaction of warfarin with antibiotics 
and antifungal agents, frequently used for side effects of chemotherapy or as a 
prophylactic measure.  In a case control and case cross over study investigating 
warfarin interactions with anti-infectives and measuring gastrointestinal bleeds, using 
Medicaid data, warfarin users who had received an anti-infective agent showed a 
substantially increased risk of GI bleeding. However, a drug-drug  interaction with 
warfarin was evident only for co-trimoxazole and fluconazole (Schelleman et al, 
2008).    It is of note that, in a retrospective analysis of 372 patients at end of life, the 
most common drug interactions involved warfarin and phenytoin.   Most interactions 
were classified as being of moderate severity (59%).  Older patients, those with 
comorbid conditions, brain tumour patients and those taking many medications were 
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at greater risk of drug interactions (Riechelmann et al, 2008).  Again, the advice from 
these reports is to monitor warfarin vigilantly and not necessarily to cease one of the 
drugs.  
 
Low molecular weight heparin (LMWHs), usually given subcutaneously, have been 
tested in the thromboprophylaxis of cancer patients with CVCs.  In addition, the 
findings from an overview of six systematic reviews on anticoagulation (with warfarin, 
unfractionated heparin and LMWHs) and cancer (Akl et al, 2008), concluded i) current 
evidence does not support a specific anticoagulant for perioperative 
thromboprophylaxis  and ii) that anticoagulants may  improve survival but more data 
will be useful in deciding which subgroups benefit most.  Therefore it is pertinent that 
other anticoagulants are examined, in particular, LMWH, in the following section.   
LMWH is a derivative of unfractionated heparin; unfractionated heparin is usually 
restricted to the hospital setting where its effect can be monitored and dosage 
adjusted frequently and, because of the limited use and patient inconvenience, is not 
covered in this section. 
 
3.3.3.2 Low Molecular Weight Heparin 
3.3.3.2.1  Mechanism of Action 
Low molecular weight heparin (LMWHs) are derived from (unfractionated) heparin by 
chemical or enzymatic depolymerisation, yielding fragments approximately one third 
the size of heparin i.e. LMWHs have a mean molecular weight of 4,500 to 5,000 
daltons. Like heparin, LMWHs produce their major anticoagulant effect by activating 
AT.  The interaction with AT is mediated by a unique pentasaccharide sequence 
found on fewer than one third of LMWHs.  Since a minimum chain length of 18 
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saccharides is required to form ternary complexes among heparin, AT and thrombin, 
only the minority of LMWHs that are above this critical chain length are available to 
inactivate thrombin. In contrast, all LMWH chains, containing the high affinity 
pentasaccharide, catalyse the inactivation of factor Xa.    
3.3.3.2.2 Pharmacokinetic Profile 
The LMWHs have half lives of some 2-4 fold larger than unfractionated heparin (UFH) 
(UFH half life is 30-150 minutes) and, coupled to their enforced bioavailability at low 
doses, means that a once daily subcutaneous dosing schedule provides a more 
convenient means of administration. 
3.3.3.2.3 Side effects 
The risk of heparin-induced bleeding is influenced by the administered dose, route of 
administration (usually subcutaneous injection but higher risk of bleeding with 
intravenous use), the concomitant use of aspirin and thrombolytic agents and the 
patient‟s clinical condition (e.g. history of peptic ulcer, thrombocytopenia, renal 
failure). The key non-haemorrhagic side effect is heparin induced thrombocytopenia, 
an antibody-mediated adverse reaction causing venous and arterial thrombosis which 
may have serious consequences.  Long-term use of LMWH carries a risk of heparin-
induced osteoporosis, although most studies investigating osteoporosis are with 
unfractionated heparin, known to cause more significant reduction in bone density 
and symptomatic vertebral fractures (Hirsh et al, 2001c).   
3.3.3.3 New Anticoagulants 
There are a number of new anticoagulants that have been studied in recent years, 
some of which are licensed for use in certain conditions including orthopaedic surgery 
(Levine, 2009).  They target the active site of factor Xa or thrombin and are 
administered in a fixed dose.  Fonadaparinux is a parenteral, indirect factor Xa 
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inhibitor; rivaroxaban is an oral direct, factor Xa inhibitor (directed again the active 
site of factor Xa); apixaban is also a direct, oral, factor X inhibitor.  Dabigatran 
etexilate is an oral direct thrombin inhibitor which does not bind to plasma proteins 
and therefore has a more predictable anticoagulant effect than heparin  .    The new 
oral drugs are mentioned as they are attractive for patients with cancer because of 
the administration route, the fixed dose and the non-requirement for laboratory 
monitoring.   It is vital that thromboprophylactic trials of the new anticoagulants are 
evaluated in the cancer population, given the high-risk of VTE.   
 
Having examined the coagulation pathways utilised under normal circumstances as a 
defence against bleeding, their regulation by anti-coagulant pathways and the 
therapeutic anticoagulants widely used in clinical practice, the effects of cancer on 
these factors are now scrutinised.  
 
3.3.4 Thrombotic Events Associated with Carcinogenesis  
3.3.4.1 Introduction 
Today, it is known that thrombosis and cancer are linked by multiple 
pathophysiological mechanisms and that tumour biology and coagulation 
mechanisms are integrally connected.  The pathophysiology of thrombosis in the 
cancer patient is multifaceted, with the haemostatic process finely balanced between 
thrombosis, invasion and metastases and bleeding, involving a complex interaction 
between the tumour cell and the patient.  The pathogenic mechanisms are dependent 
on the tumour type, extent of disease, host response, therapies used and other risk 
factors (section 3.3.5.5).  VTE may indicate an occult cancer or a complication of a 
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known malignancy.    In most studies of VTE and its treatment, a diagnosis of cancer 
is a poor prognostic sign and similarly, a diagnosis of a DVT in cancer patients also 
indicates a poor prognosis.   Cancer patients who undergo surgery, receive 
chemotherapy or have CVCs inserted for the administration of chemotherapy are at 
increased risk of VTE, compared to non-cancer patients and cancer patients with 
established VTE are at increased risk of not only recurrent thromboembolism but also 
anticoagulant associated bleeding, in comparison to non-cancer patients.   All these 
factors will be explored, with the molecular biology which underlies the clinical 
ramifications of thrombosis and malignancy briefly covered and the clinical factors 
pertinent to cancer patients with central venous catheters, examined in more detail.  
 
3.3.4.2 Tumour Biology: Link between Cancer and Thrombosis 
The cancer cell phenotype is characterised by loss of the normal features which 
control cell proliferation, a capacity to invade normal tissue and further to metastasise 
or spread to distant organs.  The extraordinary advances in molecular biology which 
have been made over the last two decades have give an series of insights into the 
biochemical pathways and cascades which are mutated in cancer and contribute to 
its dysfunctional state.  Perhaps the best characterised of the carcinogenic pathways 
has been described for colorectal cancer patients in which there are well recognised 
pre-malignant precursors which have been described by pathologists, the so-called 
adenoma-carcinoma sequence.  Adenomas are benign, hyperproliferative wart-like 
lesions lining the large bowel.  These accumulate further genetic mutations which 
eventually transform these lesions into fully invasive and metastatic cancer cells.  
Molecular biologists have characterised the approximate sequence of genetic events 
during the transition from normal to dysplastic to adenoma to carcinoma.  Many of 
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these changes implicate pathways involved in cell cycle control (C-MYC, cyclins, 
p53), proliferation (RAS, MAP kinase, transforming growth factor-α), cell adhesion 
(matrix metalloproteinase overexpression) and angiogenesis (vascular endothelial 
growth factor [VEGF]).  It is clear that cancer cells, in their de-differentiated state, can 
synthesise and secrete a number of factors which are otherwise strictly confined to 
specific normal tissues of stage of foetal development.  There is therefore the 
potential to interact with proteins involved in the thrombotic cascade, outlined in 
section 3.3.2.3.  It has only recently been recognised that the genetic mechanism 
responsible for neoplastic transformation, as in the example above (activation of 
tumour oncogenes e.g. RAS and inactivation of tumour suppressor genes e.g. p53), 
modulate the expression of genes at the core of haemostasis control.   The 
thrombotic diathesis in the cancer patient may be induced by intrinsic or extrinsic 
factors.   
 
3.3.4.3 Intrinsic Factors 
The process of subclinical activation of the coagulation system has been widely 
described in untreated cancer patients (Bluff et al, 2008; Winter, 2006).   In general, 
the subclinical activation of prothrombotic mechanisms reflects the host response to 
the growing cancer and is thought to arise from the activation of thrombin and fibrin 
formation; directly, by the release of procoagulants by the tumour cell and indirectly, 
through the activation of endothelial cells, leucocytes and platelets by augmenting 
pro-inflammatory cytokines and the production of factor X-activating cysteine 
protease, mucinous glycoproteins and circulating tissue factor-bearing microparticles 
(Petralia et al, 2005) [section 3.3.4.3.1.1].  
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3.3.4.3.1 Tissue Factor in Malignancy 
As in non-malignancy, TF localises the coagulation serine protease factor VII/VIIa to 
the cell surface.   The primary function of TF is to activate the clotting cascade 
(Section 3.3.2.3).  TF expression has been reported in a number of cancers including 
glioma, pancreatic, non-small cell lung, colorectal, renal cell, ovarian, prostate, 
hepatocellular and breast (Rickles et al, 1995) with the level of TF expression varying 
among different types of cancer and, in general, increases with advanced cancer 
stage (Kakkar et al, 1995).   The incidence of thrombosis in patients with tumours 
expressing higher levels of TF such as brain and pancreatic cancer is greater that 
those expressing lower levels such as breast (White et al, 2007), so the use of TF as 
a biomarker (Table 3.3.5.1) is currently being evaluated.  TF expression by cancer 
cells is under the transcriptional control of oncogenes and tumour suppressor genes 
such as members of the epidermal growth factor receptor (EGFR) family, RAS, p53, 
and PTEN (Boccaccio and Comoglio, 2009). 
 
Tumour-infiltrating macrophages also express tissue factor (TF) activity; activated 
macrophages produce interleukin-1 (IL-1) and tumour necrosis factor alpha (TNF-), 
stimulating endothelial cell TF, downregulating endothelial cell anticoagulant activity 
and stimulating releases of fibrinogen/factor VIII (Sutherland et al, 2003).   An 
increased fibrin formation supports the metastatic process (Falanga A et al, 2003).  It 
has been proposed that anticoagulant therapy therefore might not only prevent 
vascular events but also may demonstrate anti-metastatic activity (Prandoni et al, 
2005).    
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In addition to procoagulant activity, TF has signalling properties.  TF can interact with 
Filamen A (a protein that participates in the anchoring of membrane proteins for the 
actin cytoskeleton), plasminogen activators and PAR 2 signalling (formation of the 
TF:VIIa complex on the surface of tumour cells leads to cleavage and activation of 
the G-protein coupled receptor, PAR2) and thereby enhance tumour growth, invasion, 
angiogenesis and haematogenous metastasis.  Inhibition of the TF:VIIa complex 
suggests a novel approach to anticancer therapy, yet to be studied in patients 
(Kasthuri et al, 2009).  PAI-1 and COX-2 genes, both strongly upregulated by the 
MET oncogene, are other examples of mechanisms that link oncogene activation to 
the procoagulant activity of cancer cells.  The measurement of COX-2 products, 
prostaglandins and thromboxane, may help assess the procoagulant properties of 
incipient neoplasia. 
3.3.4.3.1.1 Microparticles and Selectins  
Microparticles [MPs] (submicron phospholipid vesicles derived from apoptotic and/or 
activated cells) (Morel et al, 2006) and selectins (transmembrane molecules 
expressed on the surface of leucocytes and endothelial cells) may both initiate blood 
coagulation and also allow thrombin generation by providing a surface for the 
generation of fibrin.   TF-bearing MPs seem to have a role not only in cancer-
associated thrombosis but also cardiovascular disease, sepsis and diabetes.  
P-selectin (CD62P), the largest of the selectins, is crucial for the localisation of MPs 
to areas of injury and inflammation.   
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3.3.4.4 Extrinsic Factors 
The increased risk of thrombosis is associated with alterations in normal blood flow, 
injury to the vascular epithelium, and alteration in the constituents of the blood, the 
so-called, Virchow‟s triad.  Stasis tends to be the result of extrinsic venous 
compression by locally advanced tumours, occurring by uncontrolled growth of the 
primary tumour or by a metastatic manifestation e.g. a large lymph node mass.  
„Performance status‟, in relation to cancer patients, is an attempt to quantify their 
general wellbeing.  Patients with advanced cancer and reduced performance status 
tend to be less mobile and more predisposed to bed rest than average and more 
prone to infection, through general immunosuppression to infection, all of which can 
lead to relative venous stasis and reduced clearance of activated clotting factors.  
CVCs by their invasive nature also cause alterations in blood flow.   Vessel damage 
may be caused by intravenous medication including antineoplastics, erythropoietin 
and anti-angiogenic agents, CVCs and by direct tumour invasion.   
 
3.3.5   Clinical Picture: Thrombosis and Carcinogenesis 
3.3.5.1 Introduction 
Around 145 years ago, Professor Armand Trousseau first recognised the association 
between thrombosis and cancer.   He noted, “there appears in the cachexia…. a 
particular condition of the blood which predisposes it to spontaneous coagulation” 
and “Should you, when in doubt as to the nature of an affection of the stomach, when 
hesitating between chronic gastritis, simple ulcer, and cancer, observe a vein become 
inflamed in the arm or leg, you may dispel your doubt, and pronounce in a positive 
manner that there is a cancer” (Trousseau A, 1865).    
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Over the years, „Trousseau‟s syndrome‟ has been expanded from a recurrent and 
migratory pattern of superficial thrombophlebitis prior to the diagnosis of cancer, to 
any thromboembolic event linked to a malignancy.  However, recently it has been 
proposed, “to restrict use of Trousseau‟s syndrome to unexplained thrombotic events 
that precede the diagnosis of an occult visceral malignancy or appear concomitantly 
with the tumour” (Varki, 2007).    
 
Thromboses have been found postmortem in up to 50% of patients with metastatic 
cancer (Walsh-McMonagle and Green, 1997).  However, despite a small group of 
dedicated scientists and clinicians working together to elucidate the association 
between thrombosis and carcinogenesis in the laboratory since the 1970s and 
despite VTE being acknowledged as a common event in cancer patients by the 
medical and nursing communities, it remains an under-diagnosed and under-treated 
condition in life.   It is really only in the last few years that the uniqueness of the 
thrombotic problem in cancer patients has become the focus of attention by the wider 
health community.  This is in some part, due to: 
 the steady increase in the overall burden of VTE because of ageing population 
and the increasing use of CVCs 
 more routine staging using sensitive imaging techniques   
 an expanded basic science research programme elucidating our 
understanding of the pathogenesis of thrombosis and cancer 
 the study of newer anticoagulants in the cancer population  
 more effective novel but prothrombotic anticancer agents, in particular the 
vascular endothelial growth factors (VEGF) inhibitors (Kamba and McDonald, 
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2007) and thalidomide and its derivatives, in which thrombosis has been found 
to be a significant complication of treatment, and  
 UK governmental and associated bodies e.g. the Chief Medical Officer and the 
National Institute of Health and Clinical Excellence raising awareness of the 
problem by developing policies and guidelines.   
 
3.3.5.2 The scale of the problem 
The problem of VTE in general is large - each year 25,000 people in the UK are 
estimated to die from venous thromboembolism (VTE).  This figure includes all types 
of patients admitted for medical care of serious illnesses, as well as, those admitted 
for surgery (House of Commons Health Committee, 2005).  However, in comparison 
with other groups of patients, the cancer population is distinctive because virtually all 
patients with active malignancy demonstrate some degree of activation of the 
coagulation cascade, although the resulting hypercoagulable state only rarely results 
in overt disseminated intravascular coagulation (Lyman et al, 1978).   The risk of VTE 
is therefore considerably elevated in cancer patients and significant morbidity may 
result from thrombotic events as well as a result of therapeutic interventions.   It is 
difficult to compare the incidence of VTE in cancer patient population because of the 
varied study methods, varied populations covered and varied methods of detecting 
and reporting VTE but the population-based studies, hospital discharge data, cancer 
registries, retrospective cohorts and prospective observational studies, all give a 
sense of a widespread problem.    
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3.3.5.2.1 Incidence of Venous Thromboembolism in Cancer 
Patients 
In a population-based study looking at risk factors of VTE, Heit et al found that 
patients with cancer account for almost 20% of all patients with VTE (Heit et al, 2002) 
and that cancer patients were found to have an overall 4-6-fold increased risk of 
thrombosis compared to non-cancer patients (Heit et al, 2000) .  An even higher risk 
was reported in a later Dutch population-based case control study of 3220 patients 
presenting with a first DVT or PE and 2131 control patients, revealing the overall VTE 
risk was increased 7-fold in patients with a malignancy (OR 6.7; 95% CI 5.2-8.6) vs 
persons without a malignancy (Blom et al, 2005b).   In retrospective cohort studies, 
thrombosis was found to be the second most common but often preventable cause of 
death in outpatients with cancer, after death from the cancer itself  (Khorana et al, 
2007b).  Levitan et al  reported an analysis of Medicare claims data for patients over 
65 years between 1988 and 1990 and found an established VTE rate of 0.6%, 
significantly higher than the comparison group with no malignancy (Levitan et al, 
1999).  A later smaller study including hospitalised patients with solid tumours 
demonstrated an higher incidence of VTE of 7.8% over 26 months for this specific 
population (Sallah et al, 2002).  The largest patient hospital discharge analysis of 
over 40 million cancer patients who were hospitalised between 1979 and 1999, found 
a DVT rate of 2% and PE rate of 1%;  this was twice the rate of VTE observed in 
patients with no malignancy (Stein et al, 2006).  The highest rates of VTE, however, 
were found in hospitalised neutropenic patients (6.4%) (Khorana et al, 2006) and in 
patients admitted to an oncology unit (VTE rate 7.8%) in the study by Sallah et al 
(2002), suggesting that the patients were on active treatment.  
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Finally, cancer-associated VTE is increasingly prevalent;  the rate of VTE increased 
by 28% from 1995 to 2003 in a study of over one million hospitalised patients with 
cancer (Khorana et al, 2007c) a diagnosis of DVT and PE was made in 3.4% and 
1.1% of patients respectively with an overall rate of VTE of 4.1%; the increase is due 
to many of the reasons postulated in the introduction (section 3.5.1). 
 
3.3.5.3 Adverse Consequences of Venous Thromboembolism in 
Patients with Cancer 
VTE is related to a variety of adverse physical and psychological consequences, 
including increased mortality.  Cancer patients developing symptomatic VTE during 
chemotherapy are at a greater risk of early mortality than those without VTE (Kuderer 
et al, 2008).  The risk of a developing a symptomatic pulmonary embolus (PE) from a 
deep vein thrombosis (DVT) in cancer patients is around 4% with approximately 1% 
of deaths during all DVT episodes related to the DVT and 1% due to the treatment for 
the DVT (Bergqvist et al, 2007; Elting et al, 2004).  The mortality from PE is difficult to 
estimate as many PEs are not suspected clinically.  However, in a retrospective study 
of all hospitalised patients, the mortality rate from PE was 14% and it was felt by 
clinicians that a significant number of cancer patient deaths compared with those of 
non-cancer patients may have been preventable (e.g.by the use of an inferior vena 
caval filter) (Scarvelis et al, 2010).  Chew et al (2006), also reported that a diagnosis 
of a VTE during the first year of follow-up was a significant predictor of death for most 
cancer types and stages (Chew et al, 2006) and in  a retrospective cohort analysis of 
cancer patients hospitalised with neutropenia, those with documented 
thromboembolism had a significantly greater in-hospital mortality than those patients 
without thromboembolism (Khorana et al, 2006).  Lastly, VTE was found to be a 
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significant predictor of decreased 2 year survival in a study of over 100,000 patients 
with breast cancer (Chew et al, 2007). 
 
Patients with cancer who suffer a VTE have an increased risk recurrent VTE, 
bleeding complications and increased utilisation of healthcare resources, in particular, 
hospitalisation (Elting et al, 2004; Prandoni et al, 2002).   There are also significant 
morbidities related to having a VTE including reduced pulmonary function for patients 
with a PE and post-thrombotic syndrome for those with a DVT.  Upon removal of 
CVCs from thrombosed vessels, thrombi often persist and 15% to 35% of patients 
with CRT were found to develop post thrombotic syndrome (Kuter, 2004).  Symptoms 
can range from mild to severe and include calf pain, discomfort, swelling, and rashes 
with skin ulceration in severe cases.  The long-term complications of this syndrome 
are hard to assess in the cancer population because of reduced life expectancy and 
co-morbidities.  Chronic thromboembolic pulmonary hypertension is a rare but serious 
complication of PE (McNeil and Dunning, 2007) .  VTE may also interrupt or 
complicate life-saving treatments e.g. chemotherapy, surgery and radiotherapy and 
profoundly affect the quality of life of the patient.  The restriction on mobility and the 
emotional strain on patients and their families further diminishes quality of life.  The 
financial burden from the management of VTE is also considerable, resulting from the 
expense of investigations, drugs, travel to the hospital to monitor anticoagulant 
therapies and loss of work productivity.  The overall patient impact, not always 
considered as a totality, can therefore be considerable.   
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3.3.5.4 Clinical Presentation of Venous Thromboembolism 
Given the high incidence of VTE in patients with cancer and the adverse 
consequences outlined above, oncology nurses, the clinical multidisciplinary team 
and the patients and their carers must remain vigilant for any signs and symptoms 
that may indicate the presence of DVT or PE.   Clinical suspicion for VTE must reflect 
the entirety of the patient‟s risk profile including age, primary cancer site, histologic 
type and stage, recent major surgery, trauma, hospitalisation or serious medical 
illness, immobility and use of chemotherapy, radiotherapy, hormone or erythropeietic 
stimulatory agents, in addition to the presence of a thrombophilia or a past history of 
VTE.  In the Multicenter Advanced Study for a Thromboembolism Registry (MASTER) 
study, a prospective cohort of 2,119 patients with VTE, the most common presenting 
symptoms and signs  associated with deep venous thrombosis were reported as 
extremity oedema (80%), pain (75%) and erythema (26%).  Patients with pulmonary 
embolism reported dyspnoea (85%), chest pain (40%), tachypnoea (30%) and 
tachycardia (23%).  Syncope (10%), and haemoptysis (2%) were less common 
(Imberti et al, 2008).  The clinical picture of indwelling CVC-associated VTE is similar 
and outlined in Section 3.3.6.4 
 
3.3.5.5 Risk Factors for Thrombosis in Cancer Patients 
Clearly, multiple factors need to be considered when attempting to calculate an 
individual cancer patient‟s risk of developing thrombosis.  Currently, there are few 
data to produce a specific algorithm; however, in general risk assessment tools for 
VTE, malignancy is considered moderate to high risk, with surgery of the abdomen 
and pelvis for cancer considered high risk (National Institute of Health and Clinical 
Excellence, 2010).   
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Cancer is an independent risk factor for thrombosis (Heit et al, 2000) with several 
molecular mechanisms for this finding being postulated in section 3.3.4.2.  Despite 
the complexities with the studies on incidence of VTE in cancer patients, there is 
broad agreement in the literature around cancer, treatment and patient risk factors for 
cancer-associated VTE which will now be scrutinised.   These evidence-based factors 
may be relevant to the multivariate analysis of risk factors in the WARP trial. 
3.3.5.5.1 Cancer-related Risk Factors 
3.3.5.5.1.1 Stage of Disease 
Although some large cohort studies have identified advanced stage as a major risk 
factor (Sallah et al, 2002), other studies in patients with good performance status 
have not (Khorana et al, 2005).  Stage may therefore be a surrogate for poor 
performance status (Khorana and Connolly, 2009).  
3.3.5.5.1.2 Tumour Type 
The incidence of VTE among patients with cancer varies between tumour types but 
the primary site of the cancer is consistently identified as a risk factor. Rates vary 
widely between cancer types and prevalent cancers contribute to the overall burden 
of VTE.  Early case reports suggested that the „mucin-producing‟ tumours were the 
most commonly associated with thrombosis.  In men, pancreatic and lung cancers 
were particularly involved, whereas in women gynaecologic, pancreatic and colorectal 
cancer were most frequently associated with risk for thrombosis (Pineo et al, 1974).  
More recent and better designed studies have shown malignant brain tumours, 
haematological malignancies and adenocarcinomas of the  pancreas, uterus, ovary 
stomach and kidney to confer the highest risk of VTE, (Blom et al, 2005a; Sallah et al, 
2002; Thodiyil and Kakkar, 2002; Levitan et al, 1999).  The US National Hospital 
Discharge survey (Stein et al, 2006) show that the highest incidence of VTE, 4.3%, 
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was in hospitalised patient with pancreatic cancer, followed by 3.5% in patients with 
brain tumours.  Other tumour types were seen as high risk in a population-based 
case control study; patients with haematological malignancies were reported to have 
the highest risk of VTE (odds ratio [OR] = 28.0; 95% Confidence Interval [CI], 4.0 – 
119.7), followed by lung (OR=22.2; 95% CI, 3.61-136.1) and gastrointestinal cancers 
[OR=20.3; 95% CI, 4.9-83.0] (Levitan et al, 1999).  The results from current 
prospective registry data are awaited e.g. PERCEIVE, an international prospective, 
registry of newly diagnosed patients with cancers of the pancreas, lung, prostate, 
breast, colon and rectum and ovary to find out accurate clinical incidence, treatment 
and outcome of thromboembolic events in those patients.  This study, in which the 
author is a principal investigator, aims to recruit 10,000 patients, to provide a more 
definitive answer to these questions. 
3.3.5.5.2 Treatment-related Risk Factors 
3.3.5.5.2.1 Surgery 
Surgery is one of the cornerstones of cancer treatment and may be the only curative 
treatment for patients with advanced disease.  The vast majority of cancer patients 
with CVCs for infusional chemotherapy have gastrointestinal or breast cancers, for 
which the first definitive treatment is generally surgery.   Historically surgery and the 
extended postoperative period have been recognised as high risk but, in recent 
reports, surgery has not been found to be a major risk factor (Rodriguez et al, 2007; 
Alcalay et al, 2006; Blom et al, 2006), with some authors suggesting that there is high 
compliance with thromboprophylaxis guidelines (Khorana et al, 2009).   
3.3.5.5.2.2 Chemotherapy and Hormone Therapy 
The direct tissue toxicity from chemotherapy can in some cases be traced directly to 
vascular endothelial damage.  Animal and tissue culture models are often used in 
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experimentation of the effects of chemotherapy on the endothelial cells (Nuver et al, 
2010; Romanov et al, 2007).    
In addition to the direct damage, there are several different mechanisms through 
which chemotherapy is capable of inducing a prothrombotic state (Haddad and 
Greeno, 2006):  
 increasing the levels of procoagulant molecules and  
 reducing the levels of endogenous anticoagulants  
 inducing tumour and endothelial cell apoptosis and cytokine release, both of 
which in turn lead to increased expression and activity of TF 
 inducing platelet activation 
 inducing expression of monocyte–macrophage TF 
 
The sclerosant potential of the chemotherapy drug (i.e. a vesicant – „a drug which 
produces blisters‟ - or non-vesicant) was a simple method of classifying potential 
damage to the vein and was used as a stratification variable in the WARP trial.  The 
clinical evidence for chemotherapy-induced thrombosis is compelling.   
Chemotherapy is an independent risk factor for VTE (Khorana et al, 2005).   In the 
Olmstead County, Minnesota population-based study from 1996 through to 1990, the 
risk of VTE was increased 6.5-fold (95% CI 2.1-20.2) in patients with malignancy 
receiving chemotherapy and 4.1 fold (95% CI 1.9-8.5) in patients with malignancy not 
receiving chemotherapy, compared with patients without malignancy (Heit et al, 
2000).  In a retrospective record linkage cohort study, chemotherapy was also 
associated with a two to six fold increased risk of VTE compared with the general 
population (Blom et al, 2006).   
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Breast cancer patients were in the past the most widely prospectively studied 
population with a landmark study by Levine in 1998 showing chemotherapy 
contributes to VTE (Levine et al, 1988).  Tamoxifen treatment increases the risk of 
VTE, especially during the first two years of exposure (Hernandez et al, 2009) and in 
combination with chemotherapy.  In a randomised trial of cyclophosphamide, 
methotrexate, and fluorouracil  (CMF) chemotherapy +/- to tamoxifen as adjuvant 
therapy in 705 postmenopausal women with breast cancer, thromboembolic events 
were reported to significantly increase in those women taking CMF plus tamoxifen in 
comparison with those who took CMF alone [p<0.0001] (Pritchard et al, 1997).  Over 
the last five years, with the new era of anticancer drugs, several specific agents have 
been implicated in high rates of VTE.  Thalidomide has been associated with VTE 
rates of 12%-28%, when given in combination with dexamethasone or chemotherapy 
(Rajkumar et al, 2006; Cavo et al, 2004).  Zangari et al discovered that regimens 
containing doxorubicin, newly diagnosed disease and presence of chromosome 11 
abnormality are predictors of thalidomide-associated VTE (Zangari et al, 2003).  
Lenalidomide, a thalidomide derivate, is similarly associated with high rates of VTE 
(Palumbo et al, 2008).  A large individual data meta-analysis of bevacizumab, an 
antiangiogenic agent, demonstrated patient with cancer receiving bevacizumab, had 
a significantly increased risk of VTE (Nalluri et al, 2008),  a feature found with other 
antiangiogenic class drugs (Kuenen et al, 2003).  
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3.3.5.5.3 Patient-related Risk Factors 
Comorbid conditions, prior thromboses, prothrombotic mutations, age, gender and 
race, performance status and mobility have all been found to be high risk factors for 
VTE.  Some factors, relevant to patients in WARP are described:  Infection, often 
seen in patients with CVCs, was identified as one of the comorbidities mostly strongly 
associated with VTE among hospitalised cancer patients (Khorana et al, 2007c).  
Older age (≥ 65 years) is associated with a slightly elevated risk of VTE in 
hospitalised patients in the study above but not in the ambulatory setting with patients 
of good performance status (Khorana et al, 2005).  Performance status has also been 
associated with higher rates of recurrent VTE in cancer patients (Sallah et al, 2004).   
3.3.5.5.4 Prediction of Venous Thromboembolism Risk 
Almost all studied cancer types have been associated with haemostatic abnormalities 
including thrombocythaemia, activated platelets, variation in prothombin and activated 
partial thromboplastin times, demonstration of circulating activated coagulation 
factors and elevation of fibrinogen and markers of thrombin generation.  Similarly, 
suppression of fibrinolytic activity has been noted.  Nevertheless, these markers do 
not yet correlate with prediction of thromboembolism or prognosis for the individual 
patient but exploratory studies have identified some „candidate‟ biomarkers that may 
be predictive of VTE in cancer patients (Table 3.3.5.1).   
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Table 3.3.5.1.  Candidate Clinical Biomarkers for Prediction of Venous 
Thromboembolism in Cancer Patients 
Potential Biomarker References 
Blood Count 
Pre-chemotherapy Platelet Count  
≥ 350,000/µL 
Prechemotherapy White Cell Count  
> 11,000/ µL 
(Khorana et al, 2008; Simanek et al, 
2007);  
Tissue Factor 
High grade of TF expression by tumour 
cells 
Elevated systemic TF (antigen or 
activity) 
(Tesselaar et al, 2009; Khorana et al, 
2008; Tesselaar et al, 2007; Uno et al, 
2007; Khorana et al, 2007a)  
D -dimer (Ay et al, 2009) 
Soluble p-selectin (Ay et al, 2008) 
C-reactive protein (Kroger et al, 2006) 
Prothrombin fragment 1+2 (Ay et al, 2009) 
Microparticles, selectin and d-dimer (Chirinos et al, 2005) 
 
 
3.3.5.6 The Impact of Anticoagulants on the Survival of Cancer Patients 
Treatment of VTE for cancer patients is not discussed in this thesis as prophylaxis is 
the focus; however, since overall survival is a secondary endpoint of the WARP trial 
and there are mounting data suggesting that components of the clotting cascade and 
associated vascular factors play an integral part in tumour progression, invasion, 
angiogenesis and metastasis formation (section 3.3.5.6.1) and indeed that 
anticoagulants may have anticancer properties, the impact of anticoagulants on the 
survival of cancer patients will be explored briefly. 
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3.3.5.6.1 Impact of Haemostatic System on Cancer Growth and 
Progression 
Patients presenting with idiopathic thrombosis are at increased risk of developing 
cancer in subsequent years (Sorensen et al, 1998; Prandoni et al, 1992).  In addition, 
cancer diagnosed within one year of an idiopathic VTE is often associated with an 
advanced stage and a poorer survival than among patients with a newly diagnosed 
cancer without a preceding VTE event (Sorensen et al, 2000).  Schulman and co-
workers (2000) performed a prospective randomised study of the duration of 
anticoagulation (six weeks or six months) after a first episode of VTE.  After a mean 
follow up of 8 years, they used the national Swedish Cancer Registry to identify all 
diagnosis of cancer and causes of death in the study population.  Observed numbers 
of cancer cases were compared with expected national incidence rates, allowing 
calculation of standardised incidence ratios.  They found that the standardised 
incidence ratio was 3.4 (95% CI, 2.2-4.6) during the first year after the VTE event and 
remained between 1.3 and 2.2 for the following 5 years.  Interestingly, cancer was 
diagnosed in 66 of 419 patients who were treated with warfarin for 6 weeks, 
compared to 45 of 435 patients treated for 6 months (odds ratio, 1.6; 95% CI, 1.1-
2.4).  These data must be treated with some caution as the initial trial was not 
powered to detect small differences in cancer survival; nevertheless, these findings 
suggest that unexplained VTE is a risk factor for cancer development and that 
warfarin may have an antineoplastic effect (Schulman and Lindmarker, 2000).   
These data amongst other studies promulgated a number of trials in which 
anticoagulants were employed in prospective randomised controlled trials of patients, 
with and without established VTE, designed to determine whether they would 
enhance overall survival.   
65 
3.3.5.6.1.1 Anticoagulation as Cancer Therapy in Patients without 
Venous Thromboembolism 
Warfarin was reported to improve survival in patients with small cell lung cancer in an 
early and small study of patients with lung, prostate, head and neck and colon 
cancers but this effect has not been subsequently confirmed (Zacharski et al, 1984). 
In a trial of 328 patients, Chahinian et al reported a significant improvement in time to 
tumour progression and in overall survival with warfarin versus no warfarin among 
small cell lung cancer patients, with no difference in other tumour types (Chahinian et 
al, 1989).  Unfractionated heparin given to 277 patients receiving chemotherapy for 
five weeks, showed improved median survival (p=0.01) (Lebeau et al, 1994). 
However, a later study of warfarin in 347 patients with limited stage small cell lung 
cancer, demonstrated no significant improvement in response rate, disease-free or 
overall survival (Maurer et al, 1997).  The most recent study in 84 patients with small 
cell lung cancer showed a median progression-free survival of 10 months with LMWH 
versus 6 months in the control arm of chemotherapy alone [p=0.01] (Altinbas et al, 
2004).  The majority of these studies are limited by their small size, heterogeneous 
cancer patient population and outdated chemotherapy.      
 
In tumour types, apart from small cell lung cancer, there is some evidence to suggest 
that heparin and its low molecular weight derivatives (LMWH) may also lead to 
survival benefits for cancer patients.  The Fragmin advanced malignancy outcome 
study (FAMOUS) was designed to investigate the efficacy of long term treatment with 
the LMWH dalteparin, compared with placebo in 385 patients with advanced cancer, 
randomised to 5000iu dalteparin or normal saline placebo subcutaneously, daily for a 
maximum of 1 year.  The powered objective, namely a 15% improvement in 1 year 
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survival was not achieved but in a post hoc analysis of 102 patients still alive at 17 
months, significant improvement in survival was found for patients receiving 
dalteparin (Kakkar et al, 2004).  Post hoc, subgroup analyses must be treated with 
caution, but these data may suggest that further trials are warranted in patients with a 
minimal cancer burden.  In another LMWH trial, 302 patients were randomly assigned 
to nandroparin or placebo for 6 weeks.  With a mean follow up of one year, a 
significant improvement in overall survival was observed (p=0.02) among patients 
receiving nadroparin (Klerk et al, 2005).  However, these findings were not confirmed 
by a later small trial in advanced solid tumour patients randomly assigned to standard 
treatment with or without dalteparin (Sideras et al, 2006). This study changed from 
placebo-controlled to open label part way through making the interpretation of the 
findings problematic (Section 5.3.2).  
3.3.5.6.1.2 Anticoagulation Therapy in Cancer Patients with an 
Established Venous Thromboembolism 
Most of the data in clinical trials of anticoagulation treatment in patient with an 
established VTE come from subgroups of studies with mixed disease types.  A trial of 
initial treatment of patients with a proximal DVT with either LMWH or unfractionated 
heparin (UFH), demonstrated that 44% of the patients with cancer in the UFH group 
died compared with 7% of patients in the LMWH group (p=0.02). In a meta-analysis 
of nine trials, Hettiarachchi et al (1998), compared the mortality of LMWH vs UFH 
treatment using nine randomised controlled trials in patients with cancer; there were 
fewer deaths reported in the first three months with patients receiving LMWH 
compared to UHF (OR, 0.61; 95% CI, 0.40-0.93) (Hettiarachchi et al, 1998).  Both 
LMWH and UHF were of brief duration and followed by warfarin in these patient 
groups.  Again, because of the post hoc analyses of cancer patients, these findings 
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remain hypothesis generating only.  A retrospective analysis of survival for cancer 
patients with established VTE and recruited to the CLOT trial (dalteparin versus 
coumarin derivative for 6 months), was undertaken (Lee et al, 2005).  During the 12 
month follow up period, 356 of 602 patients died.  In a post-hoc analysis of patients 
with non-metastatic disease, the probability of death at one year was 20% 
(dalteparin) vs 36% (oral coumarin) (HR, 0.5; 95% CI 0.27-0.95, p=0.003).  In 
patients with metastatic cancer (n=452), no statistically significant difference in 
mortality between the treatment groups was observed (72% and 69%, respectively; 
hazard ratio, 1.1; 95% CI, 0.87 to 1.4; p=0.46).  The observed effects of dalteparin on 
survival were statistically significantly different between patients with and without 
metastatic disease (p= 0.02).  
 
As survival was a secondary endpoint of the trial, a meta-analysis of the trials above 
in mortality in cancer patients treated with warfarin versus control or LMWH versus 
control was carried out as part of this thesis, in order to place the WARP survival 
results in context.    Although plausible antineoplastic properties associated with 
LMWHs (inhibition of heparanase, disruption of P-selectin function, and inhibition of 
coagulation proteases) have been put forward, it is difficult to separate putative 
survival benefits which may be accrued from a direct anticancer effect leading to 
reduced rates of tumour progression, or by reduction in deaths from silent or 
asymptomatic VTE. Further, well designed trials, especially in the adjuvant setting, 
are required to provide a definitive proof of benefit or refutation thereof.   
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This thesis is based on a clinical trial on a specific population - cancer patients who 
have indwelling central venous catheters for the administration of chemotherapy.  
This patient population has the potential to fulfil the three categories in the triad of 
Virchow for risk of thrombosis:  hypercoagulability due to the cancer cells and host 
reaction; blood stasis due to the catheter sitting in the vein; and injury to the vessel 
wall due to the catheter and/or or the vesicant nature of the chemotherapy.  Central 
venous catheters have been recognised as an additional and independent risk factor 
for thrombosis in cancer patients and warrant close examination.  
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3.3.6 Central Venous Catheters and Thrombosis 
3.3.6.1 Central Venous Catheters  
Initial experiments with venous catheters in the mid-17th century, through which the 
physicians of the day administered animal blood, purgatives, ale and opiates, were 
plagued with controversy and iatrogenic deaths.  Not surprisingly, intravenous 
therapy fell into abeyance for a few centuries.  However, the last three decades have 
seen the development of much more sophisticated cannulation devices, particularly 
long-term catheters which can stay in place for months or years (summarised in 
Table 3.3.6.1). A central venous catheter by definition is one whose tip lies in the 
superior vena cava (Goodwin and Carlson, 1993).  Central placement is direct 
insertion into a „central vein usually on the chest wall, most commonly the internal 
jugular or subclavian veins and peripheral insertion is placement in the cephalic or 
basilic veins in arm – see Figure 3.3.6.1.  Ultrasound guidance is commonly utilised 
during the placement procedure as suggested in the National Institute of Health and 
Clinical Excellence (NICE) Technology Appraisal Guidance (NICE, 2005) but, there is 
by no means, comprehensive use despite the national guidance.  Traditionally, the 
insertion of tunneled catheters was the domain of surgeons, anaesthetists and 
radiologists; however, in the last decade, nurse-led services for centrally placed, as 
well as peripherally placed, have demonstrated high quality care (Hamilton, 2004; 
Kelly, 2003; Benton and Marsden, 2002). 
Table 3.3.6.1   Types of Central Venous Catheters used for Intravenous Chemotherapy 
Type of Device Material Veins Commonly Used Number of 
Lumens 
Associated non 
thrombotic 
complications 
 Peripherally Inserted 
Central Catheter 
(PICC) 
Polyurethane 
Silicone 
Basilic 
Cepahalic 
Median 
Cubital 
Single or double Phlebitis, infection, 
malposition, occlusion 
Skin tunneled catheter Polyurethane 
Silicone 
Internal jugular 
Subclavian 
Femoral 
Single, double or 
triple 
Infection, thrombosis, 
occlusion 
Implanted Port Portal Body – 
titanium or plastic; 
Catheter - silicone 
Internal jugular 
Subclavian 
Femoral 
Single or double Infection, thrombosis, 
extravasation 
 
The type of central catheter employed by UK clinicians varies from centre to centre.   
3.3.6.1.1 Types of Central Venous Catheters 
The types of catheters, using a generic taxonomy, are shown in Table 3.3.6.1.   
Totally implanted devices tend to be utilised in routine practice more frequently within 
European countries other than the UK, e.g. in one of the largest cancer centres in 
France, Institut Gustave Roussy in Villejuif, where the author has worked, 99% of 
central venous devices inserted, are „Port-a Caths‟ (implantable).   However, these 
are becoming more popular in the UK in the last 5 years, because by their very 
nature, they are not exposed on the external skin and have an associated expected 
reduction in the risk of infection and less thrombosis than peripherally inserted 
catheters (odds ratio [OR] = 0.43; 95% CI, 0.23-0.80)  (Saber et al, 2008).  Catheter 
material, lumen number and internal tip forms are claimed by the manufacturers to be 
of differing thrombogenicity amongst other features and merit discussion.  
3.3.6.1.1.1 Catheter Material 
Polyurethane and polyvinylchloride (PVC) were used in the past due to their stiff 
nature that allowed for percutaneous insertion.  However, they are associated with 
increased thrombogenicity due to the rigidity of the catheter.  Polyurethane is now 
available as a rigid, semi-rigid and flexible material. Some of the newer polyurethane 
catheters soften after insertion in response to body temperature and some have 
silicone tips to reduce potential damage to the endothelium.  Polyurethane has tensile 
strength that permits the catheter to be constructed with thinner walls and smaller 
external diameters, thereby reducing the foreign material in the vein and allowing 
higher infusion pressures through smaller catheters (Hadaway, 1995).  Silicone, 
alternatively, is a very soft biocompatible material that floats within the vein and is 
less likely to cause damage to the wall of the vessel. The majority of CVCs are made 
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of silicone which necessitates thicker walls to achieve strength and therefore smaller 
internal diameters (Dougherty, 2006).   
3.3.6.1.1.2 Further Catheter Variables 
Catheters are available with a number of lumens for simultaneous infusion of 
incompatible agents; double lumens are usually required for complex chemotherapy 
regimens for patients with haematological malignancies; however, an increase in the 
number of lumens is associated with infection (Pratt et al, 2001).    There are two 
types of internal tip endings: open, which can be cut to size and „valved‟, developed 
to ensure there is no blood reflux when the catheter is not in use.  The Groshong 
valve, in the tip of the catheter is pressure activated. Positive pressure connectors 
can also be added to the external catheter end to maintain pressure and minimize 
occlusion (Jacobs et al, 2004).  Lastly, catheter size is measured in „French‟ or in 
„gauge‟.  French size is the outside diameter of the catheter (in millimeters, multiplied 
by three); gauge is the inner or outer diameter, ranging from 13-28 with the smallest 
number indicating the largest diameter.  
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Figure 3.3.6.1. The main veins used for central venous catheter placement   
Source: Central Venous Access Devices (Dougherty, 2006) with author permission 
 
3.3.6.2 CVC Use in Cancer Therapy 
Long-term central venous catheters (CVCs) have been in clinical use for over 20 
years for the administration of infusional cytotoxic therapy to patients with both 
haematological and solid malignancies.  This practice is increasing rapidly due to 
ease of catheter insertion, novel high dose chemotherapy regimens requiring long 
term vascular access and increased use of ambulatory infusional regimens.   
Additional indications for placement of a CVC include poor venous access and the 
administration of chemotherapy drugs known to be venous sclerosants (vesicants).  
3.3.6.2.1 Basis of infusional chemotherapy 
The reason for giving infusional chemotherapy instead of bolus is based on the cell 
cycle and the chemotherapy‟s mode of action.  The vast majority of cytotoxic drugs 
inhibit the synthesis of DNA, albeit, through a range of different molecular targets.  
Empirical observations on the shape of dose response curves for all the major 
antineoplastic agents led Skipper and Schabel (Wilcox et al, 1965) to postulate that 
there was a class of drugs which was cell cycle and phase specific.  This implied 
that cancer cells were sensitive to these drugs for a limited period of time only.  For 
example, if the cell cycle lasted, arbitrarily 24 hours and S-phase (the period during 
which the DNA doubles) is of 8 hours duration, then in a typically desynchronised 
cancer cell population, only one third of the cells would be in S-phase at any point; 
and therefore vulnerable to the cell killing effects of the anticancer drugs.  A classical 
phase specific agent is the antimetabolite, 5-FU, used in on its own and in 
combination with other cytotoxic agents for the majority of patients having infusional 
chemotherapy.  This prodrug is activated within cells to 5-fluorodeoxyuridine 
monophosphate (5-dUMP) which binds to and inhibits one of the key enzymes 
involved in DNA synthesis, thymidilate synthase (TS).  There are good experimental 
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data which show that prolonged exposure to lower concentrations of 5-FU is much 
more effective at killing cancer cells than brief exposure to higher drug quantities.  
This is consistent with its S-phase specificity and would imply that prolonged 
exposure might be more effective that an intermittent, high dose regimen.  5-FU has 
a brief plasma half life of 10-15 minutes (Young et al, 1999), and has proven very 
difficult to formulate in a slow-release, pharmaceutically stable form.  Infusional 5-FU 
is better tolerated, induces a higher tumour response rate and marginally improves 
survival compared to intermittent bolus injections (Louvet et al, 1992).  These clinical 
data have supported a very large increase in infusional delivery of 5-FU, using a 
variety of schedules (48 hour infusion every 2 weeks; 24 hour infusion every week; 7 
day continuous infusion, repeated for 8 weeks) for patients with advanced disease.   
 
3.3.6.3 Catheter-related Thrombosis 
CVCs are consistently identified as an independent risk factor for VTE (Heit et al, 
2000)  and a common cause of upper extremity or neck DVT.   Using the data from a 
prospective multicentre US DVT registry, the „DVT-FREE‟ steering group reported 
that an indwelling CVC was the strongest independent predictor of upper extremity 
DVT (odds ratio [OR], 7.3; 95% CI, 5.8 to 9.2). and risk factors for upper extremity 
VTE differ somewhat from the conventional risk factors for lower-extremity DVT 
(section 3.5.5) by virtue of the foreign body location (the catheter) (Joffe et al, 2004).   
A more recent multivariate analysis also demonstrated that the presence of a central 
venous catheter and no thromboembolic prophylaxis during hospitalisation were 
independently associated with VTE in patients with cancer (Seddighzadeh et al, 
2007).   
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3.3.6.3.1 Pathophysiology of Catheter-related Thrombosis 
The pathogenesis of CRT is multifactorial:  injury to the vessel wall from placement, 
venous stasis around the catheter and vessel occlusion caused by size of the 
catheter in relation to the smaller veins of the upper extremity are all factors 
involved.   The loss of vessel integrity from the insertion procedure causes changes 
in the endothelium with resultant production of procoagulant factors and activation of 
platelets and blood coagulation.  These events may cause a thrombus which is 
reversible in the majority of patients but, in some, leads to the formation of collagen 
and stabilisation of the thrombus (Xiang et al, 1998).    
3.3.6.3.2 Types of Catheter-related Thromboses 
Venographic studies have shown that a catheter sleeve, an extraluminal adherent 
coating of fibrin and collagen that envelopes the CVC in up to 47% of patients, is 
formed within 24 hours (De Cicco et al, 1997).   This sleeve is in itself a benign 
complication but can travel the whole length of the catheter, interfere with catheter 
function, produce a nidus for local infection and may lead to a mural thrombus, 
although formation of a sheath does not predict subsequent VTE (Starkhammar et 
al, 1992) (Figure 3.3.6.2).  One other common thrombotic event is intraluminal 
clotting, most commonly noted when the infusional pump fails to work.  The 
frequency of this event is probably significantly underreported as nursing staff readily 
handle this complication;  initial management is thrombolysis with urokinase (or 
equivalent) or removal and replacement.   Published figures suggest that 15-20% of 
patients suffer this inconvenience (Shivakumar et al, 2009).  Lastly a fibrin tail occurs 
when fibrin, platelets and blood cells adhere to the end of the catheter, often 
lengthening.   The ability to flush but not withdraw blood („ball valve effect‟), is 
commonly experienced because of the tail which may lead to a luminal or vessel 
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thrombosis but again, is not predictive.  Non-thrombotic mechanical problems 
commonly prevent blood flow.  In an venographic study of patients with problems 
with blood withdrawal from catheters, 58% were found to have a thrombosis [and 
42% did not have a thrombosis] (Stephens et al, 1995).      
 
Figure 3.3.6.2 Types of Central Venous Catheter Thromboses 
Source:   Vascular Access Devices (Dougherty, 2000) 
  With permission from the author, Lisa Dougherty 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.6.2  Types of Central Venous Catheter Thromboses 
Intraluminal:   within the catheter and often under-reported 
Fibrin Tail:     fibrin, blood cells and platelets adhere to the top of the 
catheter 
Fibrin Sheath:    an extraluminal fibrin sheath is formed normally around 
the top of the catheter and may extend back along the catheter 
Mural Thrombosis:   fibrin from the vessel wall attaches to the catheter 
surface and is often a total occlusion  
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3.3.6.3.3 Incidence of Catheter-related Venous Thromboembolism 
The incidence of catheter-related VTE has been described in a number of clinical 
observational and interventional studies; however, as with incidence of VTE in 
cancer patients, it is impossible to define incidence precisely, given the variation in a 
range of relevant factors that make an inter-study comparison difficult.  These 
include differences in study design and the observed patient population, variation in 
the method of catheter type and insertion, inconsistent description of the thrombotic 
event, significant differences in patient follow up and the sensitivity and specificity of 
the radiological methods used to confirm the diagnosis.  This gives a wide range in 
the published incidence of symptomatic CRT in adult cancer patients, from 0.7-
28.3% (Table 3.3.6.2).  If the study endpoint is venography- detected VTE, the 
thrombosis rate rises to a range of 3.7-66% (Table 3.3.6.3).  In summary, from all 
published studies of VTE carried out in adult cancer patients with CVCs, since 1983, 
presented in Tables 3.3.6.2 and 3.3.6.3, a median of 6.75% of patients develop 
symptomatic thrombi.  In those studies in which symptomatic plus venographically 
screened CRTs were measured, a median of 28% of patients develop a VTE.  By 
extrapolation, for every one symptomatic VTE (mean 10.4%), there may be around 
two to three asymptomatic VTE (mean 27.7%).   
 
With respect to timing, there are relatively few prospective studies with multiple 
venography.  Di Cicco and coworkers reported a longtitudinal study with venography 
repeated 8, 30 and 105 days after CVC insertion.  They found that 64% of thrombi 
occurred by day 8, and 98% by day 30 (De Cicco et al, 1997). 
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Table 3.3.6.2   Incidence of Symptomatic Catheter-related Thromboses in Adult 
Cancer Patients  
Study Design Sample 
Number  
CRT 
% 
Reference 
Retrospective 53 28.3 (Lokich and Becker, 1983) 
Prospective 826 28.7 (Raaf, 1985) 
Retrospective 92 16.3 (Lokich et al, 1985) 
Retrospective 115 7.8 (Stanislav et al, 1987) 
Prospective 190 3.7 (Moss et al, 1989) 
Prospective 168 17 (Anderson et al, 1989) 
Prospective 123 4.1 (Jansen et al, 1990) 
Prospective 162 12.9 (Haire et al, 1990) 
Prospective 46 41 (Conlan et al, 1991) 
Prospective 92 6.0 (Mueller et al, 1992) 
Prospective 22 5.0 (Soh and Ang, 1993) 
Prospective 322 10.0 (Eastridge and Lefor, 1995) 
Prospective 50 21.0 (Horne, III et al, 1995) 
Retrospective 223 3.0 (Laurenzi et al, 1996) 
Prospective 18 26.0 (Cunningham et al, 1996) 
Prospective 949 4.7 (Nightingale et al, 1997) 
Retrospective 177 4.8 (Meisenberg et al, 1997) 
Prospective 223 9.0 (Boraks et al, 1998) 
Retrospective 110 9.0 (O'Neill et al, 1999) 
Retrospective 409 2.2 (Lyon et al, 1999) 
Prospective 923 3.1 (Schwarz et al, 2000) 
Prospective 390 6.9 (Lagro et al, 2000) 
Retrospective 209 11 (Minassian et al, 2000) 
Retrospective 65 21 (Carr and Rabinowitz, 2000) 
Prospective 100 5.0 (Povoski, 2000) 
Prospective, 
RCT 
304 6.6 (Biffi et al, 2001) 
Prospective 98 2.1 (Coccaro et al, 2001) 
Prospective 233 1.5 (Harter et al, 2002) 
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Study Design Sample 
Number  
CRT 
% 
Reference 
Prospective, 
RCT 
88 14.7 (Heaton et al, 2002) 
Prospective, 
RCT 
255 4.3 (Couban et al, 2005) 
Prospective 458 7.6 (Cortelezzi et al, 2005) 
Prospective 247 1.8 (Magagnoli et al, 2005) 
Prospective 443 4.3 (Lee et al, 2006) 
Prospective 1390 2.5 (Fagnani et al, 2007) 
TOTAL 9573  Median Catheter-related thrombosis 
rate = 6.75% 
 
Interestingly, for the 34 „symptomatic CRT‟ studies (Table 3.3.6.2), the sample size 
was found to be correlated with %CRT (spearman‟s r = -0.48, p = 0.004); the larger 
the sample, the lower the CRT rate.   
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 For the 13 venographically determined VTE rate studies (Table 3.3.6.3), sample 
size was not found to be correlated with %CRT (spearman‟s r = -0.43, p = 0.14).   
Caution should be applied in the interpretation of the above results because of the 
small numbers of studies.  
 
Table 3.3.6.3  Incidence of Venographically determined Catheter-related 
Thromboses in Cancer Patients 
Study Design Sample  
Number 
CRT 
% 
Authors 
Prospective, RCT 121 15.7 (Bern et al, 1990) 
Prospective, match  17 35 (Haire et al, 1990) 
Case Series, post 
mortem  
72 36 (Raad et al, 1994) 
Prospective 57 56 (Balestreri et al, 1995) 
Retrospective, 
RCT 
32 28 (Monreal et al, 1996) 
Prospective, RCT 127 66.0 (De Cicco et al, 1997) 
Prospective, RCT 80 21 (Park K et al, 1999) 
Retrospective 319 35.1 (Frank et al, 2000) 
Prospective, RCT 302 5.6 (Biffi et al, 2001) 
Prospective, RCT 252 30 (van Rooden et al, 2004) 
Prospective, RCT 385 16 (Verso et al, 2005) 
Prospective 439 3.6 (Karthaus et al, 2006) 
Prospective, RCT 87 12.6 (Niers et al, 2007) 
TOTAL 2203  Median Catheter-related 
thrombosis rate = 28% 
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3.3.6.3.4 Risk Factors for Central Venous Catheter-related 
Thrombosis 
Very few prospective randomised studies have been undertaken to compare 
different types of catheters, ports, surface coatings etc. in relation to CRT and 
therefore most of the published data on risk factors for CRT has come from 
retrospective multivariate analyses of sequential patient cohorts, others with 
historical controls.  Although limited, these have suggested a number of plausible 
catheter-related risk factors (catheter and host associated).  Data from randomised 
studies with sufficient power offer the most robust answers.   
 
The factors found to be associated with an increased risk of CRT in patients with 
cancer include the type of malignancy e.g. ovarian (Tesselaar et al, 2004), lung 
(Anderson et al, 1989), metastatic vs localised disease (Verso et al, 2008); 
anticancer treatment type ((Verso et al, 2008; Bern et al, 1990; Baglin and 
Boughton, 1986); pre-existing haematological conditions e.g. Antithrombin III 
deficiency (De Cicco et al, 1995), and characteristics of the catheter itself e.g. 
previous insertion (Lee et al, 2006), tip position (Nightingale et al, 1997).   
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Catheter tip placement is an important risk factor for CRT.  The optimal tip 
placement is the upper portion of the lower third of the superior vena cava (Eastridge 
and Lefor, 1995) – Figure 3.3.6.3 
 
Figure 3.3.6.3  Optimal placement for central venous catheters 
Source: Bard Catheters, 'PICC Training Poster‟ - with permission from the company 
 
 
 
 
 
3.3.6.4 Clinical Presentation of Catheter-related Thrombosis 
Around one third of VTE events in cancer patients with CVCs involve the upper limb 
(33%).  Another third are in the veins feeding the superior vena cava (SVC) with the 
remainder in the SVC (3%), the leg (23%), pulmonary emboli (11%) and inferior 
vena cava (<1%).  As previously mentioned, approximately 7% of patients screened 
by venography were symptomatic, presumably because thrombosis is more chronic 
and less likely to be occlusive.  Patients typically present with upper extremity or 
head or neck swelling, erythema, and/or discomfort with congestion of subcutaneous 
Figure 3.3.6.3  Schematic of optimal catheter placement:  the upper portion of the 
lower third of the Superior Vena Cava.  A peripherally inserted central catheter 
(PICC) is illustrated. 
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collateral veins.  CVC dysfunction is also a common presentation although this can 
also result from a fibrin sheath in the catheter lumen itself.    Less commonly, 
symptoms of PE, headache and distal parasthesiae are the first signs of a CVC 
thrombus (Linenberger, 2006).  In addition to being a complication of CRT, 
pulmonary embolism may present as the first clinical manifestation of catheter 
thrombosis, with a reported incidence of 15-25% in adult cancer patients.  These 
data are collected from three small prospective studies which recruited a total of 147 
patients (Kuter, 2004). 
 
3.3.6.5 Other Complications of Central Venous Catheters 
Thrombotic complications are associated with CVCs. However, there are other 
sequelae of catheter insertion (summarised in Table 3.3.6.4).  These may be early 
and associated with puncture wounds (arterial, pneumothorax, venous 
haemorrhage) and malposition (failure of insertion, arrhythmia, misplacement of 
reservoir) or later (infection, catheter fracture or migration of catheter tip).  These 
complications are rarer than thrombosis but can nevertheless be the source of 
significant morbidity.   
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Table 3.3.6.4 – Non-thrombotic Complications of Central Venous Catheters 
Source:  Vascular Access Devices (Dougherty, 2000), with permission 
 Incidence (%) 
Early  
Arrhythmia  
Arterial Puncture 
Malposition of Reservoir 
Pneumothorax 
Wound dehiscence 
Haemorrhage 
Failure of Insertion  
13 
2.8-3.8 
2 
1-2 
1.5 
1.2 
1.2 
Late  
Infection 
Catheter fracture and embolisation 
Migration of catheter tip 
4-38 
3 
7.4 
 
3.3.6.6 Diagnosis of Venous Thromboembolism in Patients with 
Central Venous Catheters 
The gold standard for diagnosis of VTE in patients with CVCs, remains contrast 
venography.  This method has not been applied uniformly across the various 
epidemiologic studies of catheter related thrombotic risk, given its invasiveness, cost 
and requirement for contrast medium.  In the case of clinical suspicion of upper limb 
VTE, modern ultrasound techniques (especially with Doppler and colour flow) are 
most widely used to confirm the diagnosis.  A systematic review of the rather sparse 
literature has indicated that the specificity of duplex ultrasound varies between 56 to 
100% and sensitivity from 94-99%.  In patients with clinical suspicion of an upper 
limb VTE, a diagnostic accuracy rate of 82-95% has been reported for colour flow 
Doppler, compared to venography as standard.  This has led clinicians instituting 
anticoagulant therapy in patients with a clinical suspicion of VTE and a positive 
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ultrasound examination, whereas it is recommended that patients with a negative 
ultrasound despite suspicious clinical factors, should have a venogram before the 
diagnosis of VTE is completely ruled out (Streiff, 2009). 
 
3.3.6.7 Managing Established Catheter-related Thrombosis 
Conventional therapy for a CVC blocked by an intraluminal thrombus only is local 
lytic therapy with a low dose of single or repeated bolus of urokinase, streptokinase 
or tissue plasminogen activator.  This is effective in restoring patency in up to 85% of 
patients.  If this proves ineffective, catheter removal and replacement, if 
chemotherapy is to continue, is mandated.   
 
For other confirmed VTE, anticoagulant therapy is the treatment of choice, using 
protocols developed for lower limb VTE.  Accordingly, treatment is generally initiated 
with adjusted dose unfractionated heparin or LMWH for 5-7 days and subsequently 
continued with oral warfarin.  If there is some contraindication to warfarin, treatment 
is continued with subcutaneous administration of LMWH.  This seems relatively 
straightforward, but given the lack of prospectively randomised trial data on this 
subject, there are areas of management which are open to local interpretation.   
Should the CVC be removed if it is still functioning?  Clearly, this will depend on 
associated symptoms, whether further chemotherapy is required, platelet count etc 
and consideration given to the fact that insertion of a second CVC on the opposite 
side is often associated with considerable morbidity and cost.   
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What is the optimal duration of anticoagulant therapy?  There are no guiding data to 
give a precise answer and there seem to be two camps of thought.  One in which 
anticoagulation is discontinued after 6 months, especially if the patient has received 
curative therapy) or the other in which patients are treated indefinitely (particularly if 
they still have an active cancer burden).  The cost-benefit ratio for either of these 
approaches has not been properly calculated and guidelines will therefore be based 
more on expert opinion than randomised trial evidence.   
 
3.3.7 Prophylaxis of Venous Thromboembolism in Cancer 
Patients with Central Venous Catheters 
The literature on which the WARP trial was based and the emerging evidence on 
anticoagulation in cancer patients with CVCs is outlined in the discussion (section 
6.2.6.1), as background to the meta-analyses of thromboprophylaxis in cancer 
patients with CVCs.   
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4. Methods 
4.1   Survey of UK Practice of Thromboprophylaxis for 
Cancer Patients with CVCs (Pre-trial Survey) 
In May 1999, a postal questionnaire with a pre-paid envelope was sent out to 769 
cancer clinicians and nurses, targeted through previous participation (i.e. selected 
population) in large-scale national trials of cancer chemotherapy.  Clinicians who did 
not have personal experience of using catheters for the administration of 
chemotherapy were asked in the covering letter to pass questionnaires onto 
interested colleagues.  This was a single postal survey and non-responders were not 
followed up due to postal costs and lack of efficiency in phoning clinicians.  The 
survey consisted of a semi-structured questionnaire with nine main questions, five 
tick box categories and four open text sections for answers on types of catheters 
and drugs used, cancer sites and any other comments (Appendix 1).  Respondents 
were asked about their current clinical practice, an estimate of incidence of 
thrombosis in their cancer patients, whether thrombosis in patients with central 
venous catheters (CVCs) receiving chemotherapy, represented an important clinical 
problem and also their confidence (certain or uncertain) in the thromboprophylactic 
use and dosage of warfarin.  
 
Results were collated using a bespoke relational database (Microsoft Access) which 
enabled the analysis to be performed.  These are summarised using descriptive 
statistics.  A Wilcoxon rank sum test (used for a non-parametric comparison of two 
groups, making no assumptions on the underlying distribution) was utilised to 
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compare clinicians who documented that they used warfarin versus those who used 
no warfarin in practice for thromboprophylaxis in cancer patients with CVCs. 
4.2 WARP Trial  
The aims and outcomes for the WARP trial, taken directly from the protocol, were 
stipulated as: 
4.2.1 Aims 
4.2.1.1 Primary:  
 To determine the utility of any warfarin in reducing CVC-related 
thrombosis rates in cancer patients 
 To determine whether variable dose warfarin is superior to fixed dose 
warfarin in reducing CVC thrombosis rates 
4.2.1.2 Secondary:  
 To assess warfarin-related toxicity and monitor the trial-related adverse events 
 To determine the effect of warfarin (fixed and variable dose) on total 
thrombosis rates 
 To compare survival of patients in the warfarin and no warfarin arms 
4.2.2 Outcomes 
4.2.2.1 Primary: 
 The number of catheter-related thrombotic events  
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4.2.2.2 Secondary: 
 The number of other thrombotic events 
 The duration of catheter patency 
 The frequency and severity of trial-related adverse events 
 The frequency of central venous catheter-related sepsis 
 Costs (dependent upon primary outcome):     
 trial-related outpatient, inpatient and GP attendances 
 diagnostic procedures for confirmation of thrombosis and  
 cost incurred by patients and patient preference for alternative 
management options  
 Patient survival 
 
4.2.3 Trial Design 
WARP was structured to encompass contemporary clinical opinion noted from the 
pre-trial survey described above.   A randomised, phase III trial was chosen to 
assess the role of warfarin in the prophylaxis of catheter-related thrombosis in 
cancer patients having chemotherapy via a central venous catheter (CVC).  The UK 
has promulgated the concept of large, pragmatic trials, designed to give clear 
answers to clinically relevant questions.  The proponents of this approach to clinical 
trials stress that focussing on data collection of the key outcome measures, 
reduction in extraneous data input and recruiting sufficient subjects to give a greater 
degree of power and reliability, is more likely to deliver practice-changing science 
(Yusuf et al, 1984).  The design of the trial was based on the principle of uncertainty 
i.e. if the clinician is certain or uncertain of the indication for the intervention, they are 
able to randomise to their preference (Freedman, 1987). This was an attempt to be 
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inclusive and provide a trial design which would allow clinicians to interpret the 
current literature in their own way and contribute patients to the trial question which 
they felt was the most relevant to their practice and the individual patient.  The 
survey demonstrated three groups of clinicians with strongly-held views; those who 
give no warfarin; those who give 1mg of warfarin daily and those who anticoagulate 
further, to a target INR.  The trial design chosen therefore was able to accommodate 
these three opinions with two questions in one linked trial: does warfarin add benefit 
or not in comparison to no warfarin in thromboprophylaxis in cancer patients with 
CVCs and, if so, what is the optimal dose of warfarin to use?  This trial design, 
based on the principle of uncertainty, had been utilised successfully in the UK in a 
trial of 8,000 patients, „QUASAR‟, a comparison of adjuvant chemotherapy vs control 
and optimal chemotherapy regime for patients with colorectal cancer (Kerr et al, 
2000).   QUASAR adopted a pragmatic trial design, with local clinical teams 
categorising patients as having either a clear or an uncertain indication for adjuvant 
chemotherapy. The indication for chemotherapy was decided by each patient's 
clinician, after consultation with the patient, rather than by any per-protocol 
definition.  This design was adapted for WARP, in response to the national clinical 
survey and a desire to develop a pragmatic study that could be supported by the 
majority of clinical sites in the UK and therefore enhance recruitment.  This design 
also allows some patients to contribute to both comparisons (Figure 4.2.3.1).   
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Figure 4.2.3.1   WARP Trial Design I 
(based on the principle of uncertainty) 
 
 
 
 
 
 
In WARP, clinicians who were „uncertain‟ of the benefits of warfarin for 
thromboprophylaxis, could randomise patients to no warfarin,  fixed dose warfarin at 
1mg per day (FDW) or dose adjusted warfarin (DAW) daily, to maintain the 
international normalised ratio (INR) between 1.5 and 2.0.   Clinicians who were 
„certain‟ of the benefits of warfarin, could randomise patients to FDW or DAW.   All 
preferences were those of the clinicians after consultation with the patient.   
 
4.2.3.1 Blinding 
The blinding (or masking) of an observer or patient so that neither can identify the 
assigned treatment is the ideal way of avoiding biased measurement (by the 
observer) or reporting (by the patient).  This was not feasible in WARP as the 
treatments are generally distinguishable by the international normalised ratio (INR) 
[prothrombin time ratio] which must be made known to the assessor and the patient 
to treat accordingly to minimise bleeding and keep within range for the dose 
adjusted warfarin arm.  Therefore, an open-label randomised trial was chosen as 
placebo-control was difficult to execute.  The clinicians and the study patients were 
aware of the group to which they were assigned and different coagulation test (INR 
Uncertain Certain 
Control Warfarin Fixed Dose Dose Adjusted  
randomise 
randomise 
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or prothrombin time ratio) monitoring guidelines were in place as per protocol for 
different arms of the study.  
4.2.3.2 Trial Design Amendment 
Initially, the „uncertain indication‟ preference had three arms as described above; no 
warfarin versus FDW versus DAW.  However, investigators subsequently requested 
that a two arm option of no warfarin vs FDW be included.   There were two important 
reasons for this: firstly, patients randomised to DAW were monitored more closely, 
as recommended by the guidelines issued, in order to maintain their INR between 
1.5 and 2.0.   However, in some centres it proved difficult to monitor those on DAW, 
as patients often were reluctant to make extra journeys to anticoagulation clinics and 
clinicians were not always available to ensure vigilant monitoring and to change the 
warfarin dose, if appropriate.   The trial design was amended accordingly by the 
steering committee after 378 patients had been randomised into the trial; 141 to 
uncertain three arm comparison and 245 to the certain preference group.  
After this design amendment, clinicians had three different randomisation options to 
choose from depending on whether they were certain or uncertain of the benefits of 
warfarin and depending on whether they and their patients were willing to be  
entered into the dose adjusted warfarin arm (for uncertain indication).  Figure 4.2.3.2 
outlines the final trial design with Figure 4.2.3.3 showing the changes in trial design 
over time. 
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Figure 4.2.3.2 Final WARP Trial Design II 
With principle of uncertainty  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Warf – Warfarin;  FDW – Fixed Dose Warfarin (1mg daily);  
DAW – Dose Adjusted Warfarin (to maintain INR between 1.5 and 2.0) 
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Figure 4.2.3.3 WARP Trial Design Adaptation over Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
FDW – Fixed Dose Warfarin;  DAW – Dose Adjusted Warfarin 
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The final design enabled six key hypotheses to be tested:  
Hypothesis 1:  
Does warfarin (any dose) reduce the incidence of catheter-related thrombosis 
(CRT)?     Endpoint, catheter-related thrombosis (CRT) 
 
Hypothesis 2:  
Is DAW superior to FDW in terms of reducing the incidence of CRT?    
Endpoint, CRT 
 
Hypothesis 3:  
Does warfarin (any dose) reduce the incidence of any thrombotic events? 
Endpoint , all thrombotic events 
 
Hypothesis 4: 
Is DAW superior to FDW in terms of reducing the incidence of any thrombotic 
events?     Endpoint, all thrombotic events 
 
Hypothesis 5:  
Does warfarin (any dose) improve overall survival compared to control? 
Endpoint, overall survival 
 
Hypothesis 6: 
Is DAW superior to FDW in terms of improving overall survival? 
Endpoint, overall survival 
 
Only randomised comparisons were used to infer results, no cross group 
comparisons were performed in any of these analyses.  
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4.2.4 Patient Eligibility 
All patients, aged 16 years or over, who were having a CVC inserted for 
administration of cytotoxic therapy, were eligible for the WARP trial.  All makes of 
catheter for both central and peripheral placement for anticancer therapy, were 
acceptable. 
4.2.4.1 Inclusion Criteria 
 Histologically or clinically confirmed diagnosis of cancer 
 Patients who are due to have a CVC inserted for administration of 
chemotherapy 
 Aged at least 16 years 
 Adequate haematological function (recommended levels – haemoglobin 
(Hb) > 10g/dl, white cell count (WCC) > 2x109/l, platelets > 100 x109/l) 
 Adequate hepatic and renal function – as determined locally 
 Able to provide written informed consent 
4.2.4.2 Exclusion Criteria 
 Patients with contraindication to warfarin (including congenital bleeding 
disorders, anatomic lesions that bleed e.g. duodenal ulcers and profound 
concomitant therapy interaction) 
 Patients currently on warfarin 
 Patients who have previously been entered into WARP 
 Use of CVC for additional purposes with the exception of antibiotic therapy 
and blood products 
 Pregnant or lactating women 
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4.2.5 Treatment Plan 
4.2.5.1.1 Overview 
All types of CVCs were permitted in the study; the correct position of the catheter tip 
(at the junction of the superior vena cava and the right atrium – Figure 3.6.3.2) was 
checked by chest X-ray post CVC insertion.  Randomisation and start of warfarin, if 
allocated, was permitted from 3 days prior to CVC insertion (to enable sufficient 
exposure to warfarin for the immediate post insertion period).  Warfarin was taken 
daily until thrombosis or catheter removal for any reason and could be temporarily 
discontinued in the face of thrombocytopenia (platelets50x109/L).  
Recommendations for monitoring warfarin therapy by carrying out the „INR‟ 
(prothrombin time ratio) blood test were contained in the protocol for all treatment 
arms and treatment of venous thromboembolism (VTE) was carried out according to 
local practice.   All other patient management was as per standard practice for the 
local centre.    The simple trial plan from the protocol is shown in Table 4.2.5.1. 
Table 4.2.5.1 Trial Plan from the WARP Protocol 
Pre-
screening 
tests 
Randomise, 
if possible 
 
Warfarin 
(arms B&C)  
Commences 
Catheter 
Insertion 
(if INR < 1.3) 
 
-7 to 0 days 
 
-7 to 0 days 
 
-3 to 0 days 
 
Day 0 
 
Patient 
monitoring 
during trial*  
Catheter withdrawal 
or thrombosis 
Follow-up  1 year data 
follow-up 
 
 
 
End of primary 
evaluation period 
As per local 
practice  
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4.2.5.1.2 WARP Catheter Care Guidelines 
Regardless of the CVC utilised, the principles of catheter care remain the same.  
High quality catheter care is crucial to minimising thrombosis, infection and other 
catheter complication.  The specialist teams caring for patients with CVCs were 
asked in the protocol to follow the manufacturer‟s instructions for the care of the 
specific catheter.  However, around 20 enquires were made by trial centre nurses for 
guidelines for the care of central venous catheters and these were then developed - 
the „WARP Catheter Care Guidelines‟.  These were published in 2000 and updated 
twice in 2002 and 2004 as new data emerged e.g. in late 2000, synerkinase 
replaced urokinase for thrombolysis therapy due to the withdrawal from the market 
of the latter because the manufacturers did not take adequate steps to test for 
infection in, or prevent contamination of, the kidney cells used to manufacture the 
drug (US Food and Drugs Administration, 1999).  The WARP Catheter Care 
Guidelines were adapted from the Vascular Access Devices chapter of The Royal 
Marsden Hospital Manual of Clinical Nursing Procedures, 5th edition, 2000 
(Dougherty, 2000) with permission from the author [Appendix 2]
4.2.6 Analytical Plan 
4.2.6.1 Outcome Measures 
In order to meet the aims and objectives of the trial (section 3.2.1), the following 
outcomes were measured: 
 The number of catheter–related thrombotic events  
 The number of other thrombotic events 
 The duration of catheter patency 
 The frequency and severity of trial-related adverse events 
 The frequency of central venous catheter-related sepsis 
 Death 
 Combination of bleeding plus thrombotic events 
The final outcome measure was added during analysis of the trial.  As thrombosis 
and bleeding events were the two major adverse outcomes associated with central 
venous catheters and anticoagulants, it was felt that the effect of treatment on this 
composite endpoint would provide a more integrated approach to examine the 
disbenefit of bleeding versus the benefit of thromboprophylaxis.  Clearly, the optimal 
situation would be a statistically significant reduction in thrombosis with treatment 
and a low bleeding rate.  However, if the bleeding rate was sufficiently high to render 
the composite endpoint (which is clinically more important) statistically neutral, then 
this could be interpreted to mean that the therapeutic gains made by reduction in 
thrombosis rates would be offset by the adverse outcome, the bleeding.   
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4.2.6.2 Categorisation, Grading and Assessment of Thrombosis 
A thrombosis was categorised as non-catheter-related if was: 
 arterial; or 
 located in the leg; or 
 known to occur on the opposite side to the catheter; or 
 occurred >5 days post catheter removal 
Thromboses were only valid if they were radiologically confirmed.  All thromboses 
were reviewed and classified as primary or secondary by the principal investigator 
and an independent second observer following a set of rules, agreed by the steering 
committee, outlined in Table 4.2.6.1: 
Table 4.2.6.1   Categorisation of Thromboses 
Primary Thrombosis Secondary Thrombosis 
Arm (Catheter Side) Arm (non-catheter side) 
Axillary Vein Leg DVT 
Internal Jugular Vein Arterial 
Subclavian Vein Internal Vena Cava 
Superior Vena Cava Pulmonary Embolus with no documented 
catheter complications 
Pulmonary Embolus with documented 
catheter complications 
 
 
Where the catheter side data were unknown (this information was not requested 
until 20 months after the start of the trial – amendment 2; Table 4.2.7.1), and where 
relevant (e.g. not in the case of PEs), these were assumed to be on the same side 
as the thrombosis.  The steering committee advised that upper extremity 
thromboses are extremely rare when there is no catheter present and are highly 
likely to be catheter-related thromboses.   Where the thrombosis side data were 
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unknown, these were assumed to be on the same side as the catheter for the same 
reason.  Catheter related and other thromboses (primary and secondary endpoints) 
were radiologically confirmed by venogram, ultrasound or ventilation-perfusion (VQ) 
/ Spiral CT and classified as CRT or non-CRT by two investigators, blinded to 
treatment allocation, using a central protocol. Thromboses that were suspected but 
not radiologically confirmed were recorded under CVC complications.    Thromboses 
were graded according to the Common Toxicity Criteria (CTC) (National Cancer 
Institute, 1999) [Table 4.2.6.2]. 
Table 4.2.6.2  Grading of Phlebitis / Thromboembolic Events 
Toxicity 0 1 2 3 4 
Arterial none - - Transient 
events 
Permanent 
Events 
Venous none Super-
ficial 
DVT not requiring 
anticoagulation 
DVT requiring 
anticoagulation 
Pulmonary 
Embolus 
 
Major bleeding episodes were defined as intracranial, retroperitoneal, requiring 
transfusion or hospitalisation or directly leading to death.  Increased INR was 
classified by the investigators as: mild (2<INR<5), moderate (5≤INR<8) or severe 
(INR8).    Dates of death were obtained from the CRFs or from the Office of 
National Statistics (ONS) in April 2007.  
 
4.2.6.3 Intention to treat 
ITT is based on the initial treatment intent and not the treatment actually given and 
therefore all patients who are randomised to the trial are counted in the analysis, 
whether they took the allocated therapy or not.  The analysis of toxicity data was 
done by ITT and not per protocol analysis.  The same ITT population was used for 
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the analysis of the combination endpoint of bleeding plus thrombosis.  A small 
number of unknown outcome patients were combined with those who did not have 
an event.  A sensitivity analysis was carried out to test the validity of this 
assumption.   Because major bleeding is life-threatening and all bleeding was found 
in the pre-trial survey to be one reason for clinicians to be hesitant about 
participation in the WARP Trial, an analysis of major bleeding was carried out 
restricted to only those patients who were known to comply with warfarin as well as 
in all patients.  One further analysis of time to CRT was not carried out on an ITT 
basis because of missing data which may have confounded an analysis performed 
on the ITT population.  The time to CRT analysis excluded 57 patients who had not 
had a thrombosis or had no data for thrombosis or not, plus no data for CVC 
removal.   
 
4.2.6.4 A Priori Patient Numbers 
The power function is the confidence with which the investigator can claim that a 
specified treatment benefit has not been overlooked.  The level of significance is an 
indication of the degree of plausibility of the „null hypothesis‟ i.e. thrombosis rates 
were the same in warfarin vs no warfarin arm.  If the null hypothesis is deemed too 
implausible, it is rejected and the „alternative hypothesis‟ that the treatments differ in 
their effect, is accepted.   Conventional significance level of 5% is a useful guide.  
The significance level, p, is the probability of obtaining a result at least as unlikely as 
the observed one if the null hypothesis of no effect is true.   
 
The thrombotic event rate for the control arm was estimated to be around 25%, 
using the published rates found in 1999, when the protocol was being developed: a 
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report (Bern et al, 1986), a historical study , a randomised trial with a low molecular 
weight heparin (LMWH) (Monreal et al, 1996) and a small randomised trial using low 
dose warfarin (Bern et al, 1990).   Treatment with warfarin was hypothesised to 
reduce this rate by 10%, i.e. down to 15%, which would be a medically worthwhile 
improvement.  With 800 patients entered into the uncertain indication part of the trial 
(400 no warfarin and 400 warfarin), there was greater than 90% power to detect a 
10% difference at a 2-tailed p-value of 0.05.  Differences between the two doses of 
warfarin were likely to be smaller than between warfarin versus not. With 1000 
patients randomised between warfarin doses (initially calculated as 400 from arms B 
and C in the uncertain indication group, and 600 from arms B and C in the certain 
indication group), there was 80% power to detect a difference of 7% in thrombotic 
event rates between the two doses (at 2p=0.05). It was unrealistic to base the 
sample size calculations on effects that were larger than this, but, if bigger than 
anticipated differences were observed during the course of the trial, accrual to the 
trial could be modified on the recommendation of the DMC.  The trial recruitment 
target for the primary endpoint gave approximately 90% power to detect (at 2p=0.05) 
a 10% difference in long term survival between the warfarin and no warfarin groups.  
This survival difference was extrapolated from the results of two small studies at the 
time, showing a trend towards a survival benefit for warfarin plus chemotherapy in 
comparison to chemotherapy alone (Maurer et al, 1997; Chahinian et al, 1989) 
 
4.2.6.5 Number of Patients - Protocol Amendment 
The trial was designed to recruit 1000 patients into the fixed versus adjusted dose 
treatment comparison.  As above, it was planned that 600 of these patients would 
originate from recruitment to the certain indication option and a further 400 patients 
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from the two warfarin arms of the uncertain indication. The trial design was changed 
in 2001 to allow 'uncertain' participants to randomise into either a two-arm option (no 
warfarin and fixed dose warfarin) or the original three-arm design. Patients 
randomised via the new uncertain two-arm option could not be included in the fixed 
versus dose adjusted comparison creating a shortfall in patients originating from the 
uncertain option.  This shortfall was addressed by increasing the target number of 
patients required from the certain indication option to an estimated 800 patients. 
 
4.2.6.6 Randomisation and Randomisation Procedure 
Randomisation is the only safeguard against selection bias – firstly, there can be 
neither unwitting or deliberate selection because there is no identifiable pattern in 
the process; secondly, it is an insurance, in the long run against accidental bias – 
the more patients entered, the larger the chance of patient characteristics being the 
same in every treatment group and lastly, the foundation for many statistical tests 
used in the analysis, is the premise that each patient could have received any one of 
the treatments allocated.  Unequal randomisation of 2:1:1 for no warfarin : FDW : 
DAW, was utilised to ensure the balance of the numbers of patients in the no 
warfarin vs any warfarin (FDW and DAW) comparison (Figure 4.2.3.2). 
 
Randomisation was executed via a computerised block algorithm and performed by 
randomisation officers at the central randomisation office in the departmental trials 
unit, accessed by telephone and fax.   The patient's name, their hospital, the name 
of the person randomising and the lead investigator with overall responsibility for the 
patient were documented and patient eligibility was checked before the treatment 
allocation was given out.   The date of the telephone call (or fax) is the date of 
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randomisation.  Details were then confirmed in writing to the person randomising, 
who then submitted a CRF1 or „on-study‟ form (parts A and B of CRF1) for the 
patient.   There was a back-up of paper randomisation forms in case of electronic 
failure.  
4.2.6.6.1 Timing of Randomisation 
The protocol stated that randomisation was possible from 3 days prior to CVC 
insertion to enable sufficient exposure to warfarin for the immediate post insertion 
period.  Permission to randomise up to 5 days after the insertion of the CVC was 
inserted was granted by the steering committee in July 2000 after requests by local 
coordinators who often discussed the trial with their patients after the CVC had been 
inserted at another centre.   Although not clinically ideal, as insertion of catheter may 
cause trauma to the vein with the potential of a thrombosis, this was within protocol 
wording and did not require an amendment. 
4.2.6.6.2 Stratification 
Stratification by factors known to affect thrombosis is a safeguard against a chance 
imbalance between treatment groups with respect to an important variable.   
Stratification was based on three thrombosis risk factors, each with two levels:  
 sclerosant potential of the cytotoxic regimen [low or high as defined in the 
protocol] (Salmon SE et al, 1998) 
 site of catheter insertion (peripheral or central) 
 duration of drug infusion (less than, or greater and equal to 24 hours; for 
duration of one chemotherapy cycle intravenous infusion).   
The stratification variables define 8 (2x2x2) different strata and separate treatment 
lists were created for each.  Lists of treatments were created using the method of 
random permuted blocks with a fixed block size of 12 for uncertain indication and 8 
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for certain indication.  This guarantees that the numbers allocated to each treatment 
are equal at the end of each block.    
The treatment lists were stored on computer and a computer programme was used 
to allocate the next treatment on the appropriate list.  
 
4.2.6.7 Interim analysis 
No patient should receive a treatment that has been established as inferior on the 
basis of substantial accumulated evidence and therefore interim analyses were 
planned, initially after 200 patients were entered and, subsequently, after 
approximately 500 more patients were recruited up to the target.   
 
4.2.6.8 Health Economics 
An academic health economist was recruited to be the health economics advisor for 
the WARP trial.  The protocol stated that a societal health economics perspective 
would be adopted such that costs incurred by both the NHS and patients themselves 
would be recorded.  Data on key elements of resource use, such as contacts with 
primary and secondary care, were requested on all trial patients.  Analysis was 
planned to be descriptive.  
 
4.2.6.9 Examination of INRs in one centre 
The steering committee suggested that in order to ascertain if the patients in the 
DAW arm were within INR range (1.5-2.0) and the patients in the FDW arm did not 
breach this range (i.e. the arms were indeed separate in practice), that INRs from 
high recruiting centres should be analysed centrally.  This analysis was, however, 
only possible for one centre, the highest recruiting centre, due to extra workload for 
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the local coordinators in collating and sending the INR data.  The local coordinators 
in this centre forwarded anonymised INR data values on paper to the principal 
investigator for analysis.   INR tests in this centre, were taken at baseline (prior to 
warfarin starting) and weekly for both FDW (1mg daily) and DAW; unless the result 
warranted more frequent monitoring patients receiving FDW, no further monitoring of 
this patient group was carried out.   In contrast, patients on DAW were monitored 
weekly until catheter removal of thrombosis.  The degree of differentiation between 
the two doses and, therefore, the interpretation of the primary outcome of the trial 
was examined, using descriptive statistics: 
 Adherence to range for the DAW arm (INR between 1.5 and 2.0) 
 Maintenance of the fixed dose warfarin arm below 1.5 as specified in the 
protocol 
 
4.2.6.10 Statistical Tests Utilised 
The analyses outlined below were performed using SAS statistical software (SAS 
Institute, SAS Circle, Cary, North Carolina, USA).  These analyses were carried out 
by the trial statistician, supervised by the author.  All frequency and descriptive 
analysis were performed using Microsoft Excel 2003 by the author. 
4.2.6.10.1 Comparison of rates of thrombotic events 
Rates of thrombotic events were compared using the Mantel Haenszel 2 test.  This 
is a test suitable for testing the null hypothesis (no treatment effect) between two 
dichotomous variables – in this case, outcome (thrombotic event or no thrombotic 
event) and treatment [warfarin or no warfarin (or DAW or FDW)].   Therefore, the 
data consisted of several 2x2 tables (variables with two possible values) in order to 
compare treatment rates. Differences were expressed between treatments as 
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relative risk (RR) with 95% confidence intervals (CIs).    The analysis was done on 
an intention-to-treat basis, with a small number of unknown-outcome patients 
combined with those who did not have an event.  Therefore, radiologically confirmed 
thrombotic events were compared with no thrombotic events plus thrombotic event 
outcomes which were „not known‟.  
4.2.6.10.2 Survival Analyses 
Survival analysis applied to both catheter patency (survival) and death.   Catheter-
related events were analysed as time to event data with time to thrombosis censored 
at date of CVC removal in those patients without an event.  The duration of catheter 
patency was calculated as the time from catheter insertion to a thrombotic event; 
CVC complication or CVC removal for those patients without an event.   However, if 
there was no CVC removal date or thrombosis date, these patients were excluded 
from the analysis; this analysis was therefore not ITT.  Patient survival time was from 
date of randomisation to the date of death or censored at the date the patient was 
last seen alive; the unknown-outcome patients were combined with those who were 
still alive.  For the WARP trial, it was not possible to follow up all patients until death: 
firstly, some patients were lost to „follow-up‟ for various reasons and, secondly, those 
entered into WARP towards the end of the study had only been followed up for 10 
months when the analysis was carried out.   
 
In analysing survival data, two functions that are dependent on time are of particular 
interest:  i) the survival function S(t) is defined as the probability of surviving to at 
least time t and ii) the hazard function is the conditional probability of dying at time t 
having survived to that time.  The graph of S(t) against t is called the survival curve.  
The statistical significance of any difference observed in a comparison of two 
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survival curves, was assessed by Kaplan Meier estimation (Kaplan EL and Meier P, 
1958) and the log rank test.  The Kaplan Meier estimator is the non-parametric 
likelihood estimate of the probability that a person from the WARP population will 
have a lifetime exceeding certain timepoints.  The number „at risk‟ just prior to time 
these timepoints and the number of deaths at timepoints are calculated.  The log 
rank test is a special application of the Mantel-Haenszel 2 procedure, carried out by 
constructing a separate 2 x 2 tables for each interval in order to compare the 
proportions dying in each interval but does not allow for other explanatory variables 
to be taken into account.  Cox‟s proportional hazards model is analogous to a 
multiple regression model (section 4.2.6.9.5.1) and enables the difference between 
survival times of particular groups of patients to be tested whilst allowing for other 
factors.  In this model the response (dependent) variable is the hazard function.  The 
hazard function describes the instant probability of dying given at a particular time 
that patients have survived up to that point.  
4.2.6.10.3 Comparison of Time to thrombosis in patients with an 
event 
A Wilcoxon Rank Sum Test, comparing a group against a hypothetical median, tests 
whether the two groups have equally large values without assuming any particular 
distribution (e.g. normal) [section 4.1].  This test was used for the comparison of the 
time to thrombosis in patients with an event.   
4.2.6.10.4 Comparison of major and minor bleeding episodes 
The Fisher‟s exact test was used to compare i) major (and minor) bleeding episodes 
between arms and ii) the randomised comparison of thrombotic events between 
FDW vs DAW.  This test is utilised for the comparison of two treatment regimes 
where the number of events is small.  The Fisher‟s exact test is based on calculating 
111 
the exact probabilities of the observed results and more extreme results that could 
occur by chance. 
4.2.6.10.5 Exploratory Prognostic Modelling 
4.2.6.10.5.1 Predictors of All Thromboses 
Logistic regression allows both the inclusion of explanatory variables and the 
assessment of interaction between the variables.  Logistic regression investigates 
the linear dependence of the logistic transformation of the proportion on several 
explanatory variables (e.g. heparin flush data, age, catheter type) where: 
the logistic transformation or log odds   =     loge 
 
 
Thrombosis was treated as a binary outcome.  The risk factors were treated as 
categorical and dummy variables were created for each category. A separate 
category was created for missing data for each variable, and a dummy variable was 
created for this category and was included in the regression analyses. This category 
(missing data category) was never chosen to be the referent group for any of the 
analyses.   Initially, pre-specified baseline factors were investigated univariately; a 
multivariate logistic regression was then conducted, using stepwise selection 
methods set at the 0.05 alpha level.   The risks for thrombosis were expressed as 
odds ratios (OR), with corresponding 95% CIs.  Due to an imbalance within factors, 
some of the factor groupings were combined for analysis.  
proportion 
1 -proportion 
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4.2.6.10.5.2 Predictors of Catheter-related Thromboses 
A second logistic regression analysis was performed to identify potential predictors 
of CRT which included catheter-related variables.   A total number of 1547/1590 
patients had complete CVC data and were included in analysis, of these 85 patients 
had suffered a CVC-related thrombosis.  Explanatory variables included 
catheter placement (central vs peripheral), treatment length (<24 vs 24 hours) and 
sclerosant potential of chemotherapy (high vs low).  CVC information was also 
considered, CVC lumen (single vs double/triple), CVC material (silicone vs other), 
type of CVC (valved vs non-valved), CVC size (<4 and 4).  Forward, backward and 
stepwise regression techniques were applied; a 10% significance level was used for 
entering and removing the model.  
4.2.6.10.5.3 Correlation between Number of Venous Thrombotic 
Events and Study Sample Number 
In the collation of all studies investigating catheter-related VTE (Section 3.6.3.1), a 
Spearman‟s Rank Correlation Test was utilised to measure the statistical 
dependence (strength of the relationship) between the number of VTE events and 
study sample size.  Spearman‟s rank correlation coefficient is used as a measure of 
linear relationship between two sets of ranked data (how tightly the ranked data 
cluster around a straight line).  A correlation of +1 or -1 will arise if the relationship 
between the two variables is exactly linear.  A correlation close to zero means there 
is no linear relationship between the ranks (Altman, 1991).  
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4.2.7 Trial Management 
4.2.7.1 Ethical Considerations 
The WARP protocol stated that the trial would be carried out, „in accordance with the 
principles laid down by the 18th World Medical Assembly, Helsinki, 1964 (RICKHAM, 
1964; World Medical Assembly, 1964) and subsequent amendments.  This 
document, of which the 1996 and 2000 updates were pertinent to WARP, provides 
the ethical foundation of all subsequent European and International Directives.  
Whilst WARP was recruiting, on the 4th April 2001, The Clinical Trials Directive 
(2001/20/ EC) of the European Parliament and of the Council, was introduced for 
member states.   The Medicines for Human Use (Clinical Trials) Regulations 
followed this in the UK, in May 2004, „transposing‟ the European Clinical Trials 
Directive into law. These directives and legal documents relate to the 
implementation of good clinical practice (GCP) in the conduct of clinical trials on 
medicinal products for human use, aimed at maintaining an appropriate level of 
protection for patients.  They seek to simplify and harmonise the administrative 
provisions governing clinical trials, by establishing clear and transparent procedures 
including:  i) international recognised principles of good clinical practice (GCP); ii) 
good manufacturing practice (GMP); iii) GCP and GMP inspections and 
enforcement; iv)  protection of incapacitated adults; v) protection of minors and  
vi) stringent pharmacovigilance arrangements.  Although these procedures were not 
in place when WARP was initiated in the summer of 1999, the principles were 
recognised by the WARP trial management group, familiar with the Declaration of 
Helsinki.   From April 2001, the documentary evidence to comply with the Clinical 
Trials Directive was collated; the WARP trial, „A Multicentre Prospective 
Randomised Controlled Trial of Thrombosis Prophylaxis with Warfarin in Cancer 
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Patients with Central Venous Catheters‟ was registered as an International Standard 
Randomised Controlled Trial, number 50312145.   The above regulatory documents 
and guidelines provided the framework for WARP trial teams to perform to optimal 
standards for the protection of their patients.   
4.2.7.1.1 Informed Consent 
The principles of the informed consent process for WARP and all other clincial trials, 
supported by the directives and guidances in section 4.2.7.1, were expected to be 
followed by all participating trials teams, who may be subject to monitoring by 
national or international auditors.  The principles adhered to are as follows:   The 
voluntary consent of the human subject is absolutely essential;  this means that the 
person involved should have legal capacity to give consent; should be able to 
exercise free power of choice and should have sufficient knowledge and 
comprehension of the elements of the subject matter involved, to enable them to 
make an understanding and enlightened decision.  Therefore the nature, duration, 
and purpose of the trial; the method and means by which it is to be conducted; all 
inconveniences and hazards reasonably to be expected and any effects upon their 
health or person which may possibly come from their participation, need to be 
explained.   
 
The duty and responsibility for ascertaining the quality of the consent rested upon 
the WARP trial team and the participating lead investigators and coodinators who 
initiated, directed or engaged in the trial.  It is a personal duty and responsibility 
which may not be delegated to another with impunity (Nuremburg Code, 1947).  
After entry, the patient must be free to withdraw from trial treatment at any time 
without giving reason or prejudicing further care. The physician (Declaration of 
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Helsinki, Section 1.9). or other delegated person (Clinical Trials Directive 2001) 
should then obtain the subject's freely given informed consent, preferably in writing.  
The local investigators were therefore responsible for obtaining informed consent in 
compliance with the above requirements, from each patient prior to entering the trial.  
In addition to verbal information, the patients were given sufficient time to read and 
comprehend the written information and to ask questions if necessary before making 
their decision. An example from the three Patient Information Sheets [uncertain (3-
arm and 2-arm options) and certain preference for warfarin therapy] is included in 
Appendix 3.  The Patient Consent Form is shown in Appendix 4.   
4.2.7.1.2 Nurses Taking Informed Consent 
During the course of WARP recruitment (October 1999 to December 2004), a 
number of specific informed consent procedures were updated and issued as part of 
the regulatory and guideline procedures in section 4.2.7.1.  Due to the many 
different local rules for nurses taking informed consent in the participating centres, 
the principal investigator gathered the growing literature on consent and produced 
„Guidance for nurses; Informed Consent for the WARP Trial‟, in November 2001. 
Because WARP was a nurse-led oncology trial and was then pushing the 
boundaries for nurses obtaining informed consent as sole signatories, WARP 
guidance for nurses obtaining informed consent was developed and sent to 
participating research nurses (Appendix 5).   
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4.2.7.1.3 Ethics Committees Approval  
The trial was submitted on a standard form to the West Midlands Multicentre 
Research Ethics Committee (MREC) in July 1999 and approved in September 1999 
via a letter to the principal investigator.   There was one change in the patient 
information sheets (PISs) required before approval, namely the addition of some 
expanded contraceptive advice for patients and partners.  This was added to the PIS 
and a final approval letter of Protocol Version 3 was received in September 1999. 
 
The local coordinators then submitted this protocol and case record forms (CRFs) on 
their headed notepaper to their Local Research Ethics Committee on an MREC 
form, Annexe A, and were then requested to forward  a copy of the LREC letter of 
approval, signed by the LREC Chairman, to the WARP Trial Office, prior to the start 
of recruitment.    
4.2.7.1.4 Protocol Amendments 
There were five were protocol amendments during the trial.  These are 
acknowledged, where appropriate, in relevant sections and summarised below in 
Table 4.2.7.1. 
Table 4.2.7.1 WARP Protocol Amendments 
Amendment  
No. 
Protocol 
Version  
Date 
Submitted 
Summary of Amendment 
1 3   
post-
amendment 
5th May 2000 Additions to CRF1, 2 and 3 to improve the quality of data collected:  
CRF1; Will the patient be on any form of heparin whilst on WARP?  
CRF3; monitoring of all thrombotic events (check), „Has patient had a 
thrombosis?     No/Yes:  Date of thrombosis:  Location of thrombosis:      
Deletion in Patient Information Sheets (PISs) -. „half of the doctors and nurses 
in the UK regularly prescribe warfarin‟ as Scottish nurses did not then do so. 
2 4 
 
28th March 
2001 
Addition on CRF1 and CRF2 of whether the catheter and the thrombosis 
respectively was on the left or right side.   Trial design change to include  
no warfarin vs 1mg warfarin arm.  New figure in protocol. 
3 5 
 
20th January 
2003 
Change to duration of study in protocol:  Protocol page 6, Study Duration, „The 
planned study initiation is October 1999; completion around September 2004‟. 
4 6 16th July 2003 Change in contact details and updated personnel in protocol 
5 7 2nd December 
2003 
PIS: Contraceptive advice changed to, “If you are allocated warfarin and become 
pregnant, you must contact your doctor to arrange to stop the warfarin as soon 
as the pregnancy is confirmed, as warfarin can damage the baby in the first part 
of pregnancy;  protocol deletion of exclusion criterion: “Fertile persons not taking 
adequate contraceptive measures”. 
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4.2.7.2 Regulatory Considerations 
4.2.7.2.1 Trial Monitoring 
Monitoring is defined as „the act of overseeing the progress of a clinical trial, and 
of ensuring that it is conducted, recorded and reported in accordance with the 
protocol, Standard Operating Procedures, GCP and the applicable regulatory 
requirements‟ (MHRA, 2010).   The determination of the extent and nature of 
monitoring should be based on considerations such as the objective, purpose, 
design, complexity, blinding, size and endpoints of the trial.  There was no 
external on-site or central monitoring requested for WARP.   However, other 
University of Birmingham Cancer Research UK Trials Unit studies were 
externally monitored during this period and although WARP was not identified as 
one of trials to be examined in detail, all trials in the unit were prepared for 
inspection.   The internal monitoring approach for the WARP trial was as follows: 
4.2.7.2.1.1 WARP Trial Management Group 
The Trial Management Group included those individuals responsible for the day-
to-day management of WARP - the principal investigator (PI), statistician and the 
trial coordinator - and they met weekly with e-mail communication in-between. 
The group monitored all aspects of the conduct and progress of the trial, 
ensuring that the protocol was adhered to and took appropriate action to 
safeguard participants and the quality of the trial itself.  Day-to-day monitoring by 
the PI and the trial coordinator typically included the following checks, that: 
•   data collected are consistent with adherence to the trial protocol 
•   CRFs are only being completed by authorised personnel; no key data are 
missing 
•   data appear to be valid (for example, range and consistency checks) 
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•   recruitment rates are appropriate, withdrawals and losses to follow-up overall 
and by clinical site are documented 
4.2.7.2.1.2 The Steering Committee 
Sixteen experts in the field of clinical trials and thromboprophylaxis in cancer 
patients, were invited by the principal investigator to sit on the WARP Trial 
Steering Committee, prior to protocol development.   They WARP Trial Steering 
Committee provided overall supervision of the trial and ensured that it was being 
conducted in accordance with the principles of GCP.   There were five steering 
committee face to face meetings with full reports prepared by the trial 
management team:  8th March 2001, 13th March 2002, 15th October 2002,  
18th September 2003 and 24th June 2004.   The trial steering committee reports 
included feedback from the data monitoring committee if appropriate, new 
literature, overall, per centre and per lead investigator recruitment, data 
completion and quality, patient characteristics and compliance, adverse events, 
serious adverse events and overall thrombotic rate.   
4.2.7.2.1.3 Independent Data Monitoring Committee 
The role of the WARP Data Monitoring Committee (DMC) was to review the 
accruing trial data and to assess whether there were any safety issues that 
should be brought to investigators‟ attention or any reasons for the trial not to 
continue.   The DMC was independent of the investigators and the funders and 
was the only committee that had access to unblinded data.   There were three 
national experts in thrombosis, cancer or trials on the DMC, chaired by a 
Professor of Statistics.  There were four DMC meetings throughout the trial –  
26th February  2002, 30th September 2002, 28th January 2003 and February 12th 
2004, each confidential with an open and closed component and report.  The 
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closed component contained a discussion of the interim analysis of unblinded 
data with the trial statistician in discussion with the DMC members.  The formal 
open report contained: 
 Literature Update – new relevant randomised controlled trials, related and 
unpublished studies 
 Actual and target recruitment by indication, treatment and randomisation 
strata.  Recruitment by centre and lead investigator 
 Centres with approval, time from LREC  approval and centres awaiting 
approval 
 Case Record Form return rates and quality 
 Overall patient baseline characteristics, compliance, timing and duration of 
warfarin with reasons for stopping early and catheter patency data 
 Toxicity and serious adverse events 
 Overall frequency of thrombotic events and location of events 
 Overall survival 
 Reasons for rejecting event as a serious adverse event (SAE) [only 
toxicity that could be associated with warfarin was required and the expert 
clinical advisors transferred non-SAE events as defined in the protocol to 
the correct data field e.g. thrombosis and toxicity] 
The closed report incorporated the additional unblinded WARP analysis. 
The notes from the open DMC committee meeting were shared with the steering 
committee. 
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4.2.7.3 Data Handling 
In order to collect the key data but keep the task of form completion as simple as 
possible thereby hoping to increase the comprehensiveness of data return, three 
one-page CRFs were designed - baseline, primary evaluation period (from 
randomisation to catheter removal or thrombosis) and follow up (one year post 
randomisation or death) [Appendix 6].  These were requested to be returned at 
certain time points (Table 4.2.7.2).  For the same reasons, follow-up data were 
only requested from centres at one year from randomisation.   Survival data not 
obtained on the CRFs were obtained from the Office of National Statistics. 
Randomisation data were entered on-line by the randomisation officers at time of 
randomisation and data were „cleaned‟ (investigate missing data and outliers) by 
the trial coordinator and the author.  A standard letter for missing data, identifying 
the missing section, was sent to relevant coordinators on two occasions and then 
followed up by a phonecall, should the data not have been sent.  If still no data 
were forthcoming, the case was generally closed and noted as missing data with 
the exception of two data fields – has the patient had a thrombosis and is the 
patient still alive?   These two crucial data fields were pursued vigorously by 
personal phonecalls to the local investigators. 
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Table 4.2.7.2 (from protocol)  Trial Plan with Case Record Form Return Schedule 
Pre-
screening 
tests 
Randomise, 
if possible 
 
Warfarin 
(arms B&C)  
commences, 
if possible 
Catheter 
Insertion 
(if INR < 1.3) 
Patient 
monitoring 
during trial*  
Catheter 
withdrawal or 
thrombosis 
Follow-up*  One year  
follow-up 
(for 
survivors) 
 
-7 to 0 
days 
 
-7 to 0 days 
 
-3 to 0 days 
 
 
Day 0 
 
 
 
End of primary 
evaluation 
period 
  
 CRF1 
randomisation 
details 
completed 
 CRF1 
completed 
and sent to 
study office 
 CRF2 
completed 
and sent to 
study office 
CRF3 
completed 
and sent to 
study office if 
patient dies 
CRF3 
completed 
and sent to 
study office 
CRF – Case Record Form;   * as per normal practice for institution;  
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4.2.7.3.1 Adverse Event Reporting  
Adverse events which were trial-related i.e. due to warfarin or to thrombosis were 
collected at the end of trial on CRF2.   The Common Toxicity Criteria (National 
Cancer Institute, 1999) was chosen as the grading system for adverse events.   
In the case of a Serious Adverse Event (SAE) - i.e. any untoward medical 
occurrence that is fatal, life threatening, disabling/ incapacitating, requires 
hospitalisation or is an overdose - believed to be due to trial therapy (i.e. 
warfarin) [or bleeding in no warfarin arm], the local investigator was asked to fill 
out an SAE form and send within 24 hrs, preferably by fax, a signed and dated 
SAE form to the WARP Study office (the clinical trials unit).  In the case of death 
or life-threatening events, investigators were asked to phone the trials office in 
office hours or a hospital switchboard out of hours, in order to notify the principal 
investigator.  In the case of a trial-related SAE, surviving patients were followed 
up until clinical recovery was complete or until death occurred.  This information 
was relayed to the WARP office at resolution of the serious event or death by 
faxing an SAE form and ticking the box marked „follow-up‟.   SAEs that were not 
considered to be related to warfarin did not need to be reported on an SAE form.  
Two expert clinical advisors reviewed all SAEs, rejected non-SAEs and agreed 
the rejected SAEs with the local coordinators who had originally sent the data.  
These were then transferred to the accurate category e.g. thrombosis or toxicity.   
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4.2.7.4 Database and Construction 
The case record and adverse event forms were created by the principal 
investigator on an electronic template.  Initially, the fields were transferred on to a 
password protected relational database (Access 2000) for data input by the 
WARP trial coordinator.   In November 2001, when 584 patients had been 
randomised, an electronic shared SQL (Structured Query Language) relational 
database for all ongoing trials at the Clinical Trials Unit in Birmingham was 
created by the programming team and WARP data were transferred to this 
electronic data capture system.   SQL is the International Organization for 
Standardization (ISO) standard language used for creating, updating and 
querying relational database management systems and therefore compatibility 
and consistency were ensured.  The new system enabled quick and secure data 
entry and storage.  
 
4.2.7.5 Trial Funding  
The trial was funded by the Medical Research Council (MRC) [clinical fellowship 
for the author] and Cancer Research UK (CRUK) [trial coordinator salary].  The 
author applied successfully to both charities for the funding.  The MRC or CRUK 
had no role in study design, data collection, data analysis, data interpretation or 
writing the ensuing publications.    
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4.2.7.6 Building and sustaining the trials network 
4.2.7.6.1 Centre Visits 
Patients from centres in the UK with nursing teams dedicated to catheter care 
including those who indicated interest in the pre-trial survey, were approached by 
post, telephone and e-mail to participate in the trial.  A personal visit was made to 
interested clinicians and trials teams at their UK cancer centres, prior to the start 
of recruitment at the centre.  Sixty-four centres were visited to educate staff 
about the trial, review understanding of the protocol and trial procedure, verify for 
relevant centres that the staff at the site have access to the necessary 
documents to conduct the trial, confirm that the required pharmacy and 
laboratory resources are in place to start the trial.    A presentation was generally 
given to the audience of nurses, doctors and trials teams.  
4.2.7.6.2 Newsletters 
Over the five years of start up, recruitment and evaluation, 12 WARP newsletters 
were produced updating the local trials teams on items such as recruitment, trial 
amendments, new recommendations, newly published literature and related 
news items such as conferences.   This was an excellent means of thanking the 
local coordinators for their participation.  An example of a newsletter is shown in 
Appendix 7. 
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4.3 Meta-analysis 
4.3.1 Overview 
A meta-analysis is defined as a statistical summary of the data (Lau et al, 1997).   
The statistical methods of meta-analysis aim to evaluate the heterogeneity 
(diversity) amongst the results of certain studies, explore and explain the 
observed heterogeneity and estimate a common pooled effect with increased 
precision.  This involves the comparison of the number of events observed (O) 
amongst the treatment-allocated patients with the number expected (E) under the 
null hypothesis of no treatment effect.   When this is done for similar trials, the O-
E could well be positive or negative and if their sum was close to zero, these 
treatments had no effect but if treatment really reduced the outcome (thrombosis 
or mortality), then the (O-E)s would tend to be negative.  This may be obscured 
by chance in individual studies but stand out clearly when the total of (O-E)s is 
calculated (Peto, 1987).  
 
For binary response variables e.g. thrombosis or no thrombosis, dead or alive, 
odds ratios are utilised as the measure of treatment effect, providing an estimate 
of the relative efficacy of the anticoagulant.   Pooling estimates into an overall 
estimate can increase statistical power to lead to more precise estimates of the 
treatment effect.  Each study is given a weight according to the precision of its 
results.  Studies with narrow confidence intervals are weighted more heavily than 
studies with greater uncertainty.    The precision is generally expressed by the 
inverse of the variance of the estimate of each study.  The variance has two 
components: the variance of the individual study and the variance between 
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different studies.  When the between-study variance is found to be or assumed to 
be zero, each study is weighted by the inverse of its own variance which is a 
function of the study size and the number of events in the study (Yusuf, 1987). 
 
A fixed effects model - i.e. where a single true treatment effect of anticoagulation 
is assumed - was utilised.   The summary statistics from the individual studies 
were used without requiring access to the full data set.  Results were combined 
to estimate overall treatment effects on CRT or VTE and mortality for the 
following treatment subgroup comparisons: 
 warfarin versus no warfarin  
 low molecular weight heparin (LMWH) versus no LMWH  
 LMWH versus oral anticoagulants  
Differences in treatment effects between trials and subgroups were assessed  
using tests of heterogeneity.  A test for trend over trials was utilised to  
investigate whether results have changed over time.  The results are presented 
in Forest Plots (also known as odds ratio plots), showing number of events and 
confidence intervals.  No bleeding analyses were carried out as different trials 
used different criteria to measure bleeding and there were many missing data.  
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4.3.2 Protocol for Meta-analysis 
4.3.2.1 PRISMA Reporting System 
This systematic approach to the description of meta-analytical data was 
introduced in 2009.  However, the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) approach undertaken in this thesis 
conformed with their published checklist (Liberati et al, 2009).   Their data flow 
diagram has been adapted and included in the results (Section 5.3.1). 
 
4.3.2.2 Data Sources and Searches 
The following databases were searched: MEDLINE, EMBASE, CINAHL 
(Cumulative Index to Nursing and Allied Health), ISI The Web of Science and 
Cochrane Central Register of Controlled Trials (CENTRAL); Scientific meetings 
databases, which include American Society of Hematology and American Society 
of Clinical Oncology; and Google scholar.  Experts in the field were also 
consulted to identify additional studies.   
 
The following search terms were used for the thromboprophylaxis and catheter 
analysis: central venous catheterisation (text and MeSH – Medical Subject 
Headings) OR thrombosis, thromboembolism (text and MeSH) NOT 
haemodialysis, renal dialysis, hemodialysis, dialysis (text and MeSH) AND 
cancer AND randomised controlled trials (text, MeSH, Publication type) AND 
1980-2008. The following search terms were used for the VTE studies for 
efficacy and survival: cancer (text and MeSH – Medical Subject Headings) AND 
thrombosis, thromboembolism (text and MeSH) AND low molecular weight 
heparin OR warfarin AND randomised controlled trials (text, MeSH, Publication 
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type) AND 1980-2009.   The MEDLINE electronic component of the searches 
was updated between March 2005 and October 2009. 
 
4.3.2.3 Study Selection – Inclusion and Exclusion Criteria 
The title and abstract were used to select the articles. A study was eligible for the 
quality assessment if it met all the following inclusion criteria: (1) a randomised 
clinical trial with stated endpoint as CRT rates or VTE rates or survival; and (2) 
published between 1980 and 31st October, 2009.  Studies were excluded if they 
met any one of the following exclusion criteria: (3) conducted mainly in children 
≤16 years of age (because of tiny doses of drug in comparison to adults); (4) did 
not use objective testing to confirm a diagnosis of VTE; (5) were duplicate 
publications containing data reported in later studies.   For the catheter meta-
analysis, the studies that dealt mainly with fibrin sheath formation and not with 
catheter-related deep vein thrombosis (DVT) and those that included non-cancer 
patient populations (e.g. all hospitalised patients) were also excluded. 
 
4.3.2.4 Quality Assessment 
Two people (the chief investigator and the trial statistician) independently and 
then together, evaluated the methodological quality of the different studies using 
criteria described by Jadad et al. for randomised clinical trials (Jadad et al, 1996).  
This quality assessment was not used to weigh the studies differently during the 
analyses.   
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4.3.2.5 Data Extraction  
Data were extracted by two independent reviewers (the chief investigator and a 
statistician from the University of Birmingham Trials Unit) and included the type 
of, the dose and duration of treatment (warfarin or LMWH), whether it was 
primary or secondary VTE prophylaxis, the number of thrombotic events during 
the trial and whether the endpoint in the catheter analysis was symptomatic or 
the composite endpoint of „asymptomatic (venographically screened) and 
symptomatic‟, VTE.   
 
4.3.2.6 Data Synthesis and Analysis 
Catheter Thromboprophylaxis Meta-analysis:  For subjects who received more 
than one catheter during the course of any of the studies, only outcomes 
observed while they had their first device in place, were evaluated.    
 
All Meta-analyses:  The analyses were carried out using a standard meta-
analytic in-house (University of Birmingham Trials Unit) software, by the trials 
statistician with advice from the chief investigator.  
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5. Results 
5.1 Pre-WARP Survey 
The summary of the pre-trial survey responses are summarised in Table 5.1.1.  
Overall, there was an informative response from 27% (213/769) of clinicians 
(73% oncologists or haematologists; 27% were oncology/haemato-oncology 
nurses), representing the majority of cancer hospitals (60%, n=116) involved in 
the delivery of cancer care in the UK.   Nearly two thirds of respondents who 
described the catheters they used according to site of placement, employed 
centrally placed (they referred to as „Hickman‟) catheters rather than peripherally 
inserted central catheters (PICCs) to treat common solid tumours (50% 
gastrointestinal ; 21% breast; 10% range of other types) and haematological 
malignancies (15%). Most clinicians routinely used warfarin prophylaxis for 
venous catheters (62% vs 26%); the majority of whom (121/131; 92%) used 
fixed, low dose warfarin at 1mg/day. Only 3% (4/131) of clinicians who used 
warfarin, adjusted the dose to maintain an INR of 1.5-2.0.   The respondents 
were asked to estimate the likely thrombosis rate in their practice, a mean of 13% 
(IQR 5% to 15%).  A Wilcoxon test on the thrombosis rates split by use of 
prophylactic warfarin demonstrated that estimated thrombosis rates were higher 
in the clinical group prescribing warfarin group than in the non-warfarin group 
(p=0.006).  Importantly, there was considerable interest in the question of 
warfarin prophylaxis within the medical community; 80% of all respondents felt 
that the questions addressed were of importance, and 70% expressed interest in 
a clinical trial of warfarin prophylaxis with 150 clinicians providing names of lead 
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contacts at their centres.  Ninety-seven of 213 clinicians provided additional 
comments.  These ranged from,  
“we are keen to participate” to “we cannot participate as most of our patients 
are in other trials with pre-set medication”;  
”this [thrombosis] is a huge problem” to “we have very little problem with 
thrombosis”.   
Of the survey lead contacts, 82 (55%) subsequently participated in WARP.  The 
largest category of comments, however, were 19 respondents (9%; 20% of all 
those who commented) who noted that they would not randomise to a „no 
warfarin‟ arm, as they were substantially certain of the benefits of 
thromboprophylaxis.  Their comments included, 
 “I would be uncomfortable with a no warfarin arm” and  
“it is unethical to have a study with a „no warfarin‟ arm”.   
 
The results of this survey informed the design of WARP as follows: 
Interest was high, supporting the concept of WARP as a multicentre study 
WARP design would be a three arm randomisation: no warfarin, a fixed dose of 
1mg of warfarin/day, and an adjusted dose, to keep the INR in the range 1.5-2.0.   
As the no warfarin arm was highlighted by some respondents as difficult to 
participate in, the principle of uncertainty was adopted:   For clinicians who felt 
there was a clear benefit for warfarin, the randomisation was restricted to the last 
two treatment groups – see Figure 5.1.1 
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Table 5.1.1 Summary of pre-trial Survey Responses 
Question  
n= total number of 
responses to question 
No. of Respondents 
Completing Question 
(% of total respondents) 
Answers 
(% of total respondents, n=213) 
Section 1 n=213 1 2 3 4 
Types of CVCs used for 
chemotherapy  
n=345 
n=213 
(100%) 
 
 
61% described site 
of CVC insertion  
(63% Hickman 
27% PICC) 
20% described 
catheter design 
(75% Groshong;  
24% Portocaths) 
12% described 
manufacturers 
(44% BARD; 
32% VYGON) 
7% „other‟ 
 
Types of cancer in 
which CVCs used 
n= 447 
n=213 
(100%) 
 
gastrointestinal 
cancers  
n=224 (50%)  
breast cancer 
 
n= 94 (21)%  
haematological 
cancers  
n=69 (15%)  
other 
cancers 
n=60(13%)  
Drugs used via CVCs  
n=268 
n=213 
(100%) 
 
Colorectal: 
continuous 5-FU / 
De Gramont  
Gastro-oesphageal: 
epirubicin /cisplatin 
FEC All Various 
Do you routinely use 
warfarin for arterial 
catheters?  n=1 
n=1 (<1%) 
 
YES 
n=1 (<1%) 
-   
If yes, dose used, n=1  1mg/day    
Do you routinely use 
warfarin for venous 
catheters?  n=187 
n=187 
(88%) 
 
NO  
n=56 (26%)  
 
YES  
n=131 (62%)  
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Question  
n= total number of 
responses to question 
No. of Respondents 
Completing Question 
(% of total respondents) 
Answers 
(% of total respondents, n=213) 
 
If yes, dose used 
n=131 
 
n=131 
(62%) 
 
1mg/day 
n=121 (57%) 
 
Variable dose for 
INR 1.5-2.0 n=4 
(2%) 
 
Other 
 
n=6 (3%) 
 
What percentage of 
your patients with CVCs 
develop a thrombosis? 
n=151 
n=151 
(70%) 
 
Median: 10%  
(IQR 5%-15%)  
Mean rate: 13% 
develop a 
thrombosis  
  
Time to thrombosis 
n=151 
n=151 
(70%) 
over 28days  
n=88 (41%) 
14-28 days  
n=33 (15%)  
7-14days  
n=22 (10%) 
0-7days  
n=6 (3%) 
 
Section 2 
     
Is this an important 
clinical question? 
n=180 
n=180 
(85%) 
YES  
n=171 (80%) 
NO  
n=9 (4%) 
-  
Are you interested in 
participating in a trial of 
thromboprohylaxis? 
n=176 
n=176 
(83%) 
 
YES  
n=150 (70%)  
NO  
n=26 (12%)  
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Figure 5.1.1 WARP Trial Design after the Results of the pre-Trial Survey 
 
 
 
A – no warfarin;    B – fixed dose warfarin, 1mg daily;    C – Dose adjusted warfarin, to maintain the INR between 1.5 and 2.0 
 
 
UNCERTAIN CERTAIN 
RANDOMISE 
A 
vs vs 
2 1 1 
B C 
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5.2 WARP Trial 
5.2.1   Overall Recruitment 
The trial opened for recruitment in October 1999 with first patient recruited on 
19th October 1999 and closed for recruitment in December 2004, with the last 
patient recruited on 17th December 2004 when protocol target number of patients 
was reached; 812 patients were randomised to the uncertain preference (404 to 
no warfarin, 408 to warfarin; 324 to Fixed Dose Warfarin (FDW) and 84 to Dose 
Adjusted Warfarin to maintain the INR between 1.5 and 2.0 [DAW]) and 778 to 
the certain preference (389 to FDW and 389 to DAW).   The imbalance in the 
numbers of patients in the uncertain preference warfarin arms (324 patients 
receiving FDW and 84 receiving DAW) was due to the popularity, by the 
randomising clinicians in discussion with the patients, of the 2 arm option (no 
warfarin vs FDW), over the 3 arm option (no warfarin vs FDW vs DAW).  This 
was possible after the trial design amendment.  The design enabled 166 (10.4%) 
patients to contribute to both comparisons (Figure 5.2.1.1).   
 
Yearly, quarterly and monthly recruitment is shown in Tables 5.2.1.1 – 5.2.1.4.  
Average monthly recruitment was 25 patients and ranged (after the first two 
months) from 4 midway through the trial (August 2002) to 69 in September 2003 
(Table 5.2.1.1).  During this period of 5.25 years, 1593 randomisations took 
place. Three of these were excluded from the analysis because they were invalid 
randomisations (see section 5.2.1.3).   
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Table 5.2.1.1 Yearly, Quarterly and Monthly Recruitment  
 Number of 
time 
periods 
Mean Median Range 
Yearly 5.25 265 279 15 – 475 
Quarterly 21 76 72 15 – 165 
Monthly 63 25 25 4 – 69* 
 
* recruitment not including the first two months, when there were 2 and 4 patients 
recruited respectively
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Figure 5.2.1.1 Numbers of Patients Randomised to Uncertain/Certain Preference by Arm 
 
 
 
 
 
DAW – Dose Adjusted Warfarin; *od - once daily; FDW – Fixed Dose Warfarin (1mg daily); CRT – Catheter-related Thrombosis 
NO – 2 arm study 
n=485 
Option 
vs Warfarin 
n=408 
(242+82+84) 
FDW; n=324 
DAW; n=84 
CRT - 24 
 
and vs 1mg warfarin od* 
n=471 (82+389) 
CRT - 34 
DAW warfarin 
n=473 
(84+389) 
CRT - 13 
2 parallel randomised studies: No warfarin 
n=404 
(161+243) 
CRT - 24 
 
Uncertain 
n=812 
1mg warfarin od* 
n=389 
CRT - 26 
DAW warfarin od* 
n=389 
CRT - 11 
No warfarin 
n=161 
CRT - 5 
Are you (clinician) willing to participate in the dose adjusted warfarin (DAW) arm?  
Certain 
n=778 
 
1mg warfarin od* 
n=82 
CRT - 8 
 
DAW warfarin od* 
n=84 
CRT - 2 
No warfarin 
n=243 
CRT - 19 
1mg warfarin od* 
n=242 
CRT - 14 
YES – 3 arm study 
n=327 
Are you (clinician) certain or uncertain of the benefits of warfarin in the prophylaxis of thrombosis in cancer patients with CVCs? 
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Recruitment was greatest in 2003 (Table 5.2.1:2), with 277 patients assigned to 
the uncertain preferences (79% to 2 arm option) and 198 to the certain 
preference (Figure 5.2.1.2) 
 
Table 5.2.1.2 Total Yearly Recruitment 
Year Number of Patients Recruited 
1999 15 
2000 273 
2001 286 
2002 223 
2003 475 
2004 318 
 
Figure 5.2.1:2 Yearly Recruitment by uncertain/certain preference 
 
*U – uncertain preference; C – certain preference; 3- 3-arm option; 2 – 2 arm 
option 
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The quarterly recruitment demonstrates broadly that clinicians were evenly split 
on their preference on the benefits of warfarin in thromboprophylaxis (Figure 
5.2.1.3) 
 
Figure 5.2.1.3 Quarterly Cumulative Recruitment by Preference 
 
 
The recruitment rates by centre and clinician are summarised in Table 5.2.1.3.  
The trial involved 68 participating centres from the United Kingdom with 12 
centres recruiting more than 50 patients and 52% of all patients were recruited by 
the top 10 recruiting centres (Appendix 8). The trial involved 175 lead 
investigators (LIs), 98% of whom were consultant oncologists, with 4 (2%) senior 
nurses.   In contrast, the randomising clinicians were predominantly research or 
clinical specialist nurses (82%) with oncologists at 12 centres supporting the 
nurses in this role.    
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Seventy six percent of clinicians always chose certain (35%) or uncertain (41%) 
preference for the benefit of warfarin whilst the remainder (24%) selected 
patients for randomisation to both certain and uncertain preferences.  Within 
centres, different clinicians randomised patients under different preferences and 
options.  The recruitment rates per centre are documented in Appendix 8. 
 
Table 5.2.1.3 Total Patient Recruitment by Centres and Clinicians 
Recruitment (number of 
patients) 
Mean 
 
Median 
 
Range 
Centres;  n=68 23 12 1 – 214  
Lead Investigators; n=175 9 4 1 – 128  
 
5.2.1.1 Recruitment by Randomised Treatment Arm 
Table 5.2.1.4 illustrates how the 1590 randomisations were split according to 
uncertain or certain preference and assigned treatment.    
 
Table 5.2.1.4 Number of patients randomised by preference and by 
treatment arm 
Indication/option No Warfarin FDW DAW Total 
Uncertain 3 arm 161 82 84 327 
Uncertain 2 arm 243 242 0 485 
Certain 2 arm 0 389 389 778 
Total 404 713 473 1590 
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5.2.1.2 Stratification Variables 
Stratification variables (central or peripheral site of insertion, chemotherapy 
sclerosant or non-sclerosant potential and infusion of less than or greater than or 
equal to 24 hours) were balanced across allocated treatments. The uncertain 3 
arm was proportionally assigned 2:1:1 for no warfarin; fixed dose warfarin of 
1mg/day (FDW); dose-adjusted warfarin (DAW), daily, (Table 5.2.1.5). 
Table 5.2.1.5   Balance of Patients per Stratification Variable 
 
Preference and Option No Warfarin FDW DAW 
Central, <24, non-sclerosant (n=35) 
Uncertain; 3 arm study 3 1 2 
Uncertain; 2-arm study 5 5 0 
Certain 0 10 9 
Central, <24, sclerosant (n=128) 
Uncertain; 3 arm study 8 3 5 
Uncertain; 2-arm study 10 12 0 
Certain 0 46 44 
Central, 24+, non-sclerosant (n=203) 
Uncertain; 3 arm study 25 12 12 
Uncertain; 2-arm study 20 21 0 
Certain 0 56 57 
Central, 24+, sclerosant (n=301) 
Uncertain; 3 arm study 47 24 24 
Uncertain; 2-arm study 28 29 0 
Certain 0 74 75 
Peripheral, <24, non-sclerosant (n=33) 
Uncertain; 3 arm study 2 3 2 
Uncertain; 2-arm study 10 8 0 
Certain 0 4 4 
Peripheral, <24, sclerosant (n=86) 
Uncertain; 3 arm study 6 3 3 
Uncertain; 2-arm study 20 20 0 
Certain 0 17 17 
Peripheral, 24+, non-sclerosant (n=477) 
Uncertain; 3 arm study 35 18 18 
Uncertain; 2-arm study 72 70 0 
Certain 0 132 132 
Peripheral, 24+, sclerosant (n=327) 
Uncertain; 3 arm study 35 18 18 
Uncertain; 2-arm study 78 77 0 
Certain 0 50 51 
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5.2.1.3 Randomisation Procedures 
At randomisation, the following parameters were checked with the randomising 
clinician specifically confirming that the patient conformed to six of these criteria: 
 Histologically or clinically confirmed diagnosis of solid or haematological 
malignancy 
 Patient is due to have (or has had within last 7 days) a central venous 
catheter inserted for chemotherapy 
 Adequate haematological, hepatic and renal function 
 No contraindication to warfarin and not on warfarin 
 Not pregnant or lactating and taking adequate contraceptive measures if 
appropriate 
 Signed consent for WARP 
The electronic computer randomisation procedure malfunctioned („crashed‟) on 
four occasions over the four years of recruitment.   Paper copies of the seven 
randomisations were documented and later added to the electronic database.   
The randomising officers found a duplication of three paper randomisation 
records on the electronic database.  These were deleted and not included in any 
analysis.  
 
5.2.1.4 Timing of Randomisation 
Randomisation and start of warfarin, if allocated, was permitted from 3 days prior 
to CVC insertion for 1186 patients who were randomised to warfarin.  After 
requests from some trial coordinators whose patients had their CVCs inserted in 
peripheral units before having their treatment administered at the regional 
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centres where WARP was recruiting, the steering committee permitted 
randomisation to take place after central venous catheter (CVC) insertion.   
There were 10% of patients assigned to FDW and 17% of patients assigned to 
DAW who started warfarin up to 3 days prior to randomisation.   However, 8% of 
patients assigned FDW and 10% of patients assigned DAW started warfarin  
>3 days prior to randomisation.  The majority of patients (59%) on warfarin 
started on the day of randomisation (Tables 5.2.1.6. and 5.2.1.7).  
Table 5.2.1.6 Timing of warfarin start in relation to randomisation 
(for patients assigned to warfarin, n=1186) 
Timing of start of warfarin FDW (n=713) DAW (n=473) 
>3 days prior to randomisation 59 (8%) 45 (10%) 
3 days prior to randomisation 34 (5%)  38 (8%) 
1-2 days prior to randomisation 36 (5%) 36 (8%) 
Same day as randomisation 447 (63%) 259 (55%) 
1- 3 days after randomisation 50 (7%) 34 (7%) 
4+ days after randomisation 41 (6%) 32 (7%) 
Missing data - start of warfarin  46 (6%) 29 (6%) 
 
Table 5.2.1.7 Timing of warfarin start in relation to randomisation by 
preference and by treatment 
Preference: Uncertain Certain 
Timing in relation to 
randomisation 
FDW 
(n=324) 
DAW 
(n=84) 
FDW 
(n=389) 
DAW 
(n=389) 
>3 days prior to randomisation 10 (3%) 3 (4%) 49 (13%) 42 (11%) 
3 days prior to randomisation 5 (2%) 1 (1%) 29 (7%) 37 (10%) 
1-2 days prior to randomisation 17 (5%) 5 (6%) 19 (5%) 31 (8%) 
Warfarin started same day 202 (62%) 49 (58%) 245 (63%) 210 (54%) 
1- 3 days after randomisation 35 (11%) 7 (8%) 15 (4%) 27 (7%) 
4+ days after randomisation 28 (9%) 12 (14%) 13 (3%) 20 (5%) 
Missing data - start of warfarin 27 (8%) 7(8%) 19 (5%) 22 (6%) 
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5.2.1.5 Eligibility 
Eligibility is specified in section 4.2.4; patients with any malignancy, receiving 
chemotherapy via a central venous catheter and clinically fit to receive warfarin.   
All patients recruited into the trial were confirmed by the local coordinators to be 
eligible at the time of randomisation. Immediately following randomisation, of the 
1590 patients, four were found to be ineligible, three on clinical parameters and 
one declining chemotherapy post randomisation (Table 5.2.1.8).   Four additional 
patients did not have CVCs inserted post randomisation.  All patients were 
included in the analysis. 
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Table 5.2.1.8 Ineligible Patients* and Patients who had no Catheter Inserted after Randomisation 
 
Preference and 
option 
Treatment 
Arm 
Reason for ineligibility for trial 
Uncertain;  
3-arm study 
DAW Platelet count not adequate to give warfarin*  
Uncertain; 
2 arm study 
No warfarin No line inserted due to technical difficulties  
FDW After randomisation, lab results showed high values of liver enzymes ALT and 
AST* Patient was withdrawn from study but did receive warfarin for 3 days 
No line inserted 
No line inserted 
Certain DAW Ulcerated tumour found post randomisation which is a contraindication to 
warfarin* 
Patient had no chemotherapy after randomisation* 
Line could not be inserted due to technical difficulties 
 
FDW – Fixed Dose Warfarin (1mg daily); DAW – Dose Adjusted Warfarin         *ineligible patients 
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5.2.2   Baseline Characteristics 
Patient baseline characteristics are presented in Table 5.2.2.1 and are well 
balanced across the study arms.   58% of all patients had peripherally inserted   
central catheters (PICCs), in keeping with a rising trend in usage. Patients were 
similar with respect to age, treatment length, performance status, disease site 
and stage of disease across all arms.  93% of patients had WHO Performance 
Status of 0 and 1, although 65% had advanced disease and 73% of patients had 
gastrointestinal cancer.   Over 50% of patients presented with colorectal cancer, 
reflecting an established European and increasing US practice for infusional 
chemotherapy with 5-FU, folinic acid and oxaliplatin or irinotecan.  There were 
only 57 (3.6%) patients in total with haematological malignancies. 
Of the 3% of patients who were on tamoxifen before the trial, 76% (39/51) 
stopped this hormone treatment and 24% (12/51) patients continued. 
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Table 5.2.2.1  Baseline Characteristics of Patients in WARP Trial 
  Warfarin Evaluation Dose Evaluation 
 Overall 
n=1590 
No Warfarin 
n=404 
Warfarin 
n=408 
FDW 
n=471 
DAW 
n=473 
Sex:  
Male 
Female 
 
913 (57%) 
677 (43%) 
 
247 (61%) 
157 (39%) 
 
252 (62%) 
156 (38%) 
 
253 (54%) 
218 (46%) 
 
265 (56%) 
208 (44%) 
Age (yrs): 
Median 
Age IQ Range 
Age Range 
 
60 
53-67 
16-91 
 
61 
53-68 
16-86 
 
60 
53-68 
19-87 
 
59 
51-66 
19-85 
 
60 
53-67 
20-91 
WHO PS: 
0 
1 
2 
3 
Not Known 
 
890 (56%) 
591 (37%) 
71 (5%) 
7 (<1%) 
31 (2%) 
 
221 (55%) 
168 (42%) 
9 (2%) 
1 (<1%) 
5 (1%) 
 
225 (55%) 
151 (37%) 
20 (5%) 
1 (<1%) 
11 (3%) 
 
263 (56%) 
178 (38%) 
22 (5%) 
1 (<1%) 
7 (1%) 
 
272 (58%) 
161 (34%) 
25 (5%) 
4 (1%) 
11 (2%) 
Disease Stage 
No residual or 
Early 
Advanced 
Not Known 
 
 
534 (34%) 
1040 (65%) 
16 (1%) 
 
 
130 (32%) 
273 (68%) 
1 (<1%) 
 
 
134 (33%) 
269 (66%) 
5 (1%) 
 
 
171 (36%) 
294 (62%) 
6 (1%) 
 
 
138 (29%) 
330 (70%) 
5 (1%) 
Disease Site: 
Colorectal 
UGI (total) 
Oesophagus 
Gastric 
Pancreatic 
Upper GI* 
Cholangio 
Hepatic 
Breast 
Other 
Lymphoma 
 
810 (51%) 
352 (22%) 
188 (12%) 
113 (7.1%) 
30 (1.9%) 
13 (1%) 
7 (<1%) 
1 (<1%) 
202 (13%) 
174 (11%) 
29 (2%) 
 
201 (50%) 
109 (27%) 
67 (16.6%) 
33 (8.2%) 
2 (<1%) 
4 (1%) 
3 (1%) 
0 (0%) 
32 (8%) 
50 (12%) 
10 (2%) 
 
217 (53%) 
92 (23%) 
46 (11.3%) 
32 (8%) 
7 (2%) 
6 (1%) 
1(<1%) 
0 (0%) 
32 (8%) 
54 (13%) 
12 (3%) 
 
226 (48%) 
95 (20%) 
46 (10%) 
36 (8%) 
9 (2%) 
2 (<1%) 
2 (<1%) 
0 (0%) 
82 (17%) 
52 (11%) 
6 (1%) 
 
243 (51%) 
98 (21%) 
49 (10%) 
27 (6%) 
17 (4%) 
3 (1%) 
1 (<1%) 
1 (<1%) 
67 (14%) 
49 (10%) 
5 (1%) 
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  Warfarin Evaluation Dose Evaluation 
 Overall 
n=1590 
No Warfarin 
n=404 
Warfarin 
n=408 
FDW 
n=471 
DAW 
n=473 
Ovarian 
Myeloma 
Sarcoma 
Renal 
Bladder 
Leukemia 
Melanoma 
Head & Neck 
Cervical  
Lung 
Testicular 
Prostate 
Ophthalmic 
Other 
Not Known 
CUO 
Blank 
26 (2%) 
19 (1%) 
12 (1%) 
10 (1%) 
9 (1%) 
9 (1%) 
7 (<1%) 
4 (<1%) 
3 (<1%) 
3 (<1%) 
3 (<1%) 
1 (<1%) 
1 (<1%) 
38 (2%) 
52 (3%) 
37 (2%) 
15 (1%) 
3 (1%) 
7 (2%) 
2 (<1%) 
2 (<1%) 
2 (<1%) 
4 (1%) 
2 (<1%) 
2 (<1%) 
0  
2 (<1%) 
0  
0  
0 
14 (3%) 
12 (3%) 
10 (2%) 
2 (<1%) 
4 (1%) 
5 (1%) 
7 (2%) 
4 (1%) 
4 (1%) 
5 (1%) 
1 (<1%) 
2 (<1%) 
0 
1 (<1%) 
0 
0 
1 (<1%) 
8 (2%) 
13 (3%) 
9 (2%) 
4(1%) 
15 (3%) 
4 (1%) 
6 (1%) 
3 (1%) 
2 (<1%) 
1 (<1%) 
3 (1%) 
1 (<1%) 
1 (<1%) 
0 
1 (<1%) 
1 (<1%) 
1 (<1%) 
7 (1%) 
16 (3%) 
11 (2%) 
5 (1%) 
7 (1%) 
6 (1%) 
3 (1%) 
3 (1%) 
5 (1%) 
4 (1%) 
2 (<1%) 
0 
2 (<1%) 
0 
2 (<1%) 
0 
0 
10 (2%) 
16 (3%) 
11 (2%) 
5 (1%) 
Pre-trial 
Tamoxifen: 
No 
Yes 
Stopped on 
trial 
Continue on 
trial 
Not Known 
 
 
1523 (96%) 
51 (3%) 
39 (2%) 
 
12 (<1%) 
 
16 (1%) 
 
 
393 (97%) 
9 (2%) 
8 (2%) 
 
1 (<1%) 
 
2 (<1%) 
 
 
396 (97%) 
7 (2%) 
5 (1%) 
 
2 (<1%) 
 
5 (1%) 
 
 
449 (95%) 
16 (3%) 
12 (3%) 
 
4 (<1%) 
 
6 (1%) 
 
 
444 (94%) 
24 (5%) 
17 (4%) 
 
7 (1%) 
 
5 (1%) 
WHO PS – WHO Performance Status; Cholangio – cholangiocarcinoma;  
CUO – Cancer of Unknown Origin;  UGI – Upper Gastrointestinal;   
*broad classification given;   Italics denotes specific UGI tumour types  
150 
5.2.3   Protocol Compliance 
5.2.3.1 Return of Case Record Forms 
CRF return was excellent; there was 100% of mandatory baseline information on 
CRF1 including treatment arm and trial number.  The remaining baseline data on 
CRF1 (permitted to be completed after randomisation) were returned in 99.2% of 
cases, 98.1% of cases for CRF2 and 98.2% of cases for CRF3.  Table 5.2.3.1 
shows the CRF return across preferences; there are no differences in return of 
any CRF between preferences. Overall, 4.4% of CRFs were missing (including 
part C of CRF1) and 0.4% of all patients had both CRF1 and CRF2 missing. 
5.2.3.2 Assigned Treatment Compliance 
Of 1186 patients who were allocated warfarin, 12 (0.1%) did not receive any 
allocated warfarin treatment (eight on warfarin 1mg and four on DAW), mostly 
due to patient choice (n=7).  The reasons for not starting warfarin were:  one 
refusal to take warfarin after consent, one patient had a slight nose bleed before 
treatment and withdrew, one patient was taking aspirin (permissible at low doses) 
and so withdrew, one patient did not start warfarin as was concerned about 
vaginal bleeding and three patients gave no reason.  Clinician error contributed 
to one patient not starting warfarin with clinician request to two patients not to 
start warfarin, because of risk of bleeding and disease progression.  One patient 
left hospital without warfarin and one omitted to start, both then withdrawing from 
treatment.  Only one patient out of 404 who were allocated no warfarin 
(0.0025%) was known to start warfarin because of a suspected thrombosis.  All 
these patients were included in the analysis.  Assigned treatment compliance is 
summarised in Figure 5.2.3.1  
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Table 5.2.3.1 CRF Return  
Preference and Option: Uncertain 3-arm  Uncertain 2-arm Certain Total  
Case Record Form 
(CRF) 
Time CRF completed 
and returned 
No 
Warfarin 
 FDW DAW No 
Warfarin 
FDW FDW DAW  
CRF1 Randomisation 
Form Part A, B 
At randomisation 
(total no. of CRFs) 
161 82 84 243 242 389 389 1590 
CRF1 Randomisation 
Form Part C 
Baseline data after 
randomisation 
160 
(1) 
81 
(1) 
84 
(0) 
243 
(0) 
239 
(3) 
385 
(4) 
386 
(3) 
1478 
(12) 
CRF2 End of Primary 
Evaluation Period Form 
At catheter removal or 
thrombosis 
156 
(5) 
82 
(0) 
82 
(2) 
238 
(5) 
234 
(8) 
386 
(3) 
382 
(7) 
1560 
(30) 
CRF3 
Follow-up Form* 
One year after 
randomisation or death  
157  
(4) 
81  
(1) 
81 
(3) 
237 
(6) 
237 
(5) 
386 
(3) 
383 
(6) 
1562 
(28) 
CRF2 and CRF3 missing  (3) (0) (1) (1) (0) (0) (1) (6) 
Total CRFs Missing*   (10) (2) (5) (11) (16) (10) (16) (70)[4.4%] 
 
(number of patients missing in brackets); * includes part C of CRF1
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5.2.3.3 Warfarin Dose Compliance 
Of 1186 patients allocated to warfarin, 1139 were known to have started 
treatment (20 did not start and there were no data for 27).  Of the 1139 patients 
who started warfarin, 26 (2.3%) patients and/or their clinicians did not conform to 
warfarin dose.  For five patients allocated FDW, the clinician chose to prescribe 
the variable dose; for 21 patients on DAW, five took 1mg warfarin in error, 12 
patients decided jointly with their clinician to change to FDW daily, three were 
prescribed 1mg warfarin in error and one reason for shifting to FDW remained 
unknown.  Of the 1139 patients taking warfarin, 106 (9%) stopped taking their 
prescribed medication early (over 7 days before the catheter was removed), 59 
patients (56%) on FDW and 47 patients (44%) on DAW.  The majority (80%) of 
these patients stopped taking warfarin at the end of their chemotherapy course, 
but over 7 days before their catheter was removed.  For the other patients, 
warfarin was stopped early due to patient choice or thrombocytopenia; data on 
warfarin compliance were incomplete on 8% of patients.   Compliance with 
warfarin dose is summarised in Figure 5.2.3.1.  
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Figure 5.2.3.1 WARP Flow Chart (Consort Diagram) 
)Diagram259) 
Target Population:  All cancer patients who are having a central venous catheter (CVC) placed for administration of cytotoxic chemotherapy with: 
(i) age>16 years (ii) adequate haematological, hepatic and renal function (iii) no contraindication to and not currently on warfarin 
Eligible patients where clinicians UNCERTAIN of 
benefit from warfarin in thromboprophylaxis n=812 
Eligible patients where clinicians CERTAIN of 
benefit from in thromboprophylaxis n=778 
3 arm Option: n=327 2 arm Option: n=485 
No Warfarin 
 
 
n=161 
Warfarin fixed  
dose 1mg/day 
 
n=82 
Dose adjusted 
warfarin to maintain 
INR between 1.5 & 2.0 
n=84 
Randomisation:     Stratified for: (i) sclerosant potential of chemotherapy (ii) duration of drug administration (iii) site of placement of catheter 
Warfarin fixed  
dose 1mg/day 
 
n=389 
Dose adjusted warfarin 
to maintain INR 
between 1.5 & 2.0 
n=389 
Protocol treatment 
64 (78%) full 
compliance 
1 (1%) did not start 
10 (12%) stopped 
early** 
 
 
 
7 (9%) incomplete 
data on compliance 
Protocol treatment 
60 (71%) full 
compliance 
4 (5%) did not start (1 
ineligible) 
13 (16%) stopped 
early** 
1 (1%) stopped early** 
and dose infringement 
6 (7%) incomplete 
data on compliance 
 
Protocol treatment 
330 (85%) full 
compliance 
1 (<1%) did not start 
 
30 (8%) stopped 
early** 
5 (1%) dose 
infringements 
23 (6%) incomplete 
data on compliance 
Protocol treatment 
304 (78%) full 
compliance 
6 (2%) did not start (2 
ineligible; 1 no CVC) 
30 (8%) stopped early** 
17 (4%) dose 
infringement 
3 (1%) stopped early 
and dose infringement 
29(8%) incomplete data  
Protocol 
treatment 
156 (97%) full 
compliance 
 
 
 
 
 
5 (3%) incomplete 
compliance data  
On-study time* 
Median: 112 days 
Range: 5-423 
12(7%) not known  
 
 
On-study time* 
Median: 119 days 
Range: 7-486 
6 (7%) not known 
On-study time* 
Median: 100 days  
Range: 4-630 
6 (7%) not known 
On-study time* 
Median: 114 days 
Range: 5-672 
13 (3%) not known 
On-study time* 
Median: 119 days 
Range: 5-1031 
27 (7%) not known 
No Warfarin 
 
 
n=243 
Warfarin fixed  
dose 1mg/day 
 
n=242 
Protocol treatment 
193 (80%) full 
compliance 
8 (3%) did not start (1 
ineligible; 2 no CVC) 
19 (8%) stopped 
early** 
 
 
22 (9%) incomplete 
data on compliance 
Protocol 
treatment 
235 (97%) full 
compliance  
1 did not start (no 
CVC) 
 
 
 
7 (3%) no data on 
compliance 
On-study time* 
Median:100 days 
Range: 2-432 
15(6%) not known 
On-study time* 
Median: 96 days 
Range: 2-443 
 15 (6%) not known 
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5.2.4    Primary Endpoint 
5.2.4.1 Catheter – related thrombotic events  
Comparisons can only be made for randomised groups, hence those receiving 
warfarin under the certain preference, could not be included in the assessment of 
warfarin vs no warfarin. Of the 1590 patients randomised, 85 (5.3%) had a 
radiologically confirmed CRT, occurring most frequently in the upper limb. There 
were also 9 clinically suspected CRT in 7 patients, not confirmed radiologically 
and therefore classified as CVC complications and not CRT.   Warfarin - any 
dose (79% was 1mg; 21% DAW) - did not reduce the incidence of CRT 
thrombotic events relative to no warfarin [24(5.9%) vs 24(5.9%); Relative Risk 
(RR)=1.00, 95% Confidence Interval (CI) 0.74–1.34, p=0.98]  
 
In contrast, there were significantly fewer CRT events in those patients allocated 
DAW compared to FDW [13(2.8%) vs 34(7.2%); RR=0.67; 95% CI 0.56–0.81, 
p=0.002] (Table 5.2.4.1).    When randomised comparisons were analysed for no 
warfarin (n=404) vs FDW (n=324), there were no significant differences in CRT; 
[24(5.9%) vs 22(6.8%), RR=1.10; 95%CI 0.64-1.89, p=0.7].  Similarly, between 
no warfarin (n=161) and DAW (n=84), DAW demonstrated no significant 
reduction in CRT [5(3.1%) vs 2(2.4%), RR=0.77, 95%CI 0.15-3.87, p>0.99] 
(Table 5.2.4.2).   
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Table 5.2.4.1: Catheter-Related Thrombotic Events 
 Warfarin Evaluation Dose Evaluation 
 
No 
Warfarin 
n=404 
Warfarin 
 
n= 408 
Relative Risk 
(95% CI) 
p-value 
FDW 
 
n= 471 
DAW 
 
n= 473 
Relative Risk 
(95% CI) 
p-value 
CRT Events 24 (5.9%) 
 
24 (5.9%) 
 
0.99 
(0.57, 1.72) 
p=0.98 
34 (7.2%) 
 
13 (2.8%) 
 
0.38 
(0.20, 0.71) p=0.002 
No event 370 (91.6%) 372 (91.2%)  433 (91.9%) 448 (94.7%)  
Not known 10 (2.5%) 12 (2.9%)  4 (0.9%) 12 (2.5%)  
 
Table 5.2.4.2 Other Randomised Comparisons of Catheter Related Thrombotic Events 
 
 No warfarin vs FDW No warfarin vs DAW* 
 
No Warfarin 
 
n=404 
FDW 
 
n= 324 
Relative Risk 
(95% CI) 
p-value 
No Warfarin 
 
n= 161 
DAW 
 
n= 84 
Relative Risk 
(95% CI) 
p-value 
CRT Events 
 
U3 
U2 
24 (5.9%) 
 
5 
19 
22 (6.8%) 
 
8 
14 
1.10 (0.64, 1.89) 
p=0.72 
5 (3.1%) 
 
2 (2.4%) 
 
0.77   (0.15, 3.87) 
p>0.99* 
No Events +  
not known 
380 (94.1%) 303 
(93.5%) 
 156 (96.9%) 82 (97.6%)  
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5.2.4.2 Location of Catheter-related Events 
The locations of the 85 CRT events were reported as follows:     
32 (38%) upper limb; 17 (20%) axillary vein; 16 (19%) subclavian vein;  
10 (12%) internal jugular; 4 (5%) superior vena cava; 2 (2%) pulmonary emboli;  
2 catheter and 2 with site not stated.  These are presented with type of venous 
thromboembolism (VTE) assessment, side of catheter and side of thrombosis if 
known (Table 5.2.4.3).    
 
5.2.4.3 Assessment Technique for Diagnosis of Catheter-related 
Events 
The most common assessment technique used for diagnosing CRT was 
ultrasound [45 (53%)], followed by venogram [32 (40%)].  Six „other‟ assessment 
techniques were used (including Ventilation-Perfusion [V-P] Scintigraphy and 
Computerised Tomography [CT] scans for the diagnosis of PE, and 2 
assessments were carried out but not specified (one of these CRTs occurred 
less than five days after the removal of the catheter) [Table 5.2.4.3].     
 
5.2.4.4 Side of Thrombosis 
The thrombosis was on the same side as the catheter in all cases (as per 
definition of CRT) unless the data were unknown (n=4) and these were assumed 
to be on the same side as the catheter.   There were 43 left-sided thromboses, 
32 right-sided and six in which the side was not applicable [4 in superior vena 
cava (SVC) and 2 PEs].   
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5.2.4.5 Removal of catheters in relation to Catheter-related 
thrombosis 
The catheters were removed after the thrombosis occurred in 57 cases; on the 
same day in 26 cases, and in 4 patients, the thrombosis occurred within 1-5 days 
after the removal of the catheter (which was the duration after catheter removal 
still categorised as a CRT).    
 
5.2.4.6 Time-to-event analysis: Catheter-related Thrombosis 
Kaplan-Meier estimates of cumulative thrombosis rates for CRT were calculated 
using all patients, by treatment and shown as curves in Figure 5.2.4.1.  The 
numbers of patients at risk of thrombosis over time are shown below the curves.  
Analysis of this primary outcome as time-to-event data is comparable to the  
-square tests shown in Table 5.2.4.1 and demonstrate no difference in the 
proportion of thromboses over time between no warfarin and warfarin (log rank 
p=0.95), whereas for the FDW versus DAW comparison, there was a significant 
advantage for the DAW group (log rank p=0.002) There are 57 patients who 
either did not have thrombosis or in whom the outcome was not known or who 
have not got a date of CVC removal (28 allocated to no warfarin and 29 to 
warfarin) who were excluded from the analysis i.e. the numbers of patients at risk 
at the (Figure 5.2.4.1).    
5.2.4.7 Time to Catheter-related Thrombosis 
For patients with a CRT event, median time to CRT was 32 days from 
randomisation (IQR=13 to 76 days).   Median time to CRT did not differ in the 
warfarin vs no warfarin (25 vs 32 days, p=0.71), or DAW vs FDW (60 vs 31 days, 
p=0.51) studies.   
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Figure 5.2.4.1 Time to Catheter-Related Thrombosis by Treatment 
a) No Warfarin (labelled control) vs Warfarin 
 
 
 
 
 
 
 
 
 
 
 
 
b) Fixed dose warfarin versus dose adjusted warfarin 
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Table 5.2.4.3  Details of Catheter Related Thromboses 
Location Diagnosis Time in relation 
to CVC removal 
Side Catheter: 
Thrombosis 
n 
Arm 
(n=32) 
Venogram Before LL 1 
RR 2 
UL 2 
UR 2 
Same LL 1 
RR 2 
RU 1 
UL 3 
Ultrasound Before LL 4 
RR 5 
UL 3 
UR 1 
Same RR 1 
UL 1 
Other Before RR 1 
Same RR 1 
NK 5 days UU 1 
Axillary 
Vein 
(n=17) 
Venogram Before LL 1 
UL 1 
UR 1 
Same UL 2 
Ultrasound Before LL 5 
UL 1 
UR 1 
Same LL 3 
1-5 after RR 1 
Other Before UU 1 
Internal 
Jugular 
(n=10) 
Ultrasound Before RR 1 
UL 2 
UR 1 
Same RR 2 
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Location Diagnosis Time in relation 
to CVC removal 
Side Catheter: 
Thrombosis 
n 
1-5 after LL 1 
NK RR 1 
UR 1 
Other Before RR 1 
Subclavian 
Vein 
(n=16) 
Venogram Before RR 2 
UL 1 
UU 1 
Same LL 1 
RR 1 
1-5 after UL 1 
Ultrasound Before RR 2 
UL 1 
UR 1 
Same LL 3 
NK LL 1 
Other Same LL 1 
SVC 
(n=4) 
Venogram Before R NA 1 
U NA 1 
Ultrasound Same RU 1 
Other NK R NA 1 
Lung - PE 
(n=2) 
Other after 
venogram 
and 
ultrasound 
Before U NA 1 
Same U NA 1 
Catheter 
(end) 
n=2 
Venogram 
 
Before RR 1 
Same LL 1 
NK 
(n=2) 
NK Same UL 1 
Venogram Same UL 1 
 
NK – not known; L – left;  R- right;   U – unknown;   NA – not applicable 
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5.2.4.8 Grading of Catheter-related Venous Thromboses 
The majority (64%) of CRT were deep vein thromboses, requiring anticoagulants 
[grade 3] (Table 5.2.4.4]. 
 
Table 5.2.4.4 Grade of Catheter-related Thromboses 
CTC Grade 1 2 3 4 NK 
 (n=85) 3 (4%) 8 (9%) 54 (64%) 4 (5%) 16 (19%) 
 
5.2.5 Secondary Outcomes 
5.2.5.1 All thrombotic events 
36 (2.3%) patients had a non catheter-related thrombosis (CRT), giving a total of 
121 VTE in 1590 patients (7.6%).  Neither warfarin (compared to no warfarin) nor 
DAW (compared to FDW) have any significant impact (p=0.30 and p=0.15 
respectively) on all thrombotic events (Table 5.2.5.1).   The inclusion of clinically 
suspected thromboses (including two non-CRT) that were not confirmed 
radiologically (one in any warfarin group vs four in no warfarin group; one in DAW 
vs five in FDW), in a sensitivity analysis of all thromboses showed that there was 
no advantage from taking warfarin over no warfarin (p=0.17) or DAW over FDW 
(p=0.06).  When randomised comparisons were analysed for no warfarin (n=404) 
vs FDW (n=324), there were no significant differences in all thrombotic events, 
[38(9.4%) vs 28(8.6%), RR=0.91, 95%CI 0.57-1.45, p=0.7].  Similarly, between 
no warfarin (n=161) and DAW (n=84), DAW demonstrated no significant 
reduction in all thrombotic events [13(8.1%) vs 2(2.4%), RR=0.29, 95%CI 0.07-
1.28, p=0.10] (Table 5.2.5.2).  
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5.2.5.2 Location of non-Catheter Related Thromboses 
The location of the 36 non-CRT events presented as: 18 (50%) lower limb; 10 
(28%) pulmonary emboli; 4 (14%) upper limb (opposite side from catheter by 
definition), 2 (5%) inferior vena cava, 1(3%) subclavian vein, and 1 portal vein. 
Non-CRT events were all venous with the exception of one upper limb arterial 
thrombosis.  Details of non-CRT are included in Table 4.2.5.3. 
 
5.2.5.3 Assessment Technique for Diagnosis of All Thromboses 
All thromboses were diagnosed by various assessment techniques, owing to the 
number of PEs.   Other methods (including V-P Scintigraphy and CT scan for 
assessment of PEs) were used for 14 patients, ultrasound for 13 patients and 
venogram in 9 patients (Table 5.2.5.3). 
 
5.2.5.4 Removal of Catheters in relation to non-Catheter-related 
Thromboses 
After the occurrence of a non-catheter-related thrombosis, 7 catheters were 
removed on the same day and 25 at least a day after the thrombosis.  There 
were no catheter removal data for 4 patients (Table 5.2.5.3).  
 
5.2.5.5 Time to All Thromboses 
For those patients who had a thrombosis, median time to all thromboses (CRT 
and non-CRT) was 44 days (IQR=13-84 days).   Median time to all thromboses 
did not differ in the warfarin vs no warfarin (34 vs 45 days, p=0.80), or DAW vs 
FDW (73 vs 31 days, p=0.14) studies.   
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Table 5.2.5.1 All Thrombotic Events 
 Warfarin Evaluation Dose Evaluation 
 
No Warfarin 
 
n=404 
Warfarin 
 
n= 408 
Relative Risk 
(95% CI) 
p-value 
FDW 
 
n= 471 
DAW 
 
n= 473 
Relative Risk 
(95% CI) 
p-value 
All thrombotic 
events 
38 (9.4%) 
 
30 (7.4%) 
 
0.78 
(0.50, 1.24) 
p=0.30 
37 (7.9%) 
 
26 (5.5%) 
 
0.70 (0.43,1.14) 
p=0.15 
No event 356 (88.1%) 368 
(90.2%) 
 430 (91.3%) 438 (92.6%)  
Not known 10 (2.5%) 12 (2.9%)  4 (0.9%) 12 (2.5%)  
 
Table 5.2.5.2 All thrombotic events – no warfarin vs fixed dose warfarin and no warfarin vs dose adjusted warfarin 
 No warfarin vs FDW No warfarin vs DAW 
 
No Warfarin 
 
n=404 
FDW 
 
n= 324 
Relative Risk 
(95% CI) 
p-value 
No Warfarin 
n= 161 
DAW 
 
n= 84 
Relative Risk 
(95% CI) 
p-value* 
All thrombotic events 
(CRT& non-CRT) 
38 (9.4%) 
 
28 (8.6%) 
 
0.91  
(0.57, 1.45) 
p=0.69 
13 (8.1%) 
 
2 (2.4%) 
 
0.29 (0.07,1.28) 
p=0.10 
No event + not known 366 (90.6%) 296 (91.4%)  148 (91.9%) 82 (97.6%)  
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Table 5.2.5.3  Details of non-Catheter Related Thromboses 
Location Type Diagnosis Time relating to 
CVC removal 
Side Catheter/ 
Thrombosis 
n 
Arm (n=4) Venous Venogram Before LR 1 
RL 1 
Ultrasound Same LR 1 
Arterial Ultrasound Before UL 1 
Leg (n=18) Venous Venogram Before RL 1 
UR 1 
Same UR 1 
NK 
 
RR 2 
UU 1 
Ultrasound Before LL 3 
LR 2 
UL 1 
UR 2 
Same UU 1 
UL 1 
Other Before LL 1 
UR 1 
Subclavian 
Vein (n=1) 
Venous Ultrasound Same RL 1 
IVC (n=2) Venous Venogram Same UR 1 
Other Before RL 1 
Portal Vein 
(n=1) 
Venous Other NK LR 1 
Lung - PE 
(n=10) 
Venous 
 
Other Before 
 
R NA 8 
L NA 1 
Same R NA 1 
 
NK – not known; L – left;  R- right;   U – unknown;   NA – not applicable 
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5.2.5.6 Grading of All Thromboses 
Grading of venous and arterial thrombosis was requested according to CTC 
criteria as specified in the protocol.   Given that there was only one known arterial 
secondary thrombosis, the majority of VTE (71%) were grades 3 and 4, with 8% 
classified as not requiring anticoagulation. 
 
Table 5.2.5.4 Grades of All Thromboses  
Grade CRT (n=85) Non-CRT (n=36) All Thromboses 
(n=121) 
1 3 (4%) 1 (3%) 4 (3%) 
2 8 (9%) 2 (6%) 10 (8%) 
3 54 (64%) 17 (47%) 71 (59%) 
4 4 (5%) 10 (28%) 14 (12%) 
NK 16 (19%) 6 (17%) 22 (18%) 
CRT – catheter-related thromboses;  NK – not known 
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5.2.5.7 Exploratory Multivariate Analysis – Patient Factors; All 
Thromboses 
Table 5.2.5.5 shows the factors entered into the analytic model. 
Table 5.2.5.5  Exploratory Prognostic Modelling for All Thromboses:  
Patient Groupings with Explanatory Variables 
Grouping Variable Number of 
Patients 
Percentage 
Catheter Insertion Site Central 667 42 
 Peripheral 923 58 
Duration of Drug Infusion  <24 hours 283 18 
not included in modelling >24Hours 1307 82 
Sclerosant Potential Non-Sclerosant 746 47 
 Sclerosant 884 53 
Disease Stage No Residual/ Early 534 34 
 Advanced 1040 66 
Tumour Site Other 765 49 
 Colorectal 810 51 
Type of Chemotherapy 5FU*- containing  346 24 
 Non- 5FU-containing 1105 76 
WHO Performance Status 0 890 57 
 1+ 663 43 
Heparin Flushing No 1059 67 
 Yes 513 33 
*  5-FU – 5-Fluorouracil; shaded are stratification factors 
The overall catheter-related thrombosis (CRT) rate in the WARP trial was 7.6%. 
In total, there were 121 thrombotic events.  Only one tumour site out seven risk 
factors above in the univariate prognostic modelling, was found to be significant.  
These are post-hoc groupings which were developed from the results of the trial. 
The result is presented in Table 5.2.5.6 
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Table 5.2.5.6 Univariate Analysis for Site of Disease 
Risk Factor Odds Ratio  
(OR) 
95% CI  for OR p-value 
Tumour Site:  
Colorectal vs other  
0.65 0.44, 0.94 0.02 
 
A multivariate logistic regression analysis for all thrombosis demonstrated that 
colorectal cancer against all other tumour sites remains an independent 
prognostic factor in the presence of all the other factors.  This is a subgroup 
analysis with the post-hoc groupings, based on results. 
 
5.2.5.8 Trial-related toxicities 
5.2.5.8.1 Major Bleeding 
Major bleeding occurred in 28 of 1590 (2%) patients.  There was evidence of an 
excess of major bleeding events in patients on warfarin compared to no warfarin 
[7(0.3%) vs 1(1.7%), RR=6.93, 95%CI 0.86-56.08, p=0.07] and in patients on 
DAW compared to FDW [16(3.4%) vs 7(1.5%) RR=2.28, 95%CI 0.95-5.48, 
p=0.09], although both failed to reach statistical significance (Table 5.2.5.7). The 
results from the analysis restricted to only those patients known to comply with 
their randomised treatment, showed a significant difference between major 
bleeding between no warfarin and warfarin respectively (7/376 (0.2%) vs 1/390 
(0.03%); p=0.04) and an excess was seen in patients receiving DAW in 
comparison to FDW [14/423 (0.03%) vs 6/451 (0.01%); p= 0.07].  According to 
participating clinicians, warfarin may have contributed to the deaths of two 
patients receiving DAW who had a major bleed, one with raised INR and one 
without raised INR; no thrombosis was reported as contributing to death.   
168 
 
 Table 5.2.5.7 Toxicity - Summary of Major Bleeding and Raised INR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Warfarin Evaluation Dose Evaluation 
 
No Warfarin 
n=404 
Warfarin 
n=408 
Relative 
Risk 
(95% CI); 
p value 
FDW 
n=471 
DAW 
n=473 
Relative 
Risk 
(95% CI); 
p value 
Major Bleeding and no reported 
raised INR 
1 3  5 7  
Major Bleeding & 
raised INR 
0 4  2 9  
Total Major Bleeding 1 (0.3%) 7 (1.7%) 
6.93 
(0.86,56.08) 
p=0.07 
7 (1.5%) 16 (3.4%) 
2.28 
(0.95,5.48) 
p=0.09 
Moderate and severe raised 
INR & no major bleeding 
0 3  1 12  
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Tables 5.2.5.8 – 5.2.5.10 illustrate the total number of trial-related toxicities.   
These are categorised into: i) raised INR and no reported bleeding (Figure 
5.2.5.8); ii) major bleeding and no reported raised INR (Figure 5.2.5.9) and iii) 
major bleeding and raised INR (Figure 5.2.5.10).  Reported Serious Adverse 
Events (SAE) are shaded.   There were 30 trial-related SAEs reported on SAE 
forms, each discussed with two physicians independently and then together, in 
order to verify the data.   Other trial-related toxicities, e.g. minor bleeding or 
raised INR, were reported on CRF2 and, if within 5 days of thrombosis or 
catheter removal, on CRF3.  An increase in moderately and severely raised INR 
without major bleeding was documented for 13 patients, in whom three were 
deemed a SAE.  Warfarin was stopped by the local investigators in all cases 
(Table 5.2.5.8).   
Table 5.2.5.8 Toxicity - Raised INR and no Reported Major Bleeding 
Severity Treatment Preference  Details 
Moderate 
(INR=5-<8) 
DAW C2 INR=5.4 
DAW U3 INR=6.8 
DAW C2 INR=5.8 
DAW U3 Unable to stabilise INR (max = 
5.5) 
DAW U3 Unable to control (INR=5.9)  
DAW C2 INR=6.2, disease progression 
FDW C2 INR=5.4 
DAW C2 INR=6.6 due to wrong dose 
Severe 
(INR=8+) 
DAW C2 SAE: INR=8 (moderate) but no 
signs of bleeding   
DAW C2 SAE: INR=9.3 plus vomiting and 
diarrhoea 
DAW C2 SAE: INR>10, alerted by 
haematoma 
Value not 
stated 
DAW C2 Unable to stabilise INR 
FDW C2 No further information available 
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Major bleeding also occurred in this patient population (patients with cancer, 
receiving chemotherapy with CVCs) with no reported raised INR in 19 patients, 
14 of whom were deemed to have a SAE.  Warfarin was a contributory factor in 
the death of one of the patients with major bleeding but no reported raised INR, 
in the opinion of the local investigators.  Six of the 14 SAE major bleeds were 
reported as tumour-related (Table 5.2.5.9).   
 
Table 5.2.5.9   Toxicity – Major Bleeding and No Reported Raised INR 
Severity Treatment Preference  Details 
Grade 3 0W U2 Haematemesis 
FDW C2 Rectum bleed, anaemia 
DAW C2 Nose bleeding 
DAW C2 Rectal bleed 
Grade 4 FDW C2 Tumour-related 
SAE - 
moderate 
FDW C2 Tumour-related 
FDW C2 Tumour-related 
FDW C2 Tumour-related 
FDW C2 Tumour-related 
FDW C2 Tumour-related 
FDW C2 Tumour-related 
SAE – severe 
 
 
 
 
 
 
 
 
DAW U3 Acute UGI bleed (INR=1.3) 
DAW C2 Acute upper GI bleed (perforated 
ulcer)  
DAW C2 GI bleed; patient has  
oesophageal carcinoma 
FDW C2 Abdominal pain and 
haematemesis, 2 units of blood 
given (recorded as moderate) 
DAW C2 Bleeding from stoma site, 
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Severity Treatment Preference  Details 
 
 
SAE -severe 
warfarin stopped (recorded as 
moderate) 
DAW C2 Admitted with haematemesis; 
confirmed myocardial infarction 
FDW C2 Admitted with raised blood 
pressure and confusion. CT 
showed bleed in parietal lobe 
consistent with intracerebral 
haemorrhage 
FDW U2 Patient Haemoglobin 6.0 g/dL on 
admission to hospital (RT sided 
abdominal pain) leading to 
cardiac arrest and death; 
warfarin may have contributed to 
death. 
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In the group of 14 patients with major bleeding and raised INR, all but one were 
reported as SAEs.  The major bleeding was deemed severe in 4 patients, one of 
whom was reported to have „warfarin sensitivity‟ and, in another, warfarin was 
thought to have contributed to their death (Table 5.2.5.10).    
 
Table 5.2.5.10   Toxicity – Major Bleeding and Raised INR 
Severity Treatment Preference  Details 
Grade 2 & 
Moderate INR 
DAW C2 Rectal bleed and INR=5.2 
SAE-Mild DAW C2 INR=8.7; bleeding into knee;  
SAE-Moderate DAW U3 INR=6.1; melaena 
DAW U3 INR>8; melaena;  
DAW C2 INR>12; haemoptysis, splinter 
haemorrhages, leg bleed; 
extreme breathlessness.  
DAW C2 Patient had epistaxis, INR=4.4 
DAW U3 Melaena for 24 hours; INR=4.4 
DAW C2 INR=8.3; haematuria and bruising 
to hip. Hb=8.9 
FDW U2 INR=11, mild epistaxis for 2 
weeks, fatigue. 2 units of fresh 
frozen plasma (FFP). Infection 
 FDW C2 INR=4.8, Patient admitted with 
increasing confusion and 
headaches, CT showed sub-dural 
bleed. Patient given 4 units FFP 
and made full recovery. 
SAE-Severe 
 
 
DAW C2 INR=11-23; renal failure and 
shock; warfarin sensitivity  
DAW C2 INR>15; Per rectum (PR) bleed; 
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Severity Treatment Preference  Details 
SAE - severe warfarin may have contributed to 
death. 
FDW  C2 INR=9.9; history of nausea and 
PR bleeding (possible GI bleed). 
DAW C2 INR=6.1, Patient unwell after 
chemotherapy, severe diarrhoea 
(melaena), exhaustion, pain in 
right shoulder, requiring 
resuscitation on admission; 
patient died next day. 
 
Key to Tables 5.2.5.8 – 5.2.5.10 
0W – no warfarin; FDW – FDWed dose warfarin; DAW – dose adjusted warfarin 
U – uncertain; C – certain.    U2 – 2 arm study (no warfarin vs FDW);   
U3 – 3 arm study (no warfarin vs FDW vs DAW) SAE – serious adverse event 
GI – gastrointestinal; UGI – upper gastrointestinal; g/dL – grams per decilitre 
 
5.2.5.8.2 Minor Bleeds 
There were 47 minor bleeds reported; 22 nasal, 12 rectal, 3 stoma, 3 haematuria, 
3 haematemesis and 4 „other‟ (wound, conjunctiva, haemorrhoid and knee joint).  
There was a significant increase in minor bleeding with any warfarin in 
comparison to no warfarin (p=0.001) but no difference in minor bleeding between 
the FDW and DAW arms [p=0.53] (Table 5.2.5.11).   
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Table 5.2.5.11 Toxicity - Minor Bleeds by Treatment Arm 
  Warfarin Evaluation 
p=0.001* 
Dose Evaluation  
p=0.53* 
Minor 
bleeding 
Overall 
(n=1590) 
No Warfarin 
(n=404) 
Warfarin  
(n=408) 
FDW 
(n=471) 
DAW 
(n=473) 
Yes 47 1 (0.3%) 13 (3%) 18 (4%) 22 (5%) 
*Fisher‟s Exact Test 
 
5.2.5.8.3 Composite Endpoint – Bleeding plus CRT 
In view of the fine balance between the clinical consequences of thrombosis and 
major bleeding, a combined endpoint of thrombotic events plus major bleeds was 
assessed.   No significant difference between treatment arms was found in either 
evaluation (Table 5.2.5.12).  
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Table 5.2.5.12 Composite Endpoint:  Catheter-related Thromboses plus Major Bleeding; All Thromboses plus Major 
Bleeding 
 
 
 
 
 
 
 
 
 
 
 Warfarin Evaluation Dose Evaluation 
 No Warfarin 
n=404 
Warfarin 
n=408 
Relative Risk  
(95% CI); p value 
FDW 
n=471 
DAW 
n=473 
Relative Risk  
(95% CI); p 
value 
Total major bleeding 
and CRT 
25 (6.2%) 31 (7.6%) 1.23 (0.83, 1.52) 
p=0.51 
41 (8.7%) 
 
29 (6.1%) 2.30 (0.72, 7.32) 
p=0.17 
Total major bleeding 
and all thromboses 
39 (9.7%) 37 (9.1%) 0.94 (0.61, 1.44) 
p=0.87 
44(9.3%) 42(8.9%) 0.95 (0.64, 1.42) 
p=0.89 
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5.2.5.9 Overall Survival 
Mortality data were collected on the follow up CRF3.  This consisted of whether 
the patient had died or not, when the date patient was last seen alive or date of 
death and the cause of death.  At the time of analysis, 532 patients were still 
alive with a median follow-up of 45 months (range 26 to 88 months).   Of the 
1058 reported deaths, 921 (87%) were due to cancer; 53 (5%), other causes; 
and 84 (8%), cause unknown.   
 
For the patients in the warfarin evaluation study, median survival was 19 months 
no warfarin group (95% CI 14–20) and 17 months for patients receiving warfarin 
(95% CI 16–22).  For the patients in the dose evaluation study, median survival 
was 21 months (95% CI 19–25) in the DAW group and  21 months in the FDW 
group (95% CI 17-24).  No overall survival advantage was found from taking 
warfarin compared to no warfarin (HR=0.98, 95%CI: 0.77-1.25, p=0.26) [Figure 
5.2.5.1] or found between the two dosing schedules (HR=0.91, 95% CI 0.73-
1.14, p=0.53) [Figure 5.2.5.2]. 
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Figure 5.2.5.1 Survival – no warfarin vs warfarin 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.5.2   Survival -  fixed dose warfarin vs dose adjusted warfarin 
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5.2.6 INR Values and Maintenance from One Centre 
All INR test results were analysed from one centre with five randomising 
clinicians and three coordinators - 54 patients on FDW and 56 patients on DAW.   
Trial number, date, INR result and warfarin dose were collected on paper and 
entered into patient notes from April 2000 until April 2005 at a minimum of 2 
weekly timepoints for FDW and weekly for DAW.  Timepoints for each test 
carried out were assigned to individual patients e.g. baseline (pre-trial), timepoint 
2 at one week, timepoint 3 at 2 weeks, timepoint 4 at 4 weeks etc.  The 
timepoints were on average at two weekly intervals, apart from the first two 
timepoints which were weekly intervals; this concurred with the monitoring of 
warfarin guidelines in section 4.6 of the WARP protocol.  One hundred and seven 
out of 110 patients had a baseline INR recorded (timepoint 1). The number of 
INR tests that individual patients underwent varied greatly, according to the dose 
of warfarin assigned and the length of time they were on treatment e.g. 5 patients 
on FDW and 1 on DAW had one entry only (baseline INR) and one patient on 
DAW had entries for 2 years and 8 months (94 timepoints).  INR determinations 
were taken on average, 6 times for FDW and 19 times for DAW groups over a 
median timespan of 1.8 months and 5.1 months respectively.    Median INR was 
1.10 (IQR 1.04-1.24) for the patients on FDW and 1.69 (IQR 1.43-1.93) for the 
DAW group.  The „loading dose‟ for patients assigned to DAW recommended in 
WARP guidelines was 3mg given for 3 days.  In this one centre with 5 named 
investigators, there was a variation seen in the loading dose for those patients on 
DAW with just over half of patients being started on 3mg warfarin. The variation 
is likely down to clinician choice (Table 5.2.6.1). 
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Table 5.2.6.1  Warfarin Loading Dose for Dose Adjusted Warfarin in One 
Centre  
Warfarin Loading Dose for 
patients assigned DAW 
Number of 
Patients;  n=56 
% of Total Number 
of Patients 
1mg 6 11 
2mg 10 18 
2.5mg 2 4 
3mg 29 52 
4mg 4 7 
4.5mg 2 4 
5mg 3 5 
 
5.2.6.1 Fixed Dose Warfarin Analysis 
Timepoints 3 (3rd blood test for INR) and 8 (8th blood test for INR) were chosen 
for further analysis.  At timepoint 3, the INR values were likely to have sufficient 
exposure to warfarin to be stable (for FDW) or to be within target (for DAW); at 
timepoint 8, there were still sufficient patients having INR tests to carry out a 
meaningful analysis.  For those 18 patients on FDW (1mg daily) with INR results 
for timepoint 3 (INR range 0.9-3.2) and timepoint 8 (INR range 0.9-1.7), the 
change in INRs in individual patients between timepoints ranged from -1.5 to 0.4, 
with median of 0.1.  There was only one patient on FDW, identified at both 
timepoints 3 and 8, who was classified with „mild‟ INR toxicity (2<INR<5).  Three 
patients over all timepoints had „labile‟ INRs on FDW; and were monitored 
throughout their study time.   The protocol stated that should the INR go above 
1.5, then warfarin may be reduced to 0.5mg/day (or 1mg every two days); this 
was adhered to in the three patients with labile INRs on FDW.   The INR was > 
1.5 (above the upper specified limit and in the range of the DAW arm) in an 
180 
 
average of 8% of tests for patients on FDW.  INR results for the first 8 timepoints 
for patients on FDW are summarised in Table 5.2.6.2  
 
Table 5.2.6.2 Summary of INR results on patients on Fixed Dose Warfarin in 
One Cancer Centre for first eight timepoints 
Timepoint No of 
patients 
INR 
median 
INR IQR INR 
Range 
No of patients 
over INR of 1.5 
1 – pre 
warfarin 
baseline 
53 1.0 1.0 - 1.1 0.9-1.3 0 
2 47 1.1 1.0 - 1.2 0.9-1.8 2 (4%) 
3 38 1.1 1.0-1.2 0.9-3.2 1 (3%) 
4 34 1.1 1.0-1.3 1.0-3.7 4 (12%) 
5 32 1.15 1.1-1.25 1.0-5.4 3 (9%) 
6 27 1.2 1.0-1.2 1.0-1.8 3 (11%) 
7 20 1.1 1.0-1.35 1.0-3.4 2 (10%) 
8 18 1.1 1.1-1.4 0.9-1.7 1 (6%) 
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5.2.6.2 Dose Adjusted Warfarin Analysis 
There were 50 patients who were assigned to DAW who had INR results for 
timepoint 3 (INR range 1.0-3.8) and timepoint 8 (INR range 1.1-7.6).  The change 
in individual patient INRs between the two timepoints ranged from -1.0 to 6.6, 
with median of 0.6.    At these two timepoints for patients on DAW, there were 17 
patients with mild INR toxicity (2<INR<5), and one patient with moderate INR 
toxicity (5≤INR<8).  At any one timepoint, there were <50% of patients within the 
specified INR range for DAW.   At timepoint 4, there were still 56% of patients 
with an INR< 1.5.  At later timepoints (6, 7 and 8), around one third of patients 
had an INR>2.0.   DAW results for the first 8 timepoints are summarised in Table 
5.2.6.3.  
Table 5.2.6.3 Proportion of Patients on Dose Adjusted Warfarin in INR 
Target Range over Time 
Timepoint No of patients 
INR < 1.5 
No of patients INR 
within range (1.5-2.0) 
No of patients INR 
>2.0 
1 53 (98%) 1(2%) 0 
2 45(85%) 7 (13%) 1 (2%) 
3 40 (73%) 10 (18%) 5 (9%) 
4 30 (56%) 17 (31%) 7 (12.9%) 
5 17 (31%) 25(46%) 12 (22%) 
6 14 (26%) 21 (38%) 19 (35%) 
7 15 (28%) 21 (39%) 17 (32%) 
8 7(14%) 25 (49%) 19 (37%) 
 
182 
 
5.2.7 Central Venous Catheters 
5.2.7.1 Central Venous Catheter Baseline Characteristics 
The Central Venous Catheter (CVC) variables are balanced across all arms 
(Table 5.2.7.1) with the exception of CVC placement side (left or right), in 
particular in the dose evaluation study in which 89 (36%) of patients on FDW 
against 65 (27%) on DAW had left-sided placements.  Over 40% of the 
placement side data are unknown.  The stratification variables were known from 
the literature or from clinical experience to be of clinical importance to CRT:  
i) out of 1590 patients, 58% of all patients had peripherally inserted central 
catheters (PICCs);  ii) the chemotherapy regimens utilised were an equal balance 
of high and low sclerosant potential and iii) infusional administration 
(administered over 24 hours or more) was favoured (82%). From the data 
submitted, central insertion of catheters was most commonly on the right side of 
the chest (49% versus 11%) [away from the heart] and the left arm was used 
more frequently for PICCs, (35% versus 23%) [right handedness is more 
common].   Most catheters were made of silicone (92%) rather than polyurethane 
(5%) or other materials and over half the catheters used were Groshong (with 
Groshong valve – section 3.6.1.1.2); only 4 catheters out of 1590 were 
implantable ports.  Lastly, single lumen catheters were by far, the most 
commonly used in the WARP trial (78% of patients) [Table 5.2.7.1].   
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Table 5.2.7.1 Central Venous Catheter Baseline Characteristics by Treatment Arm 
  Total n=1590 No Warfarin n=404 Warfarin n=408 FDW n=471 DAW n=473 
Length of 
infusion: 
<24 hours 
24hours+ 
283 (18%) 
1307 (82%) 
64 (16%) 
340 (84%) 
68 (17%) 
340 (83%) 
87 (18%) 
384 (82%) 
86 (18%) 
387 (82%) 
Sclerosant:  
 
No 
Yes 
746 (47%) 
844 (53%) 
172 (43%) 
232 (57%) 
169 (41%) 
239 (59%) 
235 (50%) 
236 (50%) 
236 (50%) 
237 (50%) 
 Catheter  
Placement:  
Central 
Peripheral 
667 (42%) 
923 (58%) 
146 (36%) 
258 (64%) 
150 (37%) 
258 (63%) 
226 (48%) 
245 (52%) 
228 (48%) 
245 (52%) 
CVC Side: 
 
Left 
Right 
Unknown 
395 (25%) 
534 (34%) 
661 (42%) 
111 (27%) 
140 (35%) 
153 (38%) 
105 (26%) 
156 (38%) 
147 (36%) 
113 (24%) 
143 (30%) 
215 (46%) 
86 (18%) 
144 (30%) 
243 (51%) 
CVC Side 
for Central: 
 
Total 
Left 
Right 
Not Known 
667 
72 (11%) 
324 (49%) 
271 (41%) 
146 
17 (12%) 
74 (51%) 
55 (38%) 
150 
16 (11%) 
80 (53%) 
54 (36%) 
226 
24 (11%) 
109 (48%) 
93 (41%) 
228 
21 (9%) 
99 (43%) 
108 (47%) 
CVC Side 
for 
Peripheral: 
 
Total 
Left 
Right 
Not Known 
923 
323 (35%) 
210 (23%) 
390 (42%) 
258 
94 (36%) 
66 (26%) 
98 (38%) 
258 
89 (35%) 
76 (29%) 
93 (36%) 
245 
89 (36%) 
34 (14%) 
122 (50%) 
245 
65 (27%) 
45 (18%) 
135 (55%) 
CVC 
Lumen: 
 
Single 
Double 
1242 (78%) 
323 (20%) 
353 (87%) 
49 (12%) 
332 (81%) 
66 (16%) 
346 (73%) 
117 (25%) 
346 (73%) 
116 (25%) 
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  Total n=1590 No Warfarin n=404 Warfarin n=408 FDW n=471 DAW n=473 
CVC Lumen 
continued 
Triple 
Not Known 
5 (<1%) 
20 (1%) 
0 (0%) 
2 (<1%) 
3 (<1%) 
7 (2%) 
1 (<1%) 
7 (1%) 
4 (<1%) 
7 (1%) 
CVC 
Material: 
 
Silicone 
Polyurethane 
Other 
Not Known 
1462 (92%) 
79 (5%) 
17 (1%) 
32 (2%) 
368 (91%) 
28 (7%) 
3 (<1%) 
5 (1%) 
357 (88%) 
35 (9%) 
1 (<1%) 
15 (4%) 
436 (93%) 
19 (4%) 
6 (1%) 
10 (2%) 
441 (93%) 
13 (3%) 
8 (2%) 
11 (2%) 
CVC Make: 
 
BARD 
Vygon 
Kimal 
Other 
Not Known 
935 (59%) 
439 (28%) 
8 (<1%) 
171 (11%) 
37 (2%) 
223 (55%) 
136 (34%) 
1 (<1%) 
35 (9%) 
9 (2%) 
207 (51%) 
133 (33%) 
5 (1%) 
48 (12%) 
15 (4%) 
295 (63%) 
117 (25%) 
2 (<1%) 
46 (10%) 
11 (2%) 
287 (61%) 
121 (26%) 
5 (1%) 
48 (10%) 
12 (3%) 
CVC Type: 
 
Groshong 
Hickman 
Lifecath 
PICC 
Leader Cuff 
Bardport 
Portocath 
Other 
Not Known 
888 (56%) 
220 (14%) 
195 (12%) 
51 (3%) 
21 (1%) 
2 (<1%) 
2 (<1%) 
189 (12%) 
22 (1%) 
217 (54%) 
59 (15%) 
66 (16%) 
11 (3%) 
9 (2%) 
0 (0%) 
0 (0%) 
39 (10%) 
3 (<1%) 
201 (49%) 
59 (14%) 
63 (15%) 
16 (4%) 
10 (2%) 
0 (0%) 
0 (0%) 
52 (13%) 
7 (2%) 
267 (57%) 
66 (14%) 
51 (11%) 
13 (3%) 
5 (1%) 
1 (<1%) 
0 (0%) 
60 (13%) 
8 (2%) 
275 (58%) 
69 (15%) 
48 (10%) 
14 (3%) 
3 (<1%) 
1 (<1%) 
2 (<1%) 
54 (11%) 
7 (1%) 
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5.2.7.2 Catheter-specific risk factors for thrombosis: 
A univariate analysis identified the number of CVC lumens as a potential risk 
factor for CRT; patients with catheters with double or triple lumens were more 
likely to suffer a thrombosis than those with a single-lumen CVC (p=0.03). CVC 
material appeared to have some importance with silicone CVCs less likely to 
suffer a CVC-related thrombosis than those with CVCs made of polyurethane or 
other materials (p=0.05) [Table 5.2.7.2].  No other factor: catheter placement 
(central vs peripheral), treatment length (<24 vs 24 hours), sclerosant potential 
of chemotherapy (high vs low), type of CVC (valved vs non-valved) or CVC size 
(<4 and 4) was found to be significant at the p=0.1 level of significance. A 
multivariate logistic regression analysis for CRT was not undertaken due to the 
small number of events.   
Table 5.2.7.2  Univariate Analysis of Catheter Risk Factors for Thrombosis 
Risk Factor Odds Ratio  
(OR) 
95% Confidence 
Interval for OR 
p-value 
CVC lumen:  
Single vs double or more 
1.73 1.06 – 2.82 0.03 
CVC material:  
Silicone vs polyurethane and 
other 
2.11 1.02-4.39 0.05 
 
5.2.7.3 CVC Patency 
CVCs were patent for a median time of 13.9 weeks for all patients.   There was 
no difference in the median duration of catheter patency in the warfarin vs no 
warfarin (13.1 vs 13.4 weeks, p=0.55) and the DAW vs FDW (13.3 vs 14.7 
weeks, p=0.27) studies.    
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5.2.7.4 Catheter Complications 
Of the 1590 patients in the trial, details were not available on CVC complications 
for 30 patients because CRF2s were not returned, including 4 patients who 
withdrew from the trial early because CVC was not inserted. In a further 11 
patients, the CRF2s were available but no CVC data were recorded and thus in 
this case, the absence of any CVC complication was regarded as missing.  In 
1212 patients, details on CVC insertion and removal dates were included but no 
CVC complication was recorded and this absence of information is assumed to 
imply that no complication was experienced.  In total, 411 catheter complications 
were reported in 327 different patients. Over 40% of all complications were due 
to infection which occured in 9.1% of all patients (Table 5.2.7.3).  
 
Most patients who experienced a CVC complication only experienced one but 
one patient experienced as many as 6 different complications with a mean 
number of complications per patient of 1.4.    The per-patient complication rate is 
the number of patients who experienced at least one catheter complication out of 
all patients randomised and is calculated to be 327/1590 x100 (20.6%).  
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Table 5.2.7.3 Central Venous Catheter Complication Type 
Complication  Compli- 
cations 
(n = 411) 
% of Total 
Compli- 
cations 
Patients 
 
(n=327) 
% of total 
patients 
n=1590 
Infection 171 41.6 144  9.1 
Suspected Fibrin Sheath / 
Blocked Catheter 
46 11.2 32 2.0 
Inflammation / Erythema / 
Rash / Phlebitis  
44 10.7 37 2.3 
Damaged or Kinked / Line 
Leaking (not exit site) 
43 10.5 39 2.5 
Misplaced or Migrated 
Catheter and 
Pneumothorax 
38 9.2 29 1.8 
Line fell or pulled out 31 7.5 23 1.4 
Exit site leaking / bleeding 12 2.9 7 0.4 
Suspected Catheter 
Thrombosis 
9 2.7 7  0.4 
Other 6 1.0 3 0.2 
Pain 11 2.7 6 0.4 
Total 411 100 327 20.6 
 
5.2.7.4.1 Infection 
144 patients (9.1%) were categorised as having one or more catheter-related 
infections. Infection as the first complication caused a further catheter 
complication in 14.6% (21/144) patients.   Eight patients who had an infection as 
a catheter complication, also had a CRT - i.e. 9.4% (8/85) of all patients who had 
a primary event also had a catheter infection and 5.6% (8/144) of all patients with 
infection as a catheter complication went on to have a CRT.  Two patients with 
188 
 
infection as a catheter complication also developed a non-catheter-related 
thrombosis.    
 
5.2.7.5 Flushing, Fibrinolytic Locks and Positive Pressure Devices 
As an anticoagulant, heparin flushing is a potential confounding factor, not 
stratified for, but is required at very low concentrations to flush non-valved 
catheters.  A fibrinolytic solution (e.g. urokinase) may also be used as a „lock‟ to 
try and prevent CRT.  Positive pressure devices may also be used to minimise 
occlusion (section 3.6.1.1.2).  Around one third of patients had their catheters 
flushed with heparin and 17% of patients had planned use of catheter positive 
pressure devices or fibrinolytic locks.   Table 5.2.7.4 shows the heparin flushing 
and use of positive pressure devices and fibrinolytic locks by treatment.   
. 
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Table 5.2.7.4 Flushing of Catheters by Treatment 
   Warfarin Evaluation Dose Evaluation 
  Overall 
n=1590 
No Warfarin 
n=404 
Warfarin 
n=408 
FDW 
n=471 
DAW 
n=473 
Flushing of catheter: 
 
No 
Yes 
Heparin & Saline 
Sodium/Saline 
Clexane 
Unspecified 
Not Known 
1059 (67%) 
513 (32%) 
438 (28%) 
24 (2%) 
3 (<1%) 
48 (3%) 
18 (1%) 
253 (63%) 
148 (37%) 
124 (31%) 
14 (3%) 
1 (<1%) 
9 (2%) 
3 (<1%) 
252 (62%) 
149 (37%) 
118(29%) 
9 (2%) 
2 (<1%) 
20 (5%) 
7 (2%) 
331 (70%) 
133 (28%) 
121 (26%) 
2 (<1%) 
1 (<1%) 
9 (2%) 
7 (1%) 
326 (69%) 
143 (30%) 
127 (27%) 
0 (0%) 
1 (<1%) 
15 (3%) 
4 (<1%) 
Planned use of fibrinolytic 
locks or positive pressure 
devices: 
No 
Yes 
Not Known 
1062 (67%) 
267 (17%) 
261 (16%) 
269 (67%) 
84 (21%) 
51 (13%) 
269 (66%) 
82 (20%) 
57 (14%) 
309 (66%) 
60 (13%) 
102 (22%) 
308 (65%) 
61 (13%) 
104 (22%) 
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5.2.8 Health Resource Usage   
Data entry for the number of inpatient stays, outpatient attendances and GP 
attendances was extremely poor.  These data were missing on 66% of CRF2s 
and deemed unreliable and therefore an economic analysis was not undertaken.  
The coordinators from the trial centres noted that it was time consuming to find 
these data with any accuracy, unless the patients had had a SAE.  The results of 
the two studies above signified that a detailed health economic analysis was not 
necessary. This was pre-specified in the protocol for the conditions that resulted:   
i) there was no advantage from taking any warfarin in comparison to no warfarin 
in thromboprophylaxis and increased major bleeding was seen in the warfarin 
group.  On balance, warfarin is therefore harmful and is not recommended. 
Cancer patients with CVCs will be safer without warfarin and will be able to save 
time on the extra hospital and GP visits required for INR testing (a mean of 6 
visits for those on FDW in one trial centre during warfarin treatment).  Patients 
were hospitalised for the management of major bleeds thought to be caused by 
warfarin; 28 patients had a major bleed documented (Tables 5.2.5.9 and 
5.2.5.10).  Hospitalisation is a key element of NHS resource and this resource 
may be saved by patients not taking warfarin.  
ii) DAW was superior to FDW but at a cost of more bleeding.  On balance, DAW 
is harmful. The extra visits required for INR testing (a mean of 19 visits for 
patients on DAW in one centre during warfarin treatment) will be saved and as 
above, the health resource consequences of the management of the excess 
bleeding seen with DAW, may be saved. 
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5.3 Meta-analyses  
5.3.1 Thromboprophylaxis for Cancer Patients having 
Chemotherapy  
5.3.1.1 Flow of Information through the Meta-Analysis 
Figure 5.3.1.1  Thromboprophylaxis Meta-analysis Study Selection 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
119 records identified through 
database searching and titles and 
abstracts independently screened 
by 2 reviewers 
2 additional papers identified 
through other sources 
106 records excluded; duplicates, 
not trials, not controlled, not 
cancer patients 
 
15 full text articles assessed 
for eligibility 
3 full text articles excluded as not 
warfarin or LMWH interventions 
only for thromboprophylaxis (n=1); 
not sufficient information in 
abstract (n=2) 
No of studies included in quantitative synthesis n=12 
Primary Thromboprophylaxis:   
Patients with CVCs – warfarin vs no warfarin,   n=5  Figure 5.3.1.1 
Patients on Chemotherapy – warfarin vs no warfarin n=1 (not in meta- 
analysis) 
Patients with CVCs – LMWH vs control   n=4 Figure 5.3.1.3 
Patients on Chemotherapy – LMWH vs control  n=2 Figure 5.3.1.4 
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5.3.1.2 Patients with Central Venous Catheter - Warfarin vs No 
Warfarin 
Of the 121 citations identified in the search, five RCTs were included with 1356 
patients with CVCs.  The pooled data provide no clear evidence of benefit from 
warfarin thromboprophylaxis (odds ratio [OR] 0.7, 95%CI 0.5-1.1; p=0.1) in 
cancer patients with central venous catheters.  These five trials are discussed in 
detail in section 6.2.6.1, „Contextualising WARP‟.  The two studies in which 
patients were screened for VTE and also underwent venography when 
symptomatic [denoted as „asymptomatic‟ in the figures] (Park K et al, 1999; Bern 
et al, 1990)  did contribute to a VTE rate reduction of 70% (p=0.001) whereas 
warfarin confers no advantage in the trials in which only symptomatic VTE is 
measured (10% increase in risk of VTE; p=0.7) [Figure 5.3.1.2].  It is important to 
note that there is a large difference in event rates in the control arms when 
comparing thrombosis rates in the asymptomatic plus symptomatic group 
(27/102, 26%) with only symptomatic VTE subjects (34/572, 6.5%).   For trials of 
cancer patients with CVCs, the addition of the WARP trial reduces the overall 
effect of warfarin such that statistical significance pre-WARP (OR 0.6; 95%CI 
0.3,1.0; p=0.05), is lost (OR=0.7; 95%CI: 0.5,1.1; p=0.1) [Figure 5.3.1.3].  There 
was some heterogeneity seen across the five trials, p=0.06, and none between 
pre-WARP and WARP subgroups, p=0.2. 
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5.3.1.3 All patients; warfarin versus no warfarin 
There was only one study identified (Levine et al, 1994) in thromboprophylaxis 
with warfarin in ambulatory patients and therefore no meta-analysis was carried 
out..  This was the first study of low dose warfarin in women with metastatic 
breast cancer receiving chemotherapy in which 311 women were given either low 
dose warfarin (1mg for 6 weeks followed by adjusted dose to a target INR 0f 1.5) 
or placebo, whilst on chemotherapy.  There was an 85% risk reduction (p = 
0.031) with a thrombosis rate of 4.4% in the placebo arm versus 1% in the 
warfarin arm, with no increase in bleeding.   
 
5.3.1.4 Patients with Central Venous Catheters - Low molecular 
weight heparin vs control 
From 121 records identified in the search, four RCTs were identified in this 
category.  Based on the pooled estimates, LMWH therapy was not associated 
with a significant reduction in VTE (OR 0.7; 95%CI 0.5, 1.1; p=0.2) [Figure 
5.3.1.4].  However, the test for heterogeneity was significant between the trials 
(p=0.03).  Mismetti et al also reported on a small pilot study of 59 cancer patients 
randomised to LMWH (nadroparin) versus warfarin in which there was found to 
be no difference in VTE between the two groups [p=0.48] (Mismetti et al, 2003). 
This paper was rejected from the meta-analysis   
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5.3.1.5 All patients – Low Molecular weight heparin vs control 
Primary Prophylaxis:  There have been four primary prophylaxis studies in 
cancer patients, using LMWHs but only one fully published article.  Firstly, Agnelli 
et al randomly assigned 1150 ambulatory patients with metastatic or locally 
advanced solid tumours receiving chemotherapy to nadroparin 3800IU anti Xa or 
placebo with a composite endpoint of symptomatic venous and arterial 
thrombotic events (Agnelli et al, 2009).  Nadroparin reduced the incidence of 
thrombotic events in comparison to placebo (2% vs 3.9%; p=0.02).  Around 40% 
of the patients in this study had a central venous catheter.   Secondly, a higher 
dose of the same LMWH, nadroparin (5000 anti Xa units), was compared with 
placebo in 389 patients with newly diagnosed glioma in a study, still in abstract 
form, which showed objectively confirmed VTE during the first 6 months: 9 on 
LMWH and 12 on placebo (11% and 17% respectively; HR=0.7, 95% CI: 0.37-
1.5, p=0.3). Over the 12 months there were 5 (5.1%) major bleeds with LMWH 
and 1 (1.2%) with placebo (HR=4.0, 95%CI: 0.5-34, p=0.2) (Perry et al, 2007).  
The authors acknowledged that the study was underpowered.   The pooling of 
these two studies showed a significant benefit for thromboprophylaxis from 
LMWH [OR 0.5; 95%CI: 0.3, 0.9; p=0.03] (Figure 5.3.1.5). There was no 
heterogeneity between the two trials (p=0.6).  Lastly, in the TOPIC 
(Thromboembolism Prevention in Cancer) I trial, 353 patients with metastatic 
breast cancer were randomised to 6 months of certoparin 3000 anti-Factor Xa 
units or placebo.  Patients were screened for DVT every 4 weeks.  VTE rate was 
4% in each treatment group.  In TOPIC II, 547 patients with stage III or IV non-
small-cell lung cancer were randomised as TOPIC I patients.   
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The VTE rate was 4.5% in the LMWH arm and 8.3% in placebo patients (p=0.7).  
In a post-hoc subgroup analysis involving stage IV lung cancer patients, there 
was a statistically significant reduction in VTE with the LMWH (10.1% vs 3.5%; 
p=0.03).   The TOPIC study results are published in one abstract (Haas et al, 
2005) and are not included in the meta-analysis as there are no data to support 
how many patients are in each arm.   Assuming equal numbers in each arm (450 
vs 450), the pooled analysis of the four trials with a total of 2,252 patients, 
reaches greater significance in favour of LMWH (OR 0.6, 95%CI: 0.4, 0.9; 
p=0.008).  
 
Secondary Prophylaxis:  From the 98 records retrieved through database 
searching for treatment of VTE and mortality in patients receiving chemotherapy, 
four studies tested LMWH (long-term) versus short-term LMWHs, followed by 
long-term warfarin, (with one exception:  Hull et al used IV unfractionated heparin 
as the short term heparin before warfarin) for the treatment of VTE (Deitcher et 
al, 2006; Hull et al, 2006; Lee et al, 2003; Meyer et al, 2002).  LMWH provided a 
statistically significant reduction in VTE (OR 0.5; 95%CI: 0.3,0.7; p=0.001) 
[Figure 5.3.1.6].     There was no heterogeneity between the four trials (p=1.0).  
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5.3.2 Anticoagulant Effect on Mortality in Patients having 
chemotherapy 
5.3.2.1 Flow of Information through the Meta-analysis 
Figure 5.3.2.1  Treatment and Mortality Meta-analysis Study Selection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow Charts, Figures 5.3.1.1 and 5.3.2.1, are adapted from Liberati et al, 2009 
„PRISMA‟, (Liberati et al, 2009)  
98 records identified through 
database searching and titles and 
abstracts independently screened 
by 2 reviewers 
0 additional papers identified 
through other sources 
83 records excluded; duplicates, 
not trials, not controlled, not all 
cancer patients 
 
15 full text articles assessed 
for eligibility 
4 full text articles excluded as trial 
changed midway (n=1); not LMWH 
(n=3) 
No of studies included in quantitative synthesis n=11 
Treatment (Secondary Thromboprophylaxis) and Mortality 
Treatment LMWH vs Oral Anticoagulants    n=4  Figure 5.3.1.5 
Mortality – warfarin vs no warfarin    n=4 Figure 5.3.2.1 
Patients on Chemotherapy – LMWH vs control  n=3 Figure 5.3.2.2 
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5.3.2.2 Warfarin vs No Warfarin 
From the 98 records retrieved through database searching for treatment of VTE 
and mortality in patients receiving chemotherapy, seven trials met the inclusion 
criteria and were included in the meta-analysis with a total of 2,453 patients 
including three trials in cancer patients with CVCs with published mortality data.  
The effect of warfarin on reduction in mortality was statistically significant (OR 
0.9; 95%CI 0.8, 1.0; p=0.03) [Figure 5.3.2.2]. 
 
5.3.2.3 Low Molecular Weight Heparin vs Control 
Three trials met the inclusion criteria for this meta-analysis.  A trial by Sideras et 
al (Sideras et al, 2006) in 138 patients with advanced cancer initially compared a 
LMWH vs placebo.  The placebo arm was eliminated part way through because 
of low accrual and therefore was deemed unreliable and the trial was excluded 
from the meta-analysis by the reviewers.   Low molecular weight heparin is 
associated with a statistically significant survival benefit (OR 0.8; 95%CI 0.7, 0.9; 
p=0.001) [Figure 5.3.2.3].   
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5.3.2.4 Summary of the Results of the Meta-analyses 
A summary of the results of the meta-analyses is outlined in Table 5.3.2.1.  
An overall test for trend over the trials (carried out in the analyses with no 
subgroups) demonstrated that the results have significantly changed over time in 
the thromboprophylaxis of CRT in cancer patients using LMWH (p=0.02) [Figure 
4.3.1.3]. There was a significant trend between trials in the pre-WARP 
thromboprophylaxis trials of cancer patients with CVCs p=0.02 [Figure 4.3.1.2]. 
No other significant changes over time were found in the meta-analyses. 
199 
 
 
Table 5.3.2.1 Summary of Meta-analyses Results 
 
Outcome 
Warfarin vs  
no Warfarin 
LMWH vs 
 no LMWH 
Warfarin vs LMWH Figure 
Reference 
Primary 
Prophylaxis 
CRT events 
OR: 0.7; CI 0.5,1.1  
p=0.1  
TTT: p=0.02 (4.3.1.2) 
OR: 0.7; CI 0.5,1.1  
p=0.2 
OTT: p=0.02 
 5.3.1.2 and 
5.3.1.3 - warfarin 
5.3.1.4 - LMWH 
Primary 
Prophylaxis 
VTE events 
- OR: 0.5; CI 0.3, 0.9; 
p=0.03 
OTT: p=0.6 
- 5.3.1.5 - LMWH 
Secondary 
Prophylaxis 
  OR 0.4; CI 0.3,0.6 
p<0.001     OTT: p=0.6 
5.3.1.6 – LMWH 
vs warfarin 
Mortality OR: 0.9; CI 0.8,1.0; 
p=0.03    
OR: 0.8, CI 0.7,0.9 
p=0.001   OTT: 0.4 
 5.3.2.2 – warfarin 
5.3.2.3 - LMWH 
 
OR – odds ratio;  CI confidence interval;  CRT – catheter-related thrombosis;   LMWH – low molecular weight heparin; 
Overall test for trend (OTT); Test for trend between trials (TTT) 
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Figure 5.3.1.2 Meta-analysis of Thromboprophylaxis in Cancer Patients with 
Central Venous Catheters: Warfarin versus Control; Symptomatic and 
Asymptomatic* plus Symptomatic Event Subgroups 
 
 
*asymptomatic + symptomatic events are denoted as „asymptomatic‟  
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Figure 5.3.1.3  Meta-analysis of Thromboprophylaxis in Cancer Patients with 
Central Venous Catheters:  Warfarin versus Control; Pre and Post WARP 
Subgroups 
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Figure 5.3.1.4 Meta-analysis of Thromboprophylaxis in Cancer Patients with 
Central Venous Catheters: Low Molecular Weight Heparin versus Control 
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Figure 5.3.1.5 Meta-analysis of Primary Thromboprophylaxis in Cancer 
Patients receiving Chemotherapy:  Low Molecular Weight Heparin versus 
Control 
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Figure 5.3.1.6 Meta-analysis of Secondary Thromboprophylaxis in Cancer 
Patients:  Low Molecular Weight Heparin versus short-term Low Molecular 
Weight Heparin then Oral Anticoagulant  
 
 
Events are subsequent VTE. 
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Figure 5.3.2.2 Meta-analysis of Mortality in Cancer Patients receiving 
Chemotherapy:   Warfarin versus No Warfarin 
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Figure 5.3.2.3 Meta-analysis of Mortality in Cancer Patients receiving 
Chemotherapy:   Low Molecular Weight Heparin versus Control 
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6. Discussion 
This thesis focuses on the prophylaxis of thrombosis in cancer patients receiving 
chemotherapy via central venous catheters (CVCs) and includes the largest study 
yet completed defining the role of warfarin as a thromboprophylactic for this specific 
group of patients.  The WARP trial adds to the new evidence published over the last 
decade on this topic and has the potential to change international clinical practice.  
The three components of the thesis are now discussed in the context of 
contemporary evidence and practice. 
 
6.1 National Survey of Anticoagulant Prescribing 
Practice  
This was the first survey undertaken in the UK with respect to thromboprophylactic 
practice for cancer patients with CVCs.   The survey provided invaluable data which 
were used to frame the questions to be answered by WARP, namely: 
 Does warfarin have any role to play in the prevention of CVC thrombosis?  
This question was primarily aimed at clinicians in equipoise. 
 Is dose-adjusted warfarin superior to fixed dose warfarin (1mg/day)? This 
question was looking towards the clinical community who have been 
sufficiently convinced by pre-existing trial data to routinely prescribe warfarin. 
 
The national survey strongly influenced the design of the WARP study and identified 
a network of interested clinicians with around 50% of the survey clinicians actually 
participating in WARP.   Twenty percent (19/93) of respondents who completed the 
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open comments box (93/213 [44%]) stated that they would not randomise to a „no 
warfarin‟ arm, four commented that this was “unethical” and two felt “uncomfortable”.   
On the back of the substantial interest in the trial and these comments, the steering 
committee adapted the design of the trial, based on the principle of uncertainty.  The 
1999 survey indicated that 62% of clinicians used warfarin routinely for 
thromboprophylaxis (this could be termed presumptive „certainty‟) and 14.5% 
(19/131) of these clinicians voluntarily stated that they would not randomise to a „no 
warfarin‟ arm.   In practice in the WARP trial, fewer clinicians chose the certain 
preference:  thirty five percent of clinicians were consistently certain of the benefit of 
warfarin whilst 24% chose either certain and uncertain.   
 
In the survey, a comparison of estimated thrombosis rates, split by clinicians using 
warfarin or not, revealed a significantly higher thrombosis rate at the centres where 
the clinicians prescribed warfarin. This is not a randomised comparison and must be 
open to question because of selection and reporting biases.   This small survey was 
successful in its objectives of identifying the current clinical practice in 1999 for 
thromboprophylaxis in patients with CVCs, ascertaining if catheter-related 
thrombosis (CRT) was an important clinical problem and garnering interest in 
participation in a national clinical trial.  However, the open question on CVC types 
generated ambiguity in the meaning of „type‟ with answers including manufacturers, 
trade names used by the companies and slang.   This warranted careful 
consideration of the categorisation of catheter type for the WARP trial and 
highlighted the importance for clinicians in using generic terms for catheters to 
minimise confusion.    Generic categories will be utilised for a future national survey, 
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aiming at assessing the uptake and implementation of the NICE thromboprophylaxis 
guidelines (National Institute of Health and Clinical Excellence, 2010).   
 
Since the pre-WARP national survey was completed, there have been two other 
surveys on thrombosis and malignancy, one in the UK and the other, an international 
on-line survey.  These offer some indication of clinical opinion on CVCs and 
thrombosis.   A small UK survey was reported when WARP was recruiting (Kirwan et 
al, 2003).  The survey was sent by post to 166 oncologists in the North of England 
with a 64% response rate.  From the 106 acceptably completed responses, more 
than a quarter of oncologists did not recognise the thrombogenic effects of 
treatments for cancer, and thromboprophylaxis was rarely used in patients 
undergoing treatment for cancer. Nine out of the 10 oncologists who used 
prophylaxis in chemotherapy noted CVCs as a thrombotic risk factor.  Only three 
oncologists mentioned that they were, „randomising patients with CVCs to different 
warfarin regimens‟ (i.e. participating in the WARP trial).  Oncologists estimated a 
surprisingly low percentage of their patients were receiving prophylaxis, bearing in 
mind that half of respondents mentioned previous VTE and immobility as indications 
for routine prophylaxis. The response from a third of oncologists that VTE does not 
pose a risk was reported as being biased by „low risk‟ specialties such as 
paediatrics.  However, although the thrombotic risk for children with cancer is lower 
than adults, 60% of childhood deep vein thromboses (DVTs) are associated with 
CVCs (Massicotte and Mitchell, 2006) and paediatrics should not perhaps be 
classed as low thrombotic risk speciality.   The North of England survey was a small 
survey without specific questions on CVCs but nevertheless demonstrates a lack of 
awareness of the thrombogenic effects of the treatments for cancer at this time.   
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The international survey, FRONTLINE (Fundamental Research in Oncology and 
Thrombosis), was designed in part to evaluate thromboprophylaxis regimens 
currently practiced by clinicians worldwide for both surgical and medical patients with 
cancer (Kakkar et al, 2003).   Over 3800 responses were received and 
demonstrated that patients undergoing surgery for their malignancy commonly 
receive thromboprophylaxis but medical patients with cancer do not, with the 
exception of patients with a central venous catheter in place.   The majority of 
respondents (80%) perceived an increased risk for venous thromboembolism (VTE) 
in patients with indwelling CVCs.  Regionally, there were substantial differences in 
the perception of risk.  In North America, most clinicians thought that up to 30% of 
their patients with CVCs would develop VTE without thromboprophylaxis.  In Europe, 
and the rest of the world, the perceived risk was lower (Figure 6.1.1).  
Thromboprophylaxis was generally considered normal practice for cancer patients 
with CVCs, particularly in North America and Eastern Europe (p<0.05), compared 
with other geographical regions (Figure 6.1.2). However, 10-20% of clinicians do not 
employ any thromboprophylaxis for their patients with CVCs.   LMWH was the 
antithrombotic of choice for patients with CVCs, except in North America, where low 
dose oral anticoagulation was the most common means employed (Table 6.1.1).  In 
Eastern Europe, a notable proportion of clinicians gave aspirin to reduce the risk of 
CRT.  Another regional difference noted was that in North America, compared with 
Europe and the rest of the world, there was much less reliance on heparin flushes to 
prevent VTE.  In summary, in the section of the FRONTLINE survey relevant to 
CVCs, there was a perceived association between CVCs and the risk of VTE with 
regional variations in the perception of that risk (North America suggesting a higher 
risk than the rest of the world).  The prophylactic regimens for patients with CVCs 
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vary, with North American clinicians using low dose oral anticoagulants rather than 
LMWH (presumably because of higher cost), as used by Western Europe and the 
rest of the world.    
 
The North of England postal survey response rate was more than double that of the 
pre-WARP survey, perhaps because it was confined to one region in the UK where 
clinicians knew of the research team or their institution.  It is impossible to gauge a 
response rate for on-line surveys such as FRONTLINE but the number of overall 
responses (n=3899) suggests a sufficient sample size for analysis.  National (UK) 
guidelines on prophylaxis for VTE during cancer treatment were requested in the 
publication from the North of England survey in 2003 and generic guidelines with a 
specific section on cancer patients, have only recently been published in 2010 
(National Institute of Health and Clinical Excellence, 2010).  Like the pre-WARP 
survey, the subsequent two surveys on thrombosis and cancer demonstrated a large 
variation in thromboprophylactic practice, a lack of standards and guidelines in this 
area and the need for more research into thrombosis and malignancy, including 
thromboprophylaxis with CVCs.  
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Table 6.1.1  Central Venous Catheter and Thrombosis Data from the FRONTLINE survey  
 
Treatment of patients with CVCs for 
thromboprophylaxis 
Thromboprophylaxis regimen used in patients 
with CVCs 
 Use of Thrombo-
prophylaxis 
Removal of Line 
when thrombosis  
 
LMWH 
 
52% 
Never 19% 4% Fixed low dose OA 28% 
Rarely 26% 13% Adjusted dose OA 14% 
Sometimes  22% 31% Aspirin 14% 
Usually  31% 46% s.c. UFH 13% 
Never 2% 6% Heparin Flushes 27% 
 
OA – oral anticoagulant 
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Figure  6.1.1  FRONTLINE Survey Data of Clinicians’ Perception of Risk of 
Thrombosis in Patients with Cancer and a Central Venous Catheter 
 
n = 3891.    *p<0.05 compared with other regions.       ROW - rest of the world 
 
Figure 6.1.2 FRONTLINE Survey Data of Thromboprophylaxis Regimens used 
in Patients with Cancer and a Central Venous Catheter 
 
 
 
 
 
 
 
 
 
Total number of respondents to survey = 3891.  
 *p < 0.05 compared with other regions.       ROW - rest of the world 
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6.2 WARP Trial 
6.2.1 Integrated Approach to Trial Implementation 
6.2.1.1 Trials Infrastructure - Teamwork 
The sound infrastructure of an established multidisciplinary clinical trials unit and 
strong multiprofessional clinical teams enabled WARP, the largest UK-wide trial of 
its kind, to be designed, recruited to, analysed and published.   Whilst all the local 
coordinators in the 68 centres participating in WARP were nurses with the exception 
of one radiographer, only four (one oncology nurse consultant and three senior 
oncology trials nurses) were named as lead investigator, even though nurses were 
encouraged to take on this role by the principal investigator.   From the 
randomisation sheets (Case Record Form [CRF] 1) and the day to day 
communications with trials centres, it was clear that the lead coordinators (nurses) 
were carrying out the vast majority of randomisation procedures in addition to 
coordinating the care pathway of the trial patient (including international normalised 
ratio [INR] monitoring, informing the patient of their trial responsibilities and being 
their first point of contact if needed) and completing the CRFs but not taking on the 
responsibility, traditionally that of the doctor, of the lead investigator (LI). 
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6.2.2 Trial Design  
6.2.2.1 Certain / Uncertain Preferences 
The clinicians‟ preference for being „certain‟ of the benefit of warfarin was reflected 
most strongly in the pattern of randomisations over the first two years of the WARP 
trial; in 2000, 69% of clinicians were certain for the indication for warfarin, and in 
2001, 61% chose the certain preference - Figure 4.2.1.2.  This initial pattern of 
certainty was similar to that of the trial QUASAR (Kerr et al, 2000), where the 
majority of clinicians opted for the certain indication for chemotherapy preference 
over the uncertain indication.  The QUASAR clinicians found it more practical to 
randomise patients into a trial comparing chemotherapy A with chemotherapy B 
(certain indication), rather than chemotherapy versus control (uncertain indication).  
They logged the fact that only one in five patients approached for the uncertain 
indication agreed to participate in the study.   In WARP, the clinician choice for the 
certain preference for warfarin at the start of the trial, may have been due to: i) the 
perception that they were benefiting the patient by offering a „treatment‟ rather than 
no treatment; ii) reliance on anecdotal evidence from their own practice or iii) that 
they were influenced by the available literature at the time, a single, small study 
showing benefit for 1mg of warfarin per day over control (Bern et al, 1990).  
However, after the major protocol amendment, with introduction of the „more 
straightforward‟ uncertain 2-arm option (no warfarin versus 1mg warfarin) at the end 
of 2001, recruitment to certain and uncertain preferences were evenly balanced in 
2002, with uncertain being the majority choice for clinicians and patients in 2003 and 
2004 (Figure 5.2.1.3).  
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One external statistical peer reviewer of one of the WARP publications commented 
that the principles of certainty and uncertainty, 
“should be used more frequently in trial design to get the best evidence from the 
largest number of clinicians in the shortest time”.    
The design enabled 166 patients to be counted in both the warfarin and dose 
evaluations, less than initially calculated, due to the introduction of the uncertain 2-
arm option and was a pragmatic means of encompassing contemporary clinical 
opinion.    This is borne out by the adaptations over time; the initial design was a 3-
arm study which after the survey was adapted to a trial of certain and uncertain 
indication.  Even that design was difficult to deliver in practice and so the 2-arm 
uncertain option was introduced (Figure 4.2.3.2).   This pragmatic approach 
hastened recruitment, whilst allowing the original research questions to be 
answered.  
 
The key question of the whole study was, „does warfarin reduce catheter related 
thrombotic events or not?‟ i.e. the uncertain preference.  After initiating recruitment 
to the WARP trial, two small and underpowered studies failed to show a difference in 
the reduction of CRTs with 1mg warfarin daily (Heaton et al, 2002; Park K et al, 
1999).  These data may also have contributed to the rise in uncertain preference 
recruitment after the first couple of years.  Early WARP newsletters highlighted the 
uncertain preference as the most important clinical question.  For example, the chair 
of the DMC published a statement in the April 2002 newsletter as follows:   
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“The DMC believes that the lack of apparent benefit from warfarin in 3 small 
previous studies – when considered alongside the potential risks from warfarin – 
make the „uncertain indication‟ randomisation between warfarin and no warfarin a 
more appropriate option than the „clear indication‟ option for most patients, and 
that participants should be encouraged to support the „uncertain indication”.  
(Newsletter in Appendix 7).   
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6.2.2.2 Design Amendment 
Following a case conference on one early serious adverse event (where in the 
opinion of the local lead investigator, warfarin may have contributed to the death of 
the patient), it became apparent that the monitoring of the dose adjusted arm (DAW) 
to maintain the INR between 1.5. and 2.0 was causing concern in some centres.  
The patients were finding the additional time and effort travelling for tests (to the 
cancer centre or to the general practitioner [GP]), troublesome and expensive of 
time and finance.   Although there were clear guidelines on monitoring INRs in the 
WARP protocol, specific practices varied between centres, and GPs were often 
asked to monitor INRs without robust systems being set up.    The need for a boost 
in the uncertain preference recruitment as discussed above and the extra burden of 
monitoring the INR for those patients assigned to the DAW arm, persuaded the 
WARP steering committee to apply to the ethics committee in March 2001 for a two 
arm option of no warfarin vs 1mg warfarin, which was granted two months later.   
Following this protocol design amendment, of those patients randomised to any 
warfarin vs no warfarin, 79.4% of patients received fixed dose warfarin (FDW) and 
20.6% received DAW daily, reflecting the intellectual position of randomising 
clinicians but also their capacity to offer DAW to their patients.   The rate of 
recruitment into the trial and the uncertain preference, increased mid-2003 due to 
the availability of the two arm option (Figures 5.2.1.1.and 5.2.1.3).  In 2003, 277 out 
of 475 patients (58.3%) were randomised against a no warfarin arm, 79% of 
clinicians choosing the two arm option.  
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6.2.2.3 Blinding 
The open label trial design of WARP was suboptimal as the observer and the patient 
are aware of the assigned treatment arm and this may lead to prejudging the side 
effects of a particular treatment arm e.g. the unconsciously biased reporting of 
bleeding.  To blind a trial using warfarin, it is possible to undertake „sham‟ INR 
testing for a placebo control arm (Levine et al, 1994) but at a huge cost to the 
patients in undergoing unnecessary tests and cost to the organisation for the 
manufacture of a placebo, extra coagulation tests and the coordination of the 
monitoring a „sham‟.  Therefore, an open-label randomised trial was chosen as 
placebo-controlled was difficult to execute and the cost was prohibitive.   
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6.2.3 Trial Recruitment 
WARP recruited 1590 patients over five years and three months, between October 
1999 and December 2004; 812 were randomised to the uncertain preference (404 to 
no warfarin, 324 to warfarin 1mg and 84 to DAW) and 778 to the certain preference 
(389 to warfarin 1mg and 389 to DAW).  There was an annual mean of 265 
randomisations with a surge in 2003 of 475 patients randomised.  The changing 
pattern of certain/uncertain preference accrual is described above.   Recruitment 
was constantly being addressed by the WARP trial monitoring groups, as it lagged 
behind predicted recruitment from the start, specified in the early versions of the 
protocol for completion, by March 2002.   This was a large overestimation of monthly 
accrual figures by the local investigators and principal investigator as it took another 
2 years and 9 months to reach target recruitment. Consequently, the steering 
committee and the data monitoring committee (DMC) prioritised recruitment 
analyses and discussed recruitment strategies at all meetings. The DMC did not, at 
any point, change the recruitment target which may have been an option for dealing 
with the low event rate, discussed in detail in section 5.2.6.3.  The design change 
along with a good communications plan of site visits, regular newsletters with 
relevant literature, and open access to the principal investigator and trial coordinator 
by phone or e-mail for support, facilitated the attainment of the accrual target, albeit 
with a lower event rate than forecast.   
 
6.2.3.1 Recruitment by clinicians and centres 
There were 175 clinical lead investigators from the 68 centres.   Seventy six percent 
always chose the same preference (41% always uncertain and 35% always certain) 
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whilst the remaining 24% randomised patients to both certain and uncertain 
preferences, presumably taking the condition or the opinion of the individual patient 
into consideration.   In the pre-trial survey, 38% of clinicians did not use warfarin as 
a thromboprophylactic measure and yet more than half of clinicians seemed 
unwilling to randomise to a no warfarin (control) arm when the trial was initiated.   
Using or not using warfarin as a thromboprophylactic measure pre-trial when the 
evidence was scanty and in equipoise, did not directly translate to being „certain‟ or 
„uncertain‟ of the benefit when it came to randomisation preferences in the actual 
trial.  The National Cancer Research Network (NCRN) infrastructure for the 
organisational delivery of clinical trials in the UK started in 2001 and introduced a 
recruitment incentive for clinicians to support NCRN-accredited trials.  WARP 
automatically became NCRN-accredited as it had been previously peer reviewed by 
the Medical Research Council and the then Cancer Research Campaign (now 
Cancer Research UK) and there is no doubt that this NCRN incentive encouraged 
clinicians to recruit to WARP.  
 
6.2.4 WARP Baseline Characteristics  
Baseline patient details are presented in Table 5.2.2.1 and were similar with respect 
to performance status, age, treatment length, disease site and stage of disease 
across all arms.  The numbers of patients randomised to the stratification variables 
were equally balanced across all arms, confirming the quality of the electronic 
randomisation programme.  There is a preponderance of males (57%), reflecting the 
dominant tumour types (gastrointestinal cancers are more common in men) 
mandating chemotherapy via central venous catheters (CVCs).  Clinicians reported 
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that 93% of patients had WHO Performance Status of 0 and 1 which seems high, 
given that 65% of patients had advanced disease but may be generally be expected 
of patients considered sufficiently fit to undergo infusional cytotoxic chemotherapy.    
Patient self-reported performance status is now in common practice throughout UK 
cancer centres and would perhaps be a more reliable measure than that of the 
clinician.  It is interesting to note that the median age of the patients recruited to the 
trial is 60 years, similar to other large reported trials of chemotherapy for advanced 
and early gastrointestinal cancers.  This is a reproducible factor; even although three 
quarters (74%) of cancer diagnoses are in people aged 60 and over, and more than 
a third of cases are in people aged 75 and over (ONS, 2009), it is common to find an 
age difference of a decade lower in patients entered into national and international 
trials of chemotherapy for patients with solid tumours.  It is likely that this reflects the 
consistent degree of selection bias that operates against elderly patients receiving 
chemotherapy (Schrag et al, 2001), which may relate to comorbidity, polypharmacy, 
or reduced performance status.   However, warfarin is safe in the elderly and the 
doses used in WARP are lower than the recommended starting doses for the elderly 
in The American College of Chest Physician Guidelines for management of 
anticoagulants (Ansell et al, 2008).   
 
The majority (51%) of patients entered in the study had early or advanced colorectal 
cancer, reflecting the predilection for 48-hour 5-flourouracil (5-FU)-based 
chemotherapy, promulgated by Professor Aimery de Gramont (Louvet et al, 1992).  
Colorectal cancer is a „thrombotic‟ tumour type (Mandala et al, 2009) [section 
3.5.5.1.2] and although 5-FU was classed as „non-sclerosant‟ in the stratification 
strata, there have been some animal and human case reports on the cytotoxic 
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effects of 5-FU on the vascular endothelium (Tham and Albertsson, 2004; Cwikiel et 
al, 1996); therefore, this significant cohort of patients represented a true test of the 
thromboprophylactic worth of warfarin.  Cancers of the pancreas, stomach, uterus, 
kidney, lung, primary brain and haematological malignancies are associated with the 
highest rates of VTE (Khorana and Connolly, 2009) and constituted another 16% of 
WARP patients (Table 5.2.2.1).  Many of the clinicians in the pre-trial survey stated 
that all their patients with haematological malignancies had a CVC inserted for 
chemotherapy.  VTE rates in patients with haematological malignancies are 
comparable with high risk tumours (Falanga and Marchetti, 2009) and, even in the 
absence of active thrombosis and/or bleeding, present with laboratory signs of a 
hypercoagulable condition or chronic disseminated intravascular coagulation.  
Different degrees of laboratory haemostatic abnormalities can occur, particularly in 
patients with acute leukaemia. Clinical manifestations range from localised small 
thromboses to diffuse bleeding and anticoagulant therapy is complicated in patients 
with haematological cancer.  However, only 3.6% of patients recruited to WARP had 
a haematological malignancy which perhaps reflects the reluctance of the 
haematologists to use warfarin for the reasons outlined above.  The expected low 
platelet counts in these patients also mean having to stop and start warfarin 
frequently.  It is only recently that in patients with multiple myeloma, 
thromboprophylaxis with low molecular weight heparin (LMWH) is employed due to 
the high thrombotic risk of thalidomide and lenalidomide (section 3.5.5.2.2).  
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6.2.5 Compliance 
Compliance is outlined in Figure 4.2.3.1 and split into compliance with i) the 
assigned treatment and ii) warfarin dose.  CRF return was excellent at 97.4% overall 
(Table 5.2.3.1) and was pursued rigorously.  There were more cases of 
patient/clinician non-compliance in the DAW arm (20/473; 4%), than in FDW (5/471; 
1.1%), this finding supports the concerns of the local coordinators and patients who 
were anxious about monitoring warfarin in the DAW arm.  Only 6% of patients 
(72/1186) started warfarin at 3 days prior to catheter insertion which was 
recommended in the protocol but in practice, was not easy to execute (Table 
5.2.1.6).  Of the 1139 patients starting warfarin, 106 (9%) stopped „early‟ (more than 
7 days before the catheter was removed), largely due to the completion of their 
chemotherapy and choosing to stop warfarin at the same time, even although the 
CVC was still in situ and they were still potentially at risk of thrombosis but, having 
gone that far without a thrombosis, the patients may not have been either aware or 
concerned about the risk.  Warfarin also had to be stopped when thrombocytopenia 
developed and, in two cases, was not restarted.  
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6.2.6 Catheter-related Thromboses 
Of the 1590 patients randomised, 85 (5.3%) had a radiologically confirmed CRT, 
occurring most frequently (38%) in the upper limb. There were also 9 clinically 
suspected CRT, not confirmed radiologically and therefore classified as CVC 
complications and not thromboses.  Any warfarin (of which 79% was 1mg and 21% 
DAW) did not reduce the incidence of CRT relative to no warfarin [24 (5.9%) vs 24 
(5.9%), p=0.98] but there were significantly fewer CRT events in those patients 
allocated DAW compared to FDW (13 (2.8%) vs 34 (7.2%), p=0.002).  
 
The no warfarin versus FDW and no warfarin versus DAW comparisons are post hoc 
analyses; the trial was not powered to address these comparisons, patient numbers 
are low in the latter comparison and therefore the analyses are exploratory only.   A 
combined endpoint of thrombosis and major bleeding was assessed to investigate 
any change in risk (of bleeding): benefit (of thromboprophylaxis) ratio.  The dose 
effect of warfarin (DAW superior to FDW) is reduced when the combined endpoint 
was assessed (Table 5.2.5.12).  One interpretation of this finding of a statistically 
significant advantage for DAW over FDW in the reduction of CRT (p=0.002) to no 
advantage seen for DAW over FDW when bleeding plus CRT is examined, is that 
the therapeutic gains made by the reduction in thrombosis rates with DAW are offset 
by the higher bleeding rates overall and it is not worth the risk of using a higher dose 
of warfarin.  This analysis helped frame the conclusion of the dose evaluation study. 
This is an interesting approach to analysis of risk: benefit, focussing on the balance 
of toxicity and efficacy within a single clinical trial. 
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The incidence of CRT was lower than expected, but is in keeping with a temporal 
trend caused by improved catheter design and care. The low event rate restricts the 
power of the warfarin evaluation comparison and is discussed in detail (section 
6.2.6.3).  In the analysis of patients with a CRT event only, median time to CRT 
thrombosis was 32 days from CVC insertion (IQR=13 to 76 days).  Given that CVCs 
were patent for a median of 13.9 weeks, most CRT occurred early.   Median time to 
CRT did not differ in the warfarin vs no wafarin (25 vs 32 days, p=0.71), or DAW vs 
1mg (60 vs 31 days, p=0.51) evaluations.  Analysis of the primary outcome as time 
to event data (with time to thrombosis in those who do not experience the event 
censored at the time of CVC removal), warfarin did not reduce the rate of CRT 
compared to no warfarin (log-rank, p=0.95); by contrast, significantly fewer CRT 
occurred in patients assigned to DAW compared to FDW (log-rank, p=0.002).  The 
time to event results were in keeping with the 2 test comparison of thrombotic 
events.   
 
The analyses of the primary endpoints indicate, therefore, that low dose warfarin 
does not have a useful role in the prophylaxis of CRT.  This is a finding of major 
clinical import, given the survey findings that 62% of the UK‟s oncologists and 
haematologists routinely prescribed warfarin 1mg to prevent catheter thrombosis 
prior to WARP.  There is now no justification for this practice.  However, WARP was 
the first study in which there was a dose comparison of warfarin.  Interestingly, DAW 
conferred a significant advantage in comparison to FDW in the reduction of CRT.  
Counterbalancing the therapeutic benefit was the doubling of major bleeding events 
(16 [3%] versus 7 [1%]) (p=0.09); likewise when the composite endpoint of major 
bleeding plus CRT was examined in the dose evaluation study, there was no 
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difference between DAW and FDW.  More powerfully for clinicians, warfarin was 
thought by the lead investigators to contribute to at least two deaths of patients who 
were assigned to DAW, giving a mortality rate of 0.4% which is similar to the toxic 
death rate in chemotherapy for adjuvant colorectal trials (Twelves, 2006).  So, on 
balance, there does not appear to be a role for the regular use of warfarin in 
thromboprophylaxis of cancer patients with CVCs in any dose.  However, with 
vigilant monitoring of patients, clinicians may wish to offer prophylaxis to specific 
patients at high risk of thrombosis, for example, those who have had a previous 
history of DVT (Saber et al, 2008) or have one of a number of risk factors identified 
e.g. ovarian cancer (Lee et al, 2006) or more than one insertion attempt, a previous 
CVC insertion or a peripherally inserted central catheter [PICC] (Saber et al, 2008), 
outlined in Table 3.6.3.3.  Then DAW would seem the most logical choice but more 
research is needed for this high risk group.   Identifying patients with cancer and 
CVCs who are most at risk of VTE is essential to better target thromboprophylaxis 
with the eventual aspiration of reducing VTE and reducing the sometimes 
devastating adverse consequences of VTE for this group of patients e.g. a 
pulmonary embolus (PE), interruption of treatment or post-thrombotic syndrome. 
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6.2.6.1 Contextualising WARP 
Our findings are in keeping with the results of the more recent studies on 
thromboprophylaxis in cancer patients with CVCs and have challenged the 
outcomes of three early studies.   Bern et al compared 1 mg warfarin for 90 days to 
control in cancer patients with long term central venous catheters (Bern et al, 1990).  
VTE were detected symptomatically and by routine venogram in 15 of 40 (37.5%) no 
warfarin patients in comparison to 4 of the 42 (9.5%) patients on warfarin (p<0.001).  
Monreal et al randomised a similar group of patients to the low molecular weight 
heparin (LMWH), dalteparin (2500iu subcutaneously, daily for 90 days) or control 
(Monreal et al, 1996).  Early trial closure was precipitated by differential upper limb 
thrombosis rates (1/16 dalteparin arm vs 8/13 in control patients, p=0.002), 
confirmed by routine venography.  A Korean group randomised 80 cancer patients 
with CVCs to 1mg warfarin vs control and reported thrombosis rates of 13% vs 29% 
respectively, p=0.07, (Park K et al, 1999).   Although small, these three trials 
suggested a benefit in using prophylactic anticoagulation, reducing thrombosis rates 
with minimal toxicity.   However, from the turn of the century trials have not 
demonstrated a benefit for anticoagulation intervention for cancer patients with 
CVCs.  Heaton et al (Heaton et al, 2002) examined the effects of 1mg fixed daily 
dose of warfarin versus control on thromboprophylaxis in 88 patients with a 
haematological malignancy receiving chemotherapy via CVCs.  No significant 
difference in symptomatic thromboses (18% vs 12% respectively, p=0.4) was 
demonstrated.  Similarly, Couban and colleagues recorded the number of 
symptomatic thrombotic events in a trial of 255 patients (80% with haematological 
malignancies) receiving warfarin 1mg or placebo for 9 weeks (Couban et al, 2005).  
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Overall CRT rates were low; 4.6% with warfarin and 4.0% with placebo (HR, 1.2, 
95% CI, 0.37 – 3.94).   
 
LMWHs, recently evaluated in trials, have also proven no more effective than control 
in the prophylaxis of CRT.  Verso et al adopted a primary endpoint of thrombosis (by 
routine investigation) in a trial of enoxaparin (40mg once daily for 6 weeks) vs 
placebo (Verso et al, 2005) .  In 385 cancer patients, thrombosis rates were not 
found to be significantly different in both arms (14% enoxaparin vs 18% placebo, 
p=0.35). Karthaus and colleagues similarly revealed no symptomatic 
thromboprophylactic effect of dalteparin (5000iu/day) in comparison to placebo 
(3.7% and 3.4% respectively, p=0.88) (Karthaus et al, 2006).  Interestingly, the 
Verso, Karthaus and Couban studies were powered on baseline event rates of 
around 30-32.5%, in keeping with older studies.   
 
In summary, recent single trials of thromboprophylaxis in cancer patients with CVCs 
have shown no benefit in using an anticoagulant – warfarin or LMWH versus control.   
WARP supports these data and is the largest study in this population.  DAW has not 
been previously tested in this population but given the increase in bleeding 
associated with DAW, the „hassle factor‟ identified in WARP by the patients travelling 
for coagulation testing, DAW should not be routinely used.  In order to put WARP in 
context of the multiple thromboprophylaxis studies undertaken and to take 
advantage of the large sample size resulting from the pooling of the results from 
these studies, meta-analyses were undertaken, allowing for greater accuracy and 
statistical power.    
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6.2.6.1.1 Thromboprophylaxis Meta-analyses 
The meta-analysis of thromboprophylaxis in cancer patients with CVCs comparing 
1mg warfarin versus control, provides no clear evidence for using warfarin  (OR 0.7; 
95% Confidence Interval (CI) 0.5, 1.1; p=0.1) [Figure 5.3.1.2] .   Likewise, the four 
randomised controlled trials that compared LMWH with placebo or no intervention, 
demonstrated no statistically significant reduction in the rates of VTE (OR 0.5; 
95%CI, 0.5, 1.1; p=0.2) [Figure 5.3.1.4].    In meta-analysis, each study is weighted 
by the inverse of its own variance which is a function of the study size and the 
number of events in the study.  The corollary for thromboprophylaxis studies is that 
when asymptomatic venographically screened plus symptomatic VTE (i.e. both 
types of event) are measured as an endpoint, these carry more weight than studies 
which measure only symptomatic events, and make comparisons difficult.  Although 
„both events‟ and symptomatic only events were subgroups of the 
thromboprophylactic analyses, combining the events in one meta-analysis has to be 
viewed with caution.  However, there were an inadequate number of trials with either 
symptomatic or both events measured separately, to perform a separate meta-
analysis, for warfarin versus control and LMWH versus control comparisons.  An 
alternative analysis would have been for both prophylactic anticoagulant 
interventions (warfarin and LMWH) to be combined in a symptomatic event only 
analysis and look at the different anticoagulants as subgroups.   As the WARP trial 
was a warfarin only intervention, it was important to observe any influence that 
WARP results had on the previous findings using warfarin only and so the separate 
anticoagulant type analyses were carried out.   WARP was by far the largest 
contributory study in the warfarin thromboprophylaxis meta-analysis and therefore 
gathers greatest statistical weight.  It was therefore of little surprise to find that the 
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inclusion of WARP reduced the odds ratio from 0.6 to 0.7 with an associated loss of 
statistical significance (p=0.1) [Figure 5.3.1.3].  As any anticoagulant intervention 
increases the risk of bleeding, a further limitation of the meta-analyses was that 
bleeding data were not included and therefore the risk / benefit ratio for thrombosis 
and bleeding could not be considered as a whole from the multiple trials.  Lastly, 
even with multiple studies, the lack of effect in some instances could be due to the 
small number of studied patients and events. Even with the WARP trial, the analysis 
of warfarin as a thromboprophylactic intervention in cancer patients with CVCs only 
had 682 patients with 47 events versus 674 control patients with 61 events, p=0.1 
and would be strengthened by increased numbers of patients.   
 
The protocol-driven approach with the double checking of searches, the acceptable 
overall methodological quality found in the studies, combined with the consistency of 
the results (lack of significant heterogeneity in the warfarin intervention trials) and a 
low likelihood of publication bias because of the searching method (e.g. asking the 
experts and inclusion of relevant abstracts), increase the confidence in the internal 
validity of the results. However, a variation between study outcomes in the four trials 
using LMWH intervention was found (test for heterogeneity, p=0.03), suggesting 
„non-combinability‟ and that the pooled results carry a warning to that effect.   The 
decrease in the baseline risk of asymptomatic plus symptomatic VTE events with 
LMWH over the years is notable (section 6.2.6.2). There was also a general 
progressive decrease in the effect size in the thromboprophylaxis studies by year of 
publication, particularly in the LMWH studies.  This may have been due to the 
smaller sizes of earlier studies as it has been reported that small trials exaggerate 
intervention effects compared with large trials (Kjaergard et al, 2001).  Another 
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explanation could be that the trial with 32 patients by Monreal was stopped early 
because of the benefit.  The early cessation of trials for benefit has been shown to 
cause questionably large treatment effects (Montori et al, 2005). 
 
There have been several systematic reviews of thromboprophylaxis in cancer 
patients receiving chemotherapy with CVCs.  A 2003 review in this population (Klerk 
et al, 2003) identified two trials (Monreal et al, 1996; Bern et al, 1990) and concluded 
in contradiction to the thromboprophylaxis meta-analyses in this thesis that warfarin 
1mg daily or LMWH significantly reduce the incidence of CRT.  The disparity is likely 
to be due to these two trials including screening detected thromboses and the later 
studies showing a smaller effect with a greater number of patients.   The findings of  
the primary thromboprophylaxis meta-analyses in patients with CVCs illustrated in 
Figures 5.3.1.2 to 5.3.1.4 are in keeping with Akl et al who published a Cochrane 
systematic review of anticoagulation for thromboprophylaxis in cancer patients with 
CVCs (Akl et al, 2007c).  They found the use of heparin in cancer patients (LMWH 
plus unfractionated heparin (UHF) [UFH is not used in practice now because it 
generally requires an inpatient stay and therefore was not included in the meta-
analyses carried out in this thesis] was associated with a trend towards a reduction 
in symptomatic DVT (relative risk (RR),0.43; 95% CI, 0.18-1.06).  However, their 
pooled results of all different types of anticoagulants [including one study of 
unfractionated heparin (Abdelkefi et al, 2004)] showed that the symptomatic only 
DVT rates were significantly reduced in cancer patients with CVCs (RR 0.56; 95%CI 
0.34, 0.92), concluding that the risk / benefit ratio of anticoagulant burden against 
anticoagulant benefit should be considered by patients.  Because the results of the 
meta-analyses in section 5.3.1.2 were strongly influenced by WARP and the 
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bleeding data from WARP are now known and noteworthy, the recommendation 
from the pooled data in the thesis is not to use warfarin 1mg/day, routinely.  The 
meta-analysis evidence suggests that LMWH should also not be used routinely in 
the thromboprophylaxis of cancer patients with CVCs.  
 
6.2.6.2  Time Trend of Decreasing Incidence of Catheter-related 
Thrombosis 
The incidence of VTE associated with long-term CVCs in cancer patients has been 
assessed in a number of studies (Tables 3.6.3.1 and 3.6.3.2).  CRT are commonly 
asymptomatic, highlighted by the difference in CRT rates in the two tables, one 
measuring symptomatic only CRT and the other, measuring both symptomatic and 
screened CRT.  However, careful definition of CRT incidence has been hampered 
by inconsistent factors that make inter-study comparison difficult.  Over time, there 
has been a general decrease in the incidence of CRT in patients with cancer.  This 
can be seen in the decline in CRT rates in the control arms of the 
thromboprophylaxis meta-analyses by year (Figures 5.3.1.2.and 5.3.1.4). The effect 
is also observed in the incidence of VTE in all catheter studies in cancer patients, 
listed in Tables 3.6.3.1 and 3.6.3.2.   After the turn of the century, there is 
approximately a halving of the rate of CRT compared to trials done before 2000, in 
studies measuring both symptomatic and asymptomatic events (a mean VTE rate of 
37% before 2000 and 17.2% from 2000) and in studies measuring symptomatic only 
events (a mean VTE rate of 11.7% before 2000 and 6.6% from 2000).  
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6.2.6.3 Low Event Rate 
The overall low symptomatic CRT rate of 5.3% in the WARP trial which was 
reflective of the more recent studies, led the Data Monitoring Committee (DMC) and 
Trial Steering Committee to discuss this matter in detail at their reviews.  No formal 
futility analysis was presented and the trial did not have formal stopping rules but, on 
every occasion, the DMC considered stopping or extending the trial and decided that 
the trial should continue as planned.  To deliver a similar proportional reduction as 
was envisaged in the initial power calculation in WARP (25% to 15% ) and given the 
event rate of 5.9% in the control arm, 750 patients in each arm would be required to 
detect a reduction in thrombosis rate to 3% (80% power, 5% level of significance, 2-
sided test).  To increase the patient recruitment target would probably not have been 
feasible, as the WARP trialists were mindful of the two small trials published after 
WARP started showing no benefit for 1mg of warfarin daily and made aware of one 
non-published study from Wake Forest Comprehensive Cancer Centre stopped by 
their DMC because of low event rates and no differences in event rates between 
warfarin and no warfarin (Owen, 1999). In the final year of recruitment, the clinicians 
seemed less enthusiastic about the WARP trial, perhaps because of the emerging 
data and because it had been open to recruitment for so long.  On the other hand, in 
the WARP dose evaluation study, the statistical power at the end of the study was 
87%, with a CRT rate of 7.2%, brought down to 2.8% with DAW, at the 5% level of 
significance (2-sided) with 470 patients in each arm.   This was therefore a well 
powered comparison, using the predicted recruitment numbers. 
 
235 
 
6.2.6.3.1 Differences in Event Rates due to Thrombosis 
Assessment 
Clearly, in the studies in which CRT are assessed on clinical presentation and on 
regular screening by venography (symptomatic and asymptomatic respectively), the 
rates are higher than assessment on symptomatic events only (27% vs 6.5% 
respectively in the meta-analysis – Figure 5.3.1.2).    Although asymptomatic VTE is, 
by definition, covert, these thrombi can embolise to the lungs (Kuter, 2004).  Studies 
have also shown that asymptomatic DVT is strongly associated with the 
development of symptomatic VTE and is also associated with an increased risk of 
death (Cronin et al, 2007).  It is therefore important to consider assessing both 
asymptomatic and symptomatic DVT when looking at the effectiveness of 
prophylactic strategies.   However, thrombosis screening was not carried out in the 
WARP trial due to the extra diagnostic tests involved and their cost.   There are 
surprisingly few data on the natural history of asymptomatic CVC thrombosis, 
although there are indirect data that these may lead to PE (Kearon, 2001; Black et 
al, 1993).  It is of note that two cases of PE were documented in patients with 
catheter complications whereas 10 were found in those with no obvious catheter 
complications.  This ratio of 5:1 corresponds with the approximate ratio of 
symptomatic: asymptomatic VTE in the meta-analysis.  These data are inferential; a 
greater understanding of the natural history as to whether screened thrombotic 
events have the same propensity for PE compared to symptomatic is required.  
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6.2.6.4 Risk Factors – Multivariate and Univariate Analyses 
When investigating baseline risk factors for CRT in a prospective cohort study, Lee 
et al found more than one insertion attempt, previous CVC insertion and ovarian 
cancer to be significant (Lee et al, 2006). The first two factors suggest that vessel 
wall trauma or endothelial damage predispose to CRT. Kraybill and Allen have made 
similar observations; they found that 42% of patients with a history of long-term 
central venous access had evidence of thrombosis on duplex scanning (Kraybill and 
Allen, 1993).  From an individual patient data-level meta-analysis, a multivariate 
logistic regression analysis revealed the use of implanted ports as compared with 
peripherally implanted central venous catheters (PICC), decreased CRT risk (OR = 
0.43; 95% CI, 0.23-0.80), whereas past history of deep vein thrombosis (DVT) (OR = 
2.03; 95% CI, 1.05-3.92), subclavian venipuncture insertion technique (OR = 2.16; 
95% CI, 1.07-4.34), and improper catheter tip location (OR = 1.92; 95% CI, 1.22-
3.02), increased CRT risk (Saber et al, 2008). Many other risk factors for CRT have 
been hypothesised using smaller studies (Table 3.6.3.3).  
  
In WARP, no data on insertion attempts and previous CVC insertion were collected.  
Of the seven factors that were entered into the univariate analysis for CRT, double 
lumen catheters (OR 1.73; p=0.03) and catheters made of polyurethane (OR 2.11; 
p=0.05) were associated with a greater likelihood of CRT.  The other factors, 
showing non-significant results do not indicate that the factors tested were not 
prognostic of CRT; it may reflect an underpowered analysis due to the low number 
of events and the limited number of patients in some of the categorised factors.   
This is somewhat in keeping with previous literature in this field (Gallieni et al, 2008; 
Eastridge and Lefor, 1995).      
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6.2.6.5 Central Venous Catheters 
Fifty eight percent of all patients had peripherally inserted central catheters (PICCs), 
in keeping with a rising trend in usage; only 4 patients had implantable ports.  After 
recruitment to WARP had ended and within the last three years, implantable ports 
are being increasingly utilised in the UK, perhaps because of their low 
thrombogenicity (Heibl et al, 2010).  
 
As mentioned above, CVCs were not fully categorised in the pre-trial survey and it 
was difficult to differentiate between catheter types from the differing terminologies.  
The CVC data collection component of CRF2 was therefore designed with an expert 
group of specialist central venous access device nurses and contained text boxes to 
document catheter manufacturer, size, type, number of lumens and material.  This 
removed the ambiguity in all but the „type‟ category where the data collected were 
not definitive (Lifecath, Groshong, Hickman, PICC, Bardport, Portocathand and 
Leader cuff) for any meaningful analysis.   A detailed log of different catheters used 
at different centres and used generic terms (PICC, central placement, valved or non-
valved, skin-tunnelled or non-tunnelled and implanted port) was therefore 
documented.  These were used for the CVC analysis with the exception of skin-
tunnelled and non-tunnelled as the majority of data were unknown.  However, 
catheters which are required for over 14 days, should always be tunnelled.  Any 
future survey or clinical trial with CVC data collection (e.g. a duration of herceptin 
trial, „Persephone‟), will use generic terms, minimising ambiguity.    
238 
 
6.2.7 All thromboses 
A further 36 (2.3%) patients had a non-CRT thrombosis, making a total of 121 
(7.6%) thromboses in 1590 patients.  Neither warfarin (compared to no warfarin) nor 
DAW (compared to FDW) had any significant impact (p=0.30 and p=0.15 
respectively) on all thrombotic events - Table 5.2.5.1.   Median time to all 
thromboses (CRT and non-CRT) was 44 days (IQR=13-84 days) which was not 
statistically different from the median time of 32 days for CRT.    The reduction in 
CRT events seen with DAW in comparison to FDW did not translate into a decrease 
in all thrombotic events and, in effect, is cancelled out when the composite endpoint 
of thrombosis plus major bleeding is considered.   The rates of all thromboses in the 
no warfarin arm of the randomised comparisons (no warfarin vs warfarin and no 
warfarin vs 1mg warfarin) is the same at 9%; the FDW arm of the two randomised 
comparisons of FDW are similar - 9% (FDW vs DAW) and 8% (no warfarin vs FDW).  
This bears out the uniformity of the groups.  However, in a non-randomised 
comparison, for the FDW arm of the dose evaluation study there is a doubling of the 
rate seen for CRT from 13 (2.8%) to 26 (5.5%) seen for all thromboses (taken from 
Tables 5.2.4.1 and 5.2.5.1).  This begs the question of whether warfarin may be less 
effective in non-CRT.  The natural history and size of CRT and non-catheter-related 
thrombosis need further investigation and this effect may be due to chance as the 
suggestion stems from a non-randomised comparison.  
 
All thromboses are clinically important and risk factors include the tumour, the 
chemotherapy as well as CVCs (section 3.5.5).  The incidence of non-CRT was 
2.3% and is a clinically significant issue.  All thromboses, including pulmonary 
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emboli, should be considered as the primary endpoint of future thromboprophylactic 
catheter trials in cancer patients, as all thromboses require immediate attention, with 
pulmonary emboli (PE) carrying the greatest risk of mortality.  PE were once thought 
to be a rare complication of upper extremity deep vein thrombosis because of the 
smaller lumen of upper extremity veins but a prospective study of 86 patients with 
CRT all of who underwent ventilation/perfusion (V/Q) scanning within 24 hours of 
diagnosis, found a 16% incidence of symptomatic and asymptomatic PE, combining 
clinical and radiological findings (Monreal et al, 1994).  In studies in which V/Q scans 
were performed on all patients with upper extremity deep vein thrombosis (DVT), 
irrespective of pulmonary symptoms, the total PE rate of 11% was twice that of the 
symptomatic PE rate (Monreal and Davant, 2001; Prandoni et al, 1997; Monreal et 
al, 1991), comparable to asymptomatic PE seen in patients with lower extremity 
DVT.   The reported incidence of pulmonary embolism in WARP was 0.8% 
(12/1590); 14% of all thromboses, two of which were related to a catheter 
complication [Tables 5.2.4.3 and 5.2.5.3].    
6.2.7.1 Risk Factors for All Thromboses – Exploratory Multivariate and 
Univariate Analyses 
Risk factors identified from the literature, for all thromboses, were categorised into 
patient, treatment, cancer and catheter related and explored in detail in sections 
3.5.5 and 3.6.3.4.  In WARP, there was one significant risk factor for all thromboses.  
Only two risk factors were found to be significant in the univariate analysis for CRT 
and this is most likely to be reflective of the low number of events and the limited 
number of patients in some of the categorised factors.   „Colorectal‟ was found to be 
a significant risk factor for all thromboses compared with all other tumour sites in the 
univariate analysis and should be explored further in trials with anticoagulants.  
240 
 
6.2.8 Major Bleeding Events 
Although there are potential risks associated with pharmacologic prophylaxis, major 
bleeding complications are reported to be very rare and the consequences of not 
preventing VTE are thought to be greater (Geerts et al, 2004).  There was an excess 
of major bleeding events in patients on warfarin vs no warfarin (RR=4.01, 95%CI 
0.64-25.11, p=0.07) and in patients on DAW vs FDW (RR=1.66, 95%CI 0.90-3.08, 
p=0.09).  An increase in moderately and severely raised INR without major bleeding 
was also demonstrated (Table 5.2.5.8).  According to participating clinicians, 
warfarin may have contributed to the deaths of two patients receiving DAW; no 
thrombosis was reported as contributing to death.   The case histories of the two 
patients who died and in whom warfarin may have contributed to their deaths were 
fully investigated by the principal investigator, with site visits and a case conference 
with key members of the multidisciplinary team including the research nurse.  Both 
patients were not monitored as per the WARP trial protocol; in one case, the GP had 
failed to follow up on an INR in the severe range and, in the other, the bank holiday 
had prevented the patient from having a coagulation test.  The major haemorrhage 
rate in over 13,000 patients receiving warfarin for non-valvular atrial fibrillation (AF) 
was 1.1% with intracranial haemorrhage associated with 90% of deaths from 
warfarin-associated haemorrhage (Fang et al, 2007).    The overall major 
haemorrhage rate in WARP was found to be 0.6%, which is less than the result from 
the above AF cohort study in which the doses of warfarin were greater than WARP.  
It has been possible to demonstrate that DAW to maintain the INR between 1.5.and 
2.0 significantly reduces catheter thrombosis rated compared to 1mg daily dose of 
warfarin, but at the cost of an increase in major bleeding events.  The absolute 
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reduction in CRT thrombosis seen in this study was 4.4% and the increase in major 
bleeding events was 2% with DAW in comparison to FDW, making it unlikely that 
most clinicians would offer routine DAW in this setting.  However, for patients at 
higher than average risk of thrombosis, then the patient must be prepared to accept 
the related toxicity profile.  This extrapolated subgroup of high risk of thrombosis 
patients discussed in section 6.2.6.4 was not sufficiently well represented in the 
present study to offer definitive advice on prescription of DAW; therefore this 
guidance is indirect and conjectural.    
 
6.2.9 Survival 
At the time of analysis, 532 patients were still alive with a median follow-up of 45 
months (range 26 to 88).   Of the 1058 reported deaths, 921 (87%) were due to 
cancer; 53, other causes and 84, cause unknown.     No benefit in overall survival 
was found from taking warfarin compared to no warfarin (HR=0.98, 95%CI: 0.77-
1.25, p=0.26) or between the two dosing schedules (HR=0.91, 95% CI 0.73-1.14, 
p=0.53).  It is perhaps unsurprising that warfarinisation had no impact on overall 
survival as the incidence of life threatening thrombotic events was low and the 
mechanistic data linking the action of warfarin to direct, antitumour effects are scanty 
and fewer than LMWH (Kuderer et al, 2009).  This hypothesis might be better tested 
in a clinical trial of a more homogenous group of patients, say with pancreatic cancer 
(who are at high risk of VTE), in which a factorial design would allow incorporation of 
a chemotherapy question, regime A vs regime B, and a second randomisation 
between anticoagulant and control, properly powered to detect a significant 
difference in overall survival in the adjuvant setting.   
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The two treatment survival curves (no warfarin and warfarin) in the warfarin 
evaluation cross over at around 8 months.  This could mean that the harmful effects 
of warfarin (i.e. bleeding) are seen early on (in the first 8 months) and that the 
benefit is seen after this time.  This is highly speculative, given that CVCs were 
patent for a median of only 13.9 weeks (3.5 months).   
 
The survival findings from the WARP trial, examining 1mg warfarin versus control 
are not consistent with the mortality meta-analysis performed (Figure 5.3.2.2) where 
a significant reduction in mortality was seen (meta-analysis, p=0.03).   The results 
from a meta-analysis of oral anticoagulation in patients with cancer (Akl et al, 2007a) 
concur with the WARP trial findings of no survival benefit from warfarin, although 
they suggested a survival benefit at six months from warfarin in a subgroup of 
patients with small cell lung cancer (SCLC), particularly when the disease was 
extensive.  Subgroup studies are often unreliable. When investigated further in 
another analysis, the authors concluded that the decision for a patient with extensive 
SCLC to start warfarin for survival benefit should balance that benefit with the 
downsides of increased bleeding risk in light of patient values for these outcomes 
(Akl et al, 2007b).   LMWH was also associated with a statistically significant survival 
benefit in cancer patients (Figure 5.3.2.3).  Akl et al demonstrated a survival benefit 
with all heparins (LMWH and UFH) in this population [Hazard Ratio (HR) 0.77; 95% 
CI 0.65, 0.91] (Akl et al, 2007d) and found, in their subgroup analysis, that patients 
with limited SCLC experienced a clear survival benefit with all heparins, not seen in 
extensive disease.   Future research should investigate the survival benefit of 
different types of anticoagulants including the new oral agents in patients with 
different tumour types and stages of cancer.  
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6.2.10 INR analysis 
The results of all the INRs for patients entered into WARP and documentation of any 
action taken were collected and collated for all patients manually in one book in the 
highest recruiting centre.  This systematic approach to monitoring INRs suggests 
that the monitoring was thorough.  The WARP newsletters emphasised vigilant 
monitoring frequently as the case discussions of severe or „high INR‟ serious 
adverse events suggested that INR monitoring could be improved and in particular, 
the coordination and systems between primary and secondary care.  Hospital 
monitoring was therefore recommended unless general practitioners, patients and 
local coordinators had a robust system in place.  The sample of INR results 
(110/1590; 6.9%), taken from a single centre, demonstrated that 8% of patients 
taking FDW at any one time, had INR>1.5 for which the protocol recommends 
reducing warfarin by 50% to differentiate between arms.   The individual variability of 
INR with warfarin in cancer patients is known to be high and the cross-over into the 
comparator arm of DAW (INR between 1.5 and 2.0) is concerning but perhaps to be 
expected in this population.  More worryingly, it took at least five weeks for around 
half of the patients receiving DAW to reach their target INR range of 1.5-2.0 and, at 
this timepoint, 31% of patients still had an INR below lower range limit.   At around 4 
months, 49% of patients were within the DAW range and the proportion of patients 
with an INR<1.5 had reduced to 14%.   These data cannot be extrapolated to other 
participating centres but given the documentary evidence that the monitoring was 
regular and by implication, stringent, there is a poor INR target achievement for 
patients on DAW which may have reduced the benefit found in the FDW vs DAW 
comparison.  
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6.2.11 Continuing Relevance of Central Venous Catheters 
Even with the increasing use of oral chemotherapy drugs for many cancers, as 
witnessed over the last five years, CVCs are still required for the majority of 
regimens noted in the pre-trial survey.  The exception to this would be the 
replacement of infusional 5-flourouracil with oral capecitabine for colorectal, breast 
and some upper-gastrointestinal cancers.  However, in some cases, clinicians and 
patients still prefer a CVC for the administration of the other combination drugs given 
with capecitabine, e.g. anthracyclines and taxanes for early breast cancer, and with 
an increase in use for patients with haematological cancers in particular.  Millions of 
CVCs are used worldwide for the administration of chemotherapies (McGee and 
Gould, 2003) and thrombotic events are a common problem.   Thromboprophylaxis 
in cancer patients with CVCs is still an important clinical question.  
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6.3 Corollary of WARP Trial 
6.3.1 NICE Guidelines 
6.3.1.1 International Guidelines 
The international consensus guidelines on the prevention of VTE from the American 
College of Chest Physicians (ACCP) in 2000 (Hirsh et al, 2001b) were available 
during the WARP trial and recommended: i) thromboprophylaxis for surgical patients 
with cancer and ii) thromboprophylaxis for acutely ill medical patients.  These have 
since been updated twice (Geerts et al, 2008; Geerts et al, 2004) with the latest 
edition including a limited discussion of patients with cancer.  Several international 
oncology societies have also produced guidelines specifically on prevention of VTE 
in patients with cancer:   The National Comprehensive Cancer Network (NCCN), the 
American Society of Clinical Oncology (ASCO), the European Society of Medical 
Oncology (ESMO), the Italian Association of Medical Oncology and the French 
National Federation of the League of Centres Against Cancer, summarised a 
consensus and disagreement paper on all the above guidelines, carried out by a 
working group from all panels (Khorana et al, 2009).   There are other general 
guidelines on thromboprophylaxis and the treatment of thrombosis which include 
cancer as a topic, with individual countries developing their individual guidelines.  
Despite all these guidelines and the evidence of increased risk of VTE amongst 
cancer patients and the benefit of thromboprophylaxis in particular high risk settings, 
surveys of oncologists and their colleagues have demonstrated poor compliance, 
(Joffe et al, 2004; Kakkar et al, 2003) with the most recent survey showing that less 
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than 40% of at-risk hospitalised medical patients receive ACCP recommended 
prophylaxis (Bergmann et al, 2010). 
 
6.3.1.2 National Institute of Health and Clinical Excellence (NICE) 
Guidelines on Thromboprophylaxis 
After the WARP trial and the meta-analysis results were published in abstract form 
at the ASCO and the American Society of Haematology (ASH) meetings in 2005, 
and presented at the annual UK National Cancer Research Institute (NCRI) 
Conference Thrombosis and Malignancy workshop, the author was invited, after 
interview, in 2007 to participate in the National Institute of Health and Clinical 
Excellence (NICE) clinical development group (CDG) to produce guidelines on, 
“Venous thromboembolism: reducing the risk.  Reducing the risk of venous 
thromboembolism (deep vein thrombosis and pulmonary embolism) in patients 
admitted to hospital” (National Institute of Health and Clinical Excellence, 2010) and 
advise on the cancer related topic areas and central venous catheters.  The 
guideline was commissioned by NICE and developed in accordance with the 
guideline development process outlined in 'The Guidelines Manual' (National 
Institute of Health and Clinical Excellence, 2009).   Clinical questions were 
developed to guide the literature searching process and to facilitate the development 
of recommendations by the CDG, based around, „What is the effectiveness of X vs Y 
in reducing the incidence of VTE, where X and Y are the mechanical, other non-
pharmacological (e.g. exercise and foot elevation) and pharmacological prophylaxis 
interventions?‟  The primary outcomes comprised all cause mortality, deep-vein 
thrombosis (DVT) [symptomatic and asymptomatic], pulmonary embolism (PE), and 
major bleeding events, similar to the WARP study. Secondary endpoints sought 
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were post-thrombotic syndrome, chronic thromboembolic pulmonary hypertension, 
heparin-induced thrombocytopenia, neurological events, quality of life, survival and 
length of stay.  The methods utilised for the guidelines generally followed that of the 
meta-analyses outlined in section 4.3.1 but over a broader range of conditions with a 
larger variety of interventions (including warfarin and LMWH). The CDG reviewed 
the results of these but also of „network‟ meta-analyses (combining direct and 
indirect evidence).   
 
6.3.1.3 Recommendations  
Risk assessment is crucial for all patients attending hospital including daycase 
patients.   
6.3.1.3.1  Patients with cancer 
Offer pharmacological VTE prophylaxis to patients with cancer who 
are assessed to be at increased risk of VTE.   Choose any one of: 
 Fondaparinux sodium 
 Low Molecular Weight Heparin 
 Unfactionated Heparin (for patients with renal failure) 
Start pharmacological VTE prophylaxis as soon as possible after a risk assessment 
has been completed. Continue until the patient is no longer at increased risk of VTE. 
Do not routinely offer pharmacological or mechanical VTE prophylaxis to patients 
with cancer having oncological treatment who are ambulant. 
 
Warfarin is not included in this list as LMWHs have been shown to be of greater 
efficacy in primary thromboprophylaxis (Figure 5.1.2.5). 
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6.3.1.3.2 Patients with central venous catheters 
 Do not routinely offer pharmacological or mechanical VTE prophylaxis to 
patients with central venous catheters who are ambulant.   
 Consider offering pharmacological VTE prophylaxis with LMWH (or UFH for 
patients with renal failure) to patients with central venous catheters who are at 
increased risk of VTE.   
All patients are to be assessed for risk of VTE and bleeding 
 
Again, warfarin is not included in this list.  
 
6.3.1.4 Assessing the risks of VTE and bleeding 
Assess all patients on admission to identify those who are at increased risk 
of VTE.  Reassess patients‟ risks of bleeding and VTE within 24 hours of admission 
and whenever the clinical situation changes. 
Medical patients are considered being at increased risk of VTE if they: 
 have had or are expected to have significantly reduced mobility for 3 days or 
more or are expected to have ongoing reduced mobility relative to their 
normal state and  
 have one or more of the risk factors shown in Table 6.3.1.1 
Surgical patients are considered as being at increased risk of VTE if they meet one 
of the following criteria: 
 surgical procedure with a total anaesthetic and surgical time of more than 90 
minutes, or 60 minutes if the surgery involves the pelvis or lower limb 
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 acute surgical admission with inflammatory or intra-abdominal condition 
expected significant reduction in mobility 
 one or more of the risk factors shown in Table 6.3.1.1 
Assess all patients for risk of bleeding before offering pharmacological VTE 
prophylaxis. Do not offer pharmacological VTE prophylaxis to patients with 
any of the risk factors for bleeding shown in Table 6.3.1.2, unless the risk of VTE 
outweighs the risk of bleeding.  
 
Table 6.3.1.1   Risk Factors for Venous Thromboembolism 
Active cancer or cancer treatment One or more significant medical 
comorbidities (for example: heart 
disease; metabolic, endocrine or 
respiratory pathologies; acute 
infectious diseases; inflammatory 
conditions) 
Age over 60 years 
 
Personal history or first-degree relative 
with a history of VTE 
Critical care admission Use of hormone replacement therapy 
Dehydration 
 
Use of oestrogen-containing 
contraceptive therapy 
Known thrombophilias 
 
Obesity (body mass index [BMI] over 30 
kg/m2) 
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Table 6.3.1.2  Risk Factors for Bleeding 
Active bleeding Acute stroke 
Acquired bleeding disorders (such as 
acute liver failure) 
Thrombocytopenia (platelets less than 
75 x 109/l) 
Concurrent use of anticoagulants 
known to increase the risk of bleeding 
(such as warfarin with international 
normalised ratio [INR] higher than 2) 
Uncontrolled systolic hypertension 
(230/120 mmHg or higher) 
 
Lumbar puncture/epidural/spinal 
anaesthesia expected within the next 
12 hours 
Untreated inherited bleeding disorders 
(such as haemophilia and von 
Willebrand‟s disease) 
Lumbar puncture/epidural/spinal 
anaesthesia within the previous 4 
hours 
 
 
Updating guidelines on a regular basis is crucial to safe practice.  Separate 
institutions and organisations in many countries are compiling guidelines from first 
principles such as the UK NICE guidelines, using the same evidence; an 
international effort with member state representation is called for to provide 
consistency.  
 
Despite the evidence for increased risk of VTE among patients with cancer and the 
benefit of prophylactic anticoagulation in high risk areas e.g. surgery, surveys of 
clinicians have demonstrated low rates of compliance with guidelines.  Further 
efforts are underway in the NHS to improve the implementation and utilisation of the 
NICE thromboprophylaxis guidelines in order to bring clinical practice in concert with 
the current recommendations.  This is being monitored nationally and carries 
financial disincentives for non-compliance.   
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6.3.2 Conclusion 
Cancer related VTE in general is increasingly prevalent, with a 28% increase found 
in hospitalised patients between 1995 and 2003 (Khorana et al, 2007c), although 
CRT rates have reduced markedly in the last two decades.  The past few years has 
seen an increasing recognition amongst health providers of the impact of thrombotic 
complications on cancer patients including catheter-related thrombosis and, with 
this, important strides in research in this field.   WARP surpassed existing trials and 
provided the data necessary to influence clinical practice.   There is no role for fixed 
dose warfarin (1mg daily) in thromboprophylaxis in cancer patients with central 
venous catheters.  Our study was unique in that for the first time a variable dose arm 
(DAW) was investigated for efficacy of thromboprophylaxis.   This was found to be 
superior to FDW; however, offsetting this therapeutic benefit, was the increase in 
bleeding incidence.  But perhaps more tellingly, there were two deaths from bleeding 
in which warfarin was a contributory factor and therefore, in balance, there does not 
appear to be a role for warfarin in any dose in the thromboprophylaxis in cancer 
patients with central venous catheters.  With vigilant monitoring, clinicians may wish 
to choose DAW in high risk cases.  However, warfarin is not recommended for use 
in this setting in the recent NICE guidelines (2010) and LMWH may be a more 
appropriate choice for this population of patients only.  The risk / benefit ratio is 
always going to be the sine qua non with respect to anticoagulation therapy.  
 
To reduce the public health burden of VTE in cancer patients with CVCs, it is vital to 
identify patients at greatest risk, for whom prophylaxis may benefit.  On the other 
hand, the majority of patients in WARP who did not have a VTE (low risk) should 
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over time be excluded from prophylaxis studies to protect them from unnecessary 
treatment.  Risk models and markers of thrombosis will therefore become 
increasingly important in order to reduce the often devastating adverse effects of 
thrombosis.  The outcomes from WARP and associated research in this thesis 
played an important role in defining relevant parts of national thromboprophylaxis 
guidelines, thus completing the research cycle from initial empirical observation to 
implementation of national guidance.    
 
6.3.3 Future Research  
From the evidence presented in this thesis; firstly, that low dose warfarin confers no 
advantage over no warfarin in the thromboprophylaxis of cancer patients with CVCs, 
secondly, that warfarin (adjusted to maintain the dose between 1.5 and 2.0) does 
reduce the thrombotic rates in comparison to warfarin 1mg daily but has a propensity 
towards higher major bleeding events and thirdly, from the meta-analysis performed, 
that LMWH does not reduce the thrombotic rates in this population, the focus of 
future thromboprophylaxis research in cancer patients is likely to be around the utility 
of the novel, emerging oral anticoagulant agents.  The scientific rationale for 
continued research of thromboprophylaxis and survival with anticoagulants, outlined 
in section 3.3.5.6, remains compelling.  With the improvements in catheter 
placement and insertion, reduced thrombosis rates and an increasing use of oral 
fluoropyrimidines, the emphasis of future research will switch from catheter-related 
thromboprophylaxis to the investigation of the effect of these novel agents on VTE, 
cancer recurrence and survival in the adjuvant setting.    
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However, one final international study of a novel oral anticoagulant in the 
prophylaxis of VTE in cancer patients with CVCs is being discussed at the 
International Society of Thrombosis and Haemostasis Malignancy Subgroup.  This 
study will require around 1000 patients in each arm to detect differences from 5% to 
2.5% with 80% power at the 5% significance level (2-sided test).  This could only be 
achieved with international collaboration, led by the newly formed Warwick Cancer 
and Thrombosis Network. 
 
Colorectal cancer emerged as a significant risk factor for thrombosis in comparison 
to all other tumour sites (grouped together) and colorectal tumours are known to be 
hypercoagulable (Alcalay et al, 2006).  To this end, a randomised phase II trial of 
placebo versus two doses of a novel oral anticoagulant, has been designed, firstly to 
investigate safety and pharmacokinetics parameters in patients with advanced 
colorectal cancer, before progressing into a large phase III trial in the adjuvant 
setting.    The development of the Warwick Cancer and Thrombosis Network which 
includes internationally renowned experts in this field, has the potential to provide 
useful insight into the natural history of colorectal cancer and the role of 
anticoagulants in changing its metastatic potential.  
 
Finally, an audit of NICE Guidelines will be executed to investigate the impact of the 
guidelines on clinical practice in the UK.  This will include specific questions on CVC 
thromboprophylaxis which can then be compared with the national survey described 
in this thesis.  
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APPENDIX 1 
 
Pre-trial Survey 
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A Randomised Study Comparing Two Warfarin Prophylactic Regimes Against No Warfarin in 
Oncological Patients With Indwelling Central Vascular Access Devices 
 
Please take a few moments to complete this questionnaire to let us know your current clinical practice 
 
Name: 
 
Address: Tel: 
 
 Fax: 
 
 Section 1 
A:  What types of central venous/arterial catheters do you use for administration of cytotoxic drugs?  Please list. 
 
 
 
 
 
 
 
 
 
B: When using such catheters, which drugs do you use and for which diseases?  Please list. 
       Disease  Drug 
 
 
 
  
 
 
 
 
 
 
 
 
C:  Do you routinely administer oral warfarin for prevention of thrombosis after insertion of central venous 
catheters? 
 
  what dose?  ___mgs      How frequently?  _____per day 
 
  please state your reasons briefly 
 
 
   
D:  Do you routinely administer oral warfarin for prevention of thrombosis after insertion of central arterial 
catheters? 
 
  what dose?  ___mgs      How frequently?  _____per day 
 
  please state your reasons briefly 
 
 
   
E:  Roughly, what percentage of patients with central venous/arterial catheters in your practice do you estimate 
have a thrombosis? 
 
At what time, post insertion of catheter, do these most commonly occur? 
 
 
          
YES 
NO 
YES 
NO 
0-7 days 7-14 days 14-28 days Over 28 days 
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Section 2 
 
We are planning to address the question:, “Does the administration of warfarin – either 1mg/day or adjusted to 
keep INR at 1.4-2.0 – post insertion of catheter, prevent thrombosis?” 
 
1.    Do you think this is an important question?  
 
 
2. Would you be interested in finding out more about the trial with a view to participation? 
 
 
 
3. If so, who would be the principal contact(s) at your hospital?   
 
 
Any other comments? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please return this questionnaire in the pre-paid envelope or send to  
 
Annie Young, Research Nurse Manager, Clinical Trials Unit, Clinical Research Block, CRC Institute for Cancer Studies, The 
Medical School, University of Birmingham B15 2TA 
 
Thank you for your time 
YES NO 
YES NO 
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WARP Catheter Care Guidelines 
September 2004 Version 3 
 
adapted from Vascular Access Devices Chapter in The Royal Marsden Hospital 
Manual of Clinical Nursing Procedures, 5th edition, 2000 (Dougherty L, 2000) 
 
 
Contents: 
Deciding on the choice of line and where to insert 
1. Preventing Infection 
2. Maintaining a closed intravenous system 
3. Maintaining Patency 
4. Preventing Damage to the CVC 
5. Discharging patients with a CVC in situ 
6. Removing the CVC safely 
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1. Deciding on the choice of line and where to insert 
The clinician responsible for the patient will decide upon choice of line and insertion 
site. If the clinician is not trained in the insertion of the particular line required, or is 
unsure what is required, advice from an expert IV team, should be sought.  Choosing 
the anatomical site: 
Internal jugular vein 
The internal jugular route is more straightforward than the subclavian in terms of 
procedural difficulty.  Internal jugular lines are more mobile than subclavian lines. 
However, the use of specially designed skin fixation devices, such as the Statlock™, 
can improve the stability of fixation of internal jugular lines and this has been shown 
to reduce the rate of infection (Crnich CJ and Maki DG, 2002) . Their use should be 
considered. 
Subclavian vein 
In general, subclavian lines are less likely to get infected because there is less 
movement of the catheter in the skin at the site of insertion. They are however, 
associated with more complications. There is a greatly increased risk of 
pneumothorax compared to the internal jugular route as the pleura lies immediately 
below the subclavian vein and artery (Galloway S and Bodenham A, 2004). Should 
inadvertent arterial puncture occur, it can be more difficult to control bleeding.  
Because of the increased risk of arterial puncture with the subclavian route, and the 
inherent difficulty of controlling haemorrhage, the patient should have clotting results 
and platelet count checked if there is a perceived or known risk of bleeding (Hadaway 
LC, 2001; Perucca R, 2001; Egan Sansivero G, 1998). 
Femoral vein 
In rare circumstances, the femoral venous route may be necessary, but this is 
associated with a higher rate of infection by virtue of the anatomical location. 
Larger peripheral veins 
PICC lines will frequently be inserted into veins at or around the antecubital fossa. 
Ultrasound guidance 
Ultrasound guidance should be considered whenever an internal jugular line is 
placed, as the technique has been shown to be safer and more efficient than the 
traditional landmark technique. This, however, depends on the appropriate  
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equipment being available and the user being competent in its use, as in unskilled 
hands, ultrasound could be more dangerous than the landmark technique. Certain 
ultrasound devices (e.g. Sonosite) also allow the patency of the vein to be assessed, 
using Colour Power Doppler techniques.  Ultrasound can be used to help identify the 
location, route and patency of the subclavian vein but the technique is limited by the 
presence of the clavicle, which blocks ultrasound transmission. NICE guidance is 
awaited. 
Choosing the type of line 
When CVC access is needed for more than two weeks: 
Because of the increased risk of colonisation or line-related septicaemia, if a CVC is 
needed for more than two weeks, consideration should be given to inserting a 
tunnelled line. This will usually require a patent subclavian vein (the left is easier 
anatomically than the right). Internal jugular lines can be tunnelled but it is technically 
more difficult and there could be a greater incidence of line occlusion due to the more 
circuitous route.  If more than one lumen is necessary, then a more specialised line 
such as a multilumen Groshong or Hickman line will be necessary. 
 Preventing Infection 
Bloodstream infections associated with the insertion and maintenance of CVC‟s are 
among the most dangerous infections that can occur further compromising a patient‟s 
health and often requiring hospitalisation (Emerson et al 1996).   
Maximum barrier precautions should be utilised during the insertion of CVC‟s in order 
to minimise the risk of an insertion related infection to the patient.  
Cleaning solutions of preferably a 2% Chlorhexidine Gluconate in 70% Isopropyl 
Alcohol, should be used for skin cleaning prior and post CVC Insertion and for 
cleaning the needle-free devices (e.g. Bionector/interlink system) prior to accessing 
the line.  If any line is not compatible, 2% aqueous solution must be used as an 
alternative.   If the patient is allergic to chlorhexidine, a povidine iodine based product 
can be utilised however the time frame that povidine iodine is efficacious is 
significantly diminished (Maki DG, Ringer M et al, 1991). 
It is recommended that the potential insertion site be cleansed in concentric circles 
moving from intended site out towards the periphery (Baranowski L, 1993).  
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An aseptic technique in line with each trust‟s infection control policy should be used 
wherever the line is accessed and during procedures involving the exit site.  This 
includes hospital wards.  Sterile powder free gloves and a non-touch technique 
should always be used when handling a CVC.  Hickman and Groshong lines are held 
in place with sutures following insertion. The top sutures should remain in place for 7 
days and the sutures around the exit site for a minimum of 14 days.  As it is likely that 
there will be some bleeding from the exit site following insertion of a CVC it is 
recommended that the dressing is changed within 24 hours of insertion.  Following 
this initial dressing change a transparent semi permeable occlusive dressing (e.g. IV 
3000, Smith and Nephew) allows for moisture vapour transmission whilst enabling 
daily inspection for any signs of infection. It is recognised that some patients may be 
sensitive to this type of dressing and therefore other dressings may be required 
which require closer monitoring.  Where dressings are utilised, they should be 
inspected regularly and renewed immediately should it become soiled, wet or 
detached.  If the dressing is intact with no signs of complications weekly dressings 
can be undertaken.  If the exit site is red, painful or exudating, a minimum of daily 
dressing is required.  Any signs of systemic or local infection should be referred to 
the specialist intravenous (IV) team for advice. 
If the patient develops pyrexia of unknown origin, then catheter sepsis should be 
suspected. In this scenario blood cultures should be taken from each lumen of the 
CVC as well as peripheral cultures. 
Patients should be advised that whilst a CVC is in situ it is advisable that a shower is 
taken in preference to a bath. However if patients wish to bathe they should be 
advised that the exit site should be kept out of the bathwater.  Patients with a CVC 
should be advised against swimming. 
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2. Maintaining a Closed Intravenous System 
If equipment becomes accidentally disconnected, there is a risk of air emboli or 
profuse blood loss.  Fatal air emboli may occur when small bubbles accumulate and 
form tenacious bubbles that block the pulmonary capillaries.  Due to the physiology of 
respiration and its impact on the central veins, if a central catheter is inserted and 
becomes open to the atmosphere air will be sucked into the circulatory system at a 
rate of up to 100ml/second (Phifer TJ, Bridges M et al, 1991).  All equipment used 
with vascular access devices should be Luerlock to minimise the risk of 
disconnection.  A needleless system is the preferred method for accessing any 
venous access device; the manufacturer‟s recommendations for frequency of 
changing of these systems must be adhered to.  The in line clamp or external clamp 
should be used to close the catheter when changing equipment.  Air in line detectors 
should be used to monitor for air bubbles in administration sets when delivered via an 
electronic infusion device.  Infusions, which are not administered via an electronic 
device, should be monitored very closely to prevent the infusion running dry 
particularly where an air inlet is utilised to enable infusion. 
The removal of a central line is a time of high risk for air emboli as for a brief period 
the vein is open to the atmosphere. When patients are able they should lie supine or 
in the Trendelenberg position for removal of a CVC. If a patient is unable to lie flat the 
line should be removed whilst the patient performs the Valsalva manoeuvre or during 
expiration. The patient should remain lying flat if possible for 30 minutes after 
catheter removal (Drewett SR, 2000).  When removing the line gentle digital pressure 
should be applied to the exit site until haemostasis is achieved.  It is documented 
there is a risk of an air emboli for up to 72 hours following a central line removal, this 
risk proportionally increases with the length of time the catheter remained in situ. This 
would appear to be due to the persistence of the skin tract to the vein (Hanley PC, 
Click RL et al, 1984). It is therefore recommended that an occlusive dressing be 
applied to the site for 24-72 hours until epithialisation has occurred (Drewett SR, 
2000). 
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3. Maintaining Patency 
Prior to the catheter being utilised the patency, position and correct functioning of the 
line should be established.  It is imperative that the patency of the catheter is 
maintained at all times, a blockage predisposes to device damage, infection and 
potential delay in treatment.  The patency of any vascular access device should be 
established prior to administration of medicines. The health care practitioner should 
aspirate the catheter and check for blood return to confirm patency.  If a vesicant is to 
be administered the location of the tip must be confirmed prior to utilisation if blood 
return is absent (Masoorli S and Angeles T, 2002).   
There is no requirement to withdraw blood prior to routine flushing of a CVC unless 
blood samples or blood cultures are required.  All lumens of indwelling CVC‟s should 
be flushed at established intervals and in accordance with manufacturer‟s guidance.  
Flushing with 0.9% sodium chloride should be performed before, between and after 
the administration of each different medication/solution to prevent precipitation inside 
the lumen. The volume of sodium chloride should be at least twice the volume of the 
catheter. Any unused lumen should be flushed at least once a week even if other 
lumens are being utilised. Heparinised saline unless contra-indicated is the preferred 
solution for maintaining patency of non-valve central venous catheters for intermittent 
use. The concentration of heparin should be the lowest possible that will maintain 
patency which is usually 10 iu/1ml 0.9% sodium chloride.  Groshong lines do not 
require a heparinised flush due to their patented non-return valve. 
Flushing of the central catheter should utilise a pulsated flush, which creates 
turbulence within the catheter lumen thereby removing debris from the internal 
catheter wall (Todd J, 1998; Goodwin ML et al, 1993).  A positive pressure technique 
should be maintained when completing the flushing procedure, which helps prevent 
blood entering the catheter after flushing. This is accomplished either by clamping the 
line as the last 0.5ml are infused, maintaining pressure on the end of syringe whilst 
removing from the injection cap or utilising positive pressure injection caps. 
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4. Preventing damage to the Central Venous Catheter 
Whenever accessing a CVC, only syringes of 10ml and above must be utilised as 
anything smaller may lead to a rupture of the catheter.  To prevent accidental 
damage to CVC, scissors or toothed forceps should never be used on or near the 
CVC‟s.  If the catheter has a clamp this should be moved at regular intervals to 
reduce the risk of damage at one point.  Patients should be informed not to wear 
brooches in the vicinity of their CVC.  Vacuum blood collection bottles should not be 
used without consulting the manufacturer‟s literature as these may create too much 
internal pressure within the catheter therefore increasing the risk of rupture. 
 
 
5. Discharging Patients Home with a Central Venous Catheter in 
situ 
Patients discharged home with a CVC should be educated regarding the care and 
maintenance of the device.  Patients should be educated on potential complications 
of CVC‟s and initial management.  Patients should be given 24-hour contact numbers 
to seek professional advice in case of any anxieties regarding CVC. 
An initial catheter care pack should be supplied with the patient on discharge, which 
includes equipment for flushing of the line and dressing change.  If patients have a 
peripherally inserted central catheter (PICC) in situ they should be educated 
regarding the importance of not placing anything heavy or sharp over the external 
portion of the PICC.  Community nurses should be informed of patients who are at 
home with a CVC in situ. Written information should be sent from the hospital to the 
community nurses stating the exact position of the catheter tip, whether blood return 
has ever been obtained and potential signs and symptoms of catheter complications. 
If PICC is in situ, community nurses should also be informed of the length of PICC 
externally visible so that monitoring for migration can be undertaken at every visit. 
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6. Removing the Central Venous Catheter 
Removal should only be undertaken by appropriately trained personnel to minimise 
pain, trauma, risk of air emboli and infection.  This is an aseptic procedure.  Prior to 
the procedure a full blood count and clotting screen may be required dependent upon 
diagnosis, treatment and concurrent medications.  Following removal the CVC should 
be inspected to ensure complete removal has occurred. If there is any uncertainty a 
CXR should be performed to assess for radio opaque fragments, any fragments will 
require surgical removal.  Following removal of CVC the tip may be sent to 
microbiology for bacterial culture and sensitivity assessment. This is particularly 
pertinent if catheter related infection is suspected or patient has pyrexia of unknown 
origin. 
These guidelines were issued to the local coordinators when updated.  No external 
monitoring of adherence to the guidelines was undertaken. 
 
 
 
References in Section 7 
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Example of Patient Information Sheet  
 
Uncertain Preference - 3-arm Option 
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Patient Information Sheet – uncertain indication for warfarin 
                                                                                         three arm study 
 
 
Patient Information Sheet  
 
WARP –DOES WARFARIN PREVENT CATHETER CLOTS? 
 
We would like to invite you to take part in a large clinical trial called the WARP study.   We hope to 
involve 1400 cancer patients who are having a long tube or line (called a central venous catheter or 
CVC) inserted into a large vein so that chemotherapy may be given more easily.  This sheet tells you 
about the study and what joining it would involve.  You do not have to decide at once and you may 
wish to take this sheet away with you and discuss it with your relatives and friends first. Taking part in 
this study is entirely voluntary. If you do not want to take part, simply say so. Your nurses and doctors 
will respect your decision and your current and future care will not be affected in any way. 
 
Why are we doing the WARP study? 
One of the complications of giving chemotherapy through a CVC is that a blood clot (a thrombosis) 
may sometimes occur, either in the tube or in the vein leading from the tube.  If this happens, it can 
cause discomfort and will interrupt your chemotherapy treatment for a short while.  Very rarely, the 
clot can extend to the lungs and this may be life-threatening. 
We want to find out if warfarin – a blood-thinning drug – given in very low doses, safely reduces the 
risk of getting a catheter clot.  At the moment, around half of the doctors in the UK regularly prescribe 
warfarin for this purpose and the other half do not.   We do not know if warfarin makes any difference 
or not in stopping clots forming. We are doing the WARP study to try and find out the most effective 
and safest way of preventing clots in and around the lines. 
 
What is the study about? 
There are three different treatments that we are comparing –  
 
Treatment 1  No warfarin and  
 
Treatment 2 Warfarin      - 1mg/day  
 
Treatment 3                      Adjusted small doses of warfarin  - to keep the blood clotting 
test  
(the ‘INR’) between 1.5 and 2.0.   The actual adjusted dose will be different for different patients.  It 
will probably mean taking more than more than 1mg/day and if necessary, changing the dose up or 
down periodically, to get your blood clotting time in the range of 1.5 – 2.0. 
   
Why is WARP important?  
We want to find out the most effective and safest way of preventing clots in and around CVCs.  To do 
this, we need to collect accurate information about large numbers of patients being treated by the three 
methods.  We will be looking at differences in the number of clots and the intensity of any side-effects 
in the different groups. 
 
What are the alternatives? 
If you decide not to take part in the trial, your nurse or doctor will advise you of what their normal 
practice is with regard to prevention of clotting. 
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What would taking part involve?  
If you agree to take part in the trial, we will telephone the Trials Office before you have your CVC 
inserted. They will tell us which ‘treatment’ you have been allocated. In order to make the choice of 
treatments for patients as fair as possible, the computer will choose one of the three treatments  (no 
warfarin; warfarin 1mg/day or adjusted doses of warfarin) for you at random, i.e. ‘randomise’ you in 
the trial.  Half the patients will draw no warfarin and half will draw warfarin. So you have a 50:50 
chance of getting either one. If you are allocated warfarin treatment, you will then have another 50:50 
chance of receiving either warfarin 1mg/day or the adjusted dose of warfarin: 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you are allocated to have no warfarin (treatment 1), your central line may be inserted anytime.  If 
you are allocated warfarin (treatments 2 and 3), you should, if possible, start taking the warfarin 
tablets 3 days before the line is inserted and have your blood ‘clotting’ checked again on the day or the 
day before your line is placed.   
For the patients who have been allocated treatments 1or 2, there should be no extra visits for 
monitoring clotting.  If you are allocated the adjusted dose of warfarin (treatment 3), there will likely 
be a few more visits to the hospital outpatient clinic (or your GP’s ‘anticoagulant’ clinic if they have 
one) to monitor your blood clotting time.  This may be around 2 visits per month and can often be 
made to coincide with chemotherapy checks or treatments.  Unfortunately we are unable to cover the 
costs of these extra clinic visits. 
If you are allocated treatments 2 or 3, you should take warfarin until your CVC is removed or a clot 
occurs (the end of the trial), unless your doctor or nurse advises you otherwise.  Your doctor and nurse 
may feel it is appropriate to continue your warfarin medication after the end of the trial, for an 
indefinite period, at the same dose. They will discuss that with you nearer the time.  If warfarin is 
continued, you will be monitored as you were on the trial. 
 
If you are allocated warfarin and become pregnant, you must contact your doctor to arrange to 
stop the warfarin as soon as the pregnancy is confirmed, as warfarin can damage the baby in the 
first part of the pregnancy. 
 
In some centres only, you may be asked to give one extra blood sample (4 ml, a teaspoon) to be taken 
at the same time as routine bloods, on three occasions, for a special clotting factors test.  These extra 
tests are entirely optional – if you are asked and do not wish to give the blood, please just tell the nurse 
or doctor. 
  
Your nurses and doctors are very interested in WARP and, therefore, your progress will be followed 
very closely. 
 
What are the side-effects ? 
The side-effects of the your particular chemotherapy and the risks of having the line inserted will have 
already been explained to you. You will also have been told how to care for your line to avoid any 
infection in or near the line.  If you have any questions about these procedures, please ask your nurse.  
 
 
1/2 patients 
draw Clinician phones 
trials office  Computer chooses  
at random i.e  
randomises 
1/4 of all 
patients  
draw 
 
1/2 patients 
draw 
 
1/4 of all 
patients  
draw 
Wish to take part 
in WARP trial 
Warfarin  
No Warfarin 
Warfarin  
1mg/day 
Adjusted warfarin dose 
to maintain the blood 
clotting test (INR) 
between 1.5 and 2.0 
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You should report any tenderness, swelling, or change in colour in the arm or the side where the line is 
as these may be early signs of a clot forming.  
If you are allocated warfarin, we are not expecting any adverse effects at the small doses prescribed in 
this trial but we will monitor your blood clotting very carefully to minimise the possibility of any 
minor bleeding– a side-effect associated with this drug.   
Very rarely, the bleeding may be large or may be life-threatening.  We will ask therefore you to tell us 
immediately of any changes in the colour of your urine or stools and of any new pains. Also, some 
medicines that you may be taking may interfere with the action of warfarin so you must tell your nurse 
or doctor of all medications you are taking at all times. 
  
What happens to the information? 
We will give your GP information relating to this trial, only if you give permission. 
Information about you collected for the trial will be kept at the Cancer Research UK Trials Unit at the 
University of Birmingham and is totally confidential. Only authorised members of the research team 
will have access to your medical records in order to collect the information we need for the study.  
Results of the study will be published but nothing that could identify you individually will be reported. 
 
Will participation in the study affect my legal rights? 
There are no special arrangements for compensation in the event of you suffering any adverse event 
from taking part in the study.  But, whether or not you take part, you would retain the same legal rights 
as any other patient treated in the National Health Service. 
 
How do I join the study? 
This is a decision for you to make and if you wish to take part, you should read this leaflet carefully 
and ask your nurse or doctor if there are things that you do not understand.  If you choose to join the 
study, you will be asked to sign a consent form and then the nurse or doctor will call the study 
organisers and enter you into WARP. You may still change your mind and leave the study at any time 
you wish without any problem. 
 
What happens at the end of the study? 
After the trial, when your CVC is removed or there is a clot, your progress will be monitored as usual.  
We will do the analysis for all the patients and will inform interested patients of the results some time 
after the study has finished. 
 
Could warfarin be a treatment for cancer? 
Warfarin has been investigated as a cancer treatment for many years.  There is little evidence to 
suggest that it makes any difference to the growth of different cancers.  We will monitor this in 
WARP.  
 
Contact Numbers 
The nurse at your hospital will give you the local contact numbers.  
 
Your local nurse contact is:   ___________________________________   Tel:  ___________ 
 
You may also contact the lead investigator Annie Young in Birmingham, pager number:  
. 
 
In addition, if you would like to discuss the study with an independent person, you can phone  
……………………………………………………………………………………………………. 
 
We thank you for taking time to read this leaflet and consider the study, the answer to which will make 
it a lot easier for us to advise on how best to prevent catheter clots in future patients 
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Patient Consent Form 
 
A MULTICENTRE PROSPECTIVE RANDOMISED CONTROLLED TRIAL 
OF THROMBOSIS PROPHYLAXIS WITH WARFARIN IN CANCER 
PATIENTS WITH CENTRAL VENOUS CATHETERS 
 
Patient Consent Form 
To be completed by the nurse/doctor 
I have explained the nature of the WARP study to ………………………………… 
 
I have explained the trial to my patient and he/she has agreed to enter the study. I have 
made it clear that he/she may withdraw at any time without giving a reason and without 
affecting any future care.  The patient has been given the opportunity to ask any questions 
about the study and his/her treatment. 
 
Nurse’s / Doctor’s name (print)………………………………………      Date.……… 
  
Signature  ………………………………………….. 
 
 
To be completed by the patient 
 
I have read and received a copy of the information sheet provided.  
    
I confirm that I am satisfied with the information provided about the WARP 
study.  
I have had the opportunity to ask any questions that I have about the study. 
   
I understand that I am free to withdraw from the study at any time without 
giving a reason. If I decide to leave the study I understand that this will not 
affect my future care. 
 
I also understand that my medical records and any data collected as part of the 
study will remain confidential and will only be handled by authorised 
personnel associated with the study. 
 
Your signature indicates that you have read the patient information sheet and this form, 
have had any questions relating to the study answered satisfactorily, and willingly 
consent to participate. 
 
 
Patients signature ……………………………………   Date    …………….   
 
 
Witness name (print) ………………………………     Status  ……….…… 
 
 
Witness signature ………………………….  Date   
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Guidance for Nurses Taking Informed Consent 
 
In many centres, nurses are key to the ongoing informed consent process within 
their oncology/haematology research team.    Nurses obtaining written informed 
consent add significant advantages (including continuity of care and reduced 
waiting times) to centres and patients. Nurses are also accountable for their 
actions in their own professional practice.  The logical corollary from these 
statements is that if the nurse has explained the nature of the trial to the patient, 
then they should be the person signing to say this and not another party on their 
behalf.   
The signature on the WARP consent form confirms that: 
1) the description/implications of the trial have been given to the patient, 
highlighting that they may withdrawal at any time. 
2) the person taking consent has given the patient the opportunity to ask 
questions: 
See WARP consent form - extract below: 
To be completed by the nurse/doctor 
I have explained the nature of the WARP study to ……………………………… 
I have explained the trial to my patient and he/she has agreed to enter the study. 
I have made it clear that he/she may withdraw at any time without giving a 
reason and without affecting any future care.  The patient has been given the 
opportunity to ask any questions about the study and his/her treatment. 
Nurse’s / Doctor’s name (print)…………………………      Date.……… 
Signature  …………………………………………………………. 
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The principal investigator and the steering committee recommend therefore that 
those nurses (and indeed other healthcare professionals) who are sole 
professional signatory on the consent form should:  
1. be deemed competent (knowledge and experience) in „taking informed 
consent‟  
2. have endorsement from their employer with indemnity made clear (The 
Royal College of Nursing (RCN) indemnity cover is available for nurses who 
are involved in the informed consent process for research purposes). 
 
Since WARP started, the team through the principal investigator has encouraged 
and supported nurses in the informed consent process, backed up by numerous 
professional guidelines and frameworks.    During the trial, some helpful 
documents have been prepared and published on the attendant responsibilities 
of the nurse in „seeking‟ and „obtaining‟ informed consent (knowledgable 
explanation of trial, signature on form and ongoing availability to answer 
questions as they arise).  These are cited below: 
Consultation Document – RCN Guidance on Informed Consent in Health and 
Social Care Research (Royal College of Nursing, 2001) – the WARP principal 
investigator is one of the authors of this Guidance 
The NCRN Clarification Statement and Briefing Paper re: „Nurse Involvement in 
the Informed Consent Process‟ 
http://www.ncrn.org.uk/downloads/informed_consent.pdf (last accessed 
December 2005).    
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A summary of the background to nurses participating in the informed consent 
process is given below: 
 ICH (International Conference on Harmonisation, 2000) Guidelines for 
Good Clinical Practice (GCP) state that informed consent process and the 
associated responsibility of being the sole signatory on a consent from may be 
delegated by a physician. 
 The Declaration of Helsinki (World Medical Assembly, 1964) states that 
obtaining consent should be done by a physician – this Declaration is currently a 
guideline and not law. 
 The Department of Health Good Practice in Consent Implementation Guide: 
the law in England (Department of Health, 2001), point 6, states:  „It is always 
best for the person actually treating the patient to seek the patient‟s consent.  
However, you may seek consent on behalf of colleagues if you are capable 
performing the procedure in question or if you have been specifically trained to 
seek consent for that procedure‟. 
 The Department of Health, „Good Practice in Consent Implementation 
Guide: Who should seek consent‟ (Department of Health, 2001)  says that the 
same legal principles apply when seeking consent for research purposes as 
when seeking consent for investigations or treatment 
 The Nursing and Midwifery Council (NMC), Code of Professional Conduct 
(Nursing and Midwifery Council, 1992) states: You (nurses) are professionally 
accountable for your practice.  This means that you are answerable for your 
omissions, regardless of advice or directions from another professional. 
This guidance was sent to all lead coordinators and lead investigators. 
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Case Records Forms 
1, 2 and 3 
 
 
 
 
Version 4- 03/03/2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Signed (randomising clinician): …………………………………………………..……. Date: ____/____/__ 
Please return this form to:  , Cancer Research UK Trials Unit 
Institute for Cancer Studies, University of Birmingham, B15 2TT  FAX:  
Randomisation telephone or fax:   or telephone  (toll free in UK) 
INDICATION FOR WARFARIN     
Is the indication for warfarin:     UNCERTAIN:                      CLEAR: 
If UNCERTAIN, are you happy to randomise between no warfarin, fixed dose and individualised dose warfarin?        N              Y IF 
or (IF NO,)  are you happy to randomise between fixed dose warfarin and no warfarin only?                                     N        Y   
If CLEAR, are you happy to randomise between fixed dose and individualised dose warfarin?                N              Y  
 
Part C – this section may be filled in after randomisation 
 
RANDOMISATION  FORM – CRF 1 
CENTRAL VENOUS CATHETER  
  Centrally placed        Peripherally placed        Left            Right   
 CHEMOTHERAPY  
Length of single treatment/infusion: Bolus or  under 24 hours                 24 hours and over                 
Scleroscant potential of regimen:                        Sclerosant                  Non – sclerosant                see appendix 1 in  
                                                                                                                     protocol  
 
ELIGIBILITY CHECKLIST 
All questions must be answered YES for the patient to be eligible. No Yes 
Histologically or clinically confirmed diagnosis of solid or haematological malignancy      
Patient is due to have (or has had within last 7 days), a central venous catheter inserted for chemotherapy      
Adequate haematological, hepatic and renal function     
No contraindication to warfarin and not on warfarin     
Not pregnant or lactating and taking adequate contraceptive measures, if appropriate     
Signed consent for WARP     
 
Patient Name:  Centre Name:   
 
Hospital No:  
 
Date of Birth:   
  
Sex:               Male    Female    please circle  
 
 
Part A – This section must be completed prior to randomisation 
Treatment Allocated:            A: No Warfarin            B: Warfarin 1mg/day         C: Warfarin– to maintain
                       INR between 1.5 and 2.0 
WARP Trial No:                               
                                                                      
         
 
Part B – to be filled in at randomisation 
Central Venous Catheter Type:                                                                 
Single/Double/Triple Size e.g. 4f     Material e.g. Silicone  Type e.g. Groshong     Manufacturer e.g. Bard  
                                     
Do you use any type of fibrinolytic locks or positive pressure devices ? Yes    No         
If yes please give details ……………………………………………………….. 
Disease: Stage of disease: 
Primary Site: No residual disease / early disease                        
 
or advanced disease          
 
 
     WHO Perf Status:        
0         1         2         3 
Was the patient on tamoxifen pre-trial? N         Y          If yes, is the patient continuing with tamoxifen whilst on WARP? N         Y     
 
For this patient are you using any form of heparin whilst on WARP, including flushing of line ?    N             Y           
If yes, please detail type, dose and  frequency             
…………………………………………………………………………………………………….. 
Person 
Randomising: 
Responsible  
Clinician: 
   
  
 
 
Please return to:  , Cancer Research UK Trials Unit 
Institute for Cancer Studies, University of Birmingham, B15 2TT   FAX:  
 
Version 4- 03/03/2003 
 
 
 
 
 
version 4
 
 
 
 
    
 
 
                                                          
 
 
Signed:…………………………………………….  Date:___/___/___ 
Has the patient received warfarin?             NO  YES               If yes, please detail below: 
 
Date warfarin started:  Date warfarin stopped:  
 
Was dose/range as per protocol    NO           YES    Continuing at dose/range:  
If no, state dose/range achieved and reason for alteration 
and non compliance
 
  Reason warfarin stopped: 
 
All patients: 
END OF PRIMARY EVALUATION PERIOD FORM – CRF 2 
 
or Affix sticker here 
Please complete (with patient if possible), at time of catheter removal 
Chemotherapy:  
 
Please continue  
overleaf if necessary 
DRUG: DOSE (mg/m2): DATES: 
Other 
Toxicity: 
Only if potentially  
related to warfarin  
CTC criteria  
on page 30 of 
 protocol  
Toxicity        Site or description  Grade (circle worst grade only)                   Duration of this grade (in days) 
Bleeding:  1   2   3   4  and major    minor     
                                                         
Other:                                     1   2   3   4                                                                                                                                
Has patient had a thrombosis?                         No Yes         please specify below : 
  
Date of thrombosis:                                                   Diagnosed by:   venogram                 ultrasound        
Location of thrombosis:                                             
                                                                            position: Left  Right  (type) Venous     Arterial  
 
Was the patient hospitalised due to thrombosis? No Yes            for                  days 
  
Was patient prescribed long-term anticoagulation?              No                       Yes 
 If Yes,    oral              subcut                 for               months – please approximate 
   Duration of this grade (in days ) 
Grade of Thrombosis (circle worst grade only):      1   2   3   4                                             …………………………………. 
   
 
 
 
Central Venous Catheter -  Date of catheter insertion:                                   Date of catheter removal: 
 
Any catheter-related complications (excluding thrombosis)? Detail below with dates: 
  
 Due to:        warfarin therapy     thrombosis 
Trial-related* inpatient stays– total in days: days days 
Total number of trial-related* outpatient attendances:                                    
Total number of trial-related* GP visits: 
          
              
  
*Trial-related means due to  
thrombosis or warfarin therapy  
(monitoring and adverse events) 
i.e. ‘EXTRA’ visits due to 
WARP trial 
Patient Name: Centre Name:   
 
Date of Birth: Consultant: 
 
Today’s date: WARP Trial No:  
  
 
 
  
 
FOLLOW-UP FORM - CRF 3 
To be completed one year after randomisation date or on death of patient 
Version 4-03/03/2003 
 
 
Patient’s Name: ...............……………………….......…… Date of Birth: ____/____/____ 
Clinician: .......................…....……………..……………… Centre Name: ……………………………. 
WARP Trial Number:   
 
Since the last form (CRF2) was sent, 
Has the patient had any late complication of warfarin treatment?  
No              Yes              N/A                     If yes, please specify type and dates: 
 
……………………………………………………………………………………………………………………… 
Since the last form (CRF2) was sent, 
Has patient had a thrombosis since CRF2 has been completed?   No    Yes         please specify 
below :  
 
Date of thrombosis:  
 
Location of thrombosis: 
 
 
Has the patient had any specialist referral or hospital admission for late toxicity? No      Yes
     
If yes, please specify: 
……………………………………………………………………………………………………………………… 
 
Since CRF2 was completed, has the patient received warfarin? 
       No  Yes  If yes, the current dose is ……………..  or date stopped____/____/___ 
 
 
Has the patient died?  No    Date patient last seen / contacted: ____/____/____   
 
 Yes      please give details: 
 
Date of Death: ___/___/___ 
Cause(s): Cancer  Site: 
 Possibly trial-related   Please specify: 
  
 Other  Please specify:  
  
 
Signed: ………………………………………………… Date: ____/____/____ 
 
Please return to:  , Cancer Research UK Trials Unit 
Institute for Cancer Studies, University of Birmingham, B15 2TT FAX:  
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APPENDIX 7 
 
Example of WARP Newsletter 
 
NEWSLETTER 1 
Contacts:   -   tel: , e-mail:  
 Annie Young  -  tel:   e-mail:  
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Newsletter 
•   Please circulate this newsletter to all colleagues 
who may be interested in WARP 
March 2004 
RECRUITMENT TO 15th March 2004 
1358 Patients Entered    688 Certain indication  and  670 Uncertain Indication 
Thank you ! 
WARP has experienced a remarkable 
increase in recruitment in 2003, in par-
ticular to the uncertain indication (2-arm 
option).  Recruitment figures doubled go-
ing from an average monthly recruitment 
of 19 patients in 2002 to an average 
monthly recruitment of 41 patient in 2003. 
We need to maintain the momentum. In 
the past two months, the number of pa-
tients entered into WARP has decreased 
slightly. Only 29 out of 64 centres have 
recruited patients in 2004.  What’s hap-
pened to the other 35? 
Let’s all give a last push to reach 
the recruitment target  
by September 2004! 
WARP NEEDS YOU!      242 PATIENTS TO GO!! 
Quarterly Recruitment 
TOP 10 RECRUITING CENTRES 
What about WARP II? 
What is your next related 
clinically important question? 
Suggestions please to  
Annie Young 
Thank you to all the 
centres for your help 
and support 
Mid-March 2003 - Mid-March 2004 
  Treatment allocation   
  No  
Warfarin 
Warfarin 
1mg 
Warfarin 
INR 
Total 
Uncertain Indication 3 arm 154 80 79 313 
Certain Indication 0 345 343 688 
Uncertain Indication 2 arm 178 179 0 357 
Total 332 604 422 1358 
Recruitment:  
Treatment by 
Indication  
NEWSLETTER 2 
Contacts:   -   tel:  , e-mail:  
 Annie Young  -  tel:  , e-mail:  
WARP is an NCRN-approved trial 
Trial forms 
Return of forms has been good so far, please remember to send forms in as soon as possible to 
 at CRUK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, 
Birmingham, B15 2TT. 
So far we have received 
1227 forms returned for CRF1: Section c (1358 expected) 
930 for CRF2 (1080 expected) and  
703 for CRF3 (846 expected) 
Keep them coming! 
 
Centre No. patients 
randomised 
Centre No. patients  
randomised 
Royal Berkshire Hospital 12 Pinderfields Hospital 2 
Western General Hospital 9 Princess Royal Hospital 2 
Belfast City Hospital 8 Russells Hall Hospital 2 
Cheltenham Hospital 6 Churchill Hospital 1 
St Mary’s Hospital. Portsmouth 6 Eastbourne District General Hospital 1 
New Cross Hospital 5 Huddersfield Royal Infirmary 1 
The Alexandra Hospital 4 Newcastle General Hospital 1 
Royal Free Hospital 4 North Hampshire Hospital 1 
Broomfield Hospital 3 Queen Elizabeth Hospital. London 1 
St. Luke’s Cancer Centre 3 South Tyneside District Hospital 1 
Stoke Mandeville Hospital 3 St Mary’s Hospital. Newport 1 
Diana Princess of Wales Hospital 2 Walsgrave Hospital 1 
Great Western Hospital 2 Wexham Park Hospital 1 
Oldchurch Hospital 2 Worcester Royal Hospital 1 
    Wycombe Hospital 1 
Recruitment in 2004 (until 15th march).    Thanks again! 
Protocol amendments 
Amendment No 5: 
Protocol  v. 7 - 2nd December 2003 
Patient Information Sheets v. 6 - 2nd 
December 2003 
Reported SAE’s since October 2003 
Type of Event Requiring  
Hospitalisation 
Life Threatening Details Recovery 
Raised INR but no  
reported bleeding 
9 9 INR>10, knock on arm that resulted in 
haematoma. Chest infection 
9 
Bleeding & raised INR 9 X Malaena, INR=4.4, Hb=8.4, WBC=6.0,  
duodenal ulcer diagnosed 
9 
Bleeding & raised INR 9 X INR=8.3, Hb=8.9, haematuria and bruising 
to hip, required blood transfusion 
9 
Please remember to report any bleeding 
events in patients on the no warfarin arm 
as well as the other two arms 
! 
NEWSLETTER 3 
Contacts:   -   tel:  , e-mail:  
 Annie Young  -  tel:  , e-mail:  
Thrombosis? 
Radiologically confirmed thrombotic events that are deemed to be catheter-related are the pri-
mary endpoint for the trial, whilst those that are not thought to be catheter-related are secondary 
endpoints.  Thromboses that are suspected but not radiologically confirmed are recorded and re-
ported under CVC complications. 
A thrombosis is categorised as non-catheter-related if: 
¾ It is arterial; or 
¾ It is located in the leg; or 
¾ It is known to occur on the opposite side of the catheter; or 
¾ It occurs >5 days post catheter removal 
All thromboses are reviewed and classified as primary or secondary by an independent second 
observer (Dr Daniel Rea) as follows: 
 Primary Thrombosis Secondary Thrombosis 
 Arm (Catheter side) Arm (not Catheter side) 
 Axilliary Leg DVT 
 Internal jugular Arterial 
 Subclavian IVC 
 SVC 
 PE (most likely) 
 Catheter 
 How much do you know about WARP? 
 Take our quiz and you could win a £10 voucher 
1. Which month did the WARP trial open to recruitment? 
2. 2003 has without doubt been WARP’s record-breaking year, but can you 
estimate how many patients were randomised into WARP in 2003? 
3. What is the recent literature demonstrating for prophylaxis of thrombosis 
in cancer patients with CVCs? - Warfarin or not? 
4. What does the WARP acronym stand for? 
If you think you know the answers, you could win a £10 Boots voucher. 
Send your answers to   
by post or e-mail:   
before 30th April 2004 
All correct answers will be entered into the draw,  
and the lucky winner will be picked at random and notified on 3rd May 2004 
 
Good Luck! 
NEWSLETTER 4 
Contacts:   -   tel:  , e-mail:  
 Annie Young  -  tel:  , e-mail:  
Literature Update 
Randomised Trials 
2003 Abstract - (full paper submitted to JCO). Look out for this publication which was listed in last 
Newsletter but still unpublished 
Anderson D, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, MacLeod D, Burton E, Andreou P 
and Couban S. A randomised double blind placebo-controlled study of low dose warfarin for the pre-
vention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Jour-
nal of Thrombosis and Haemostasis 2003; Supplement 1 July (abstract no. P1982).   
255 patients with solid (70%) and haematological malignancies were randomised between 1mg and no warfarin 
(placebo). There were 11(4%) symptomatic CVC-associated thromboses; 5/125 (4%) in the placebo group and 
6/130 (4.6%) in the warfarin group p=NS.  Low dose warfarin did not reduce the incidence of symptomatic CVC-
associated thrombosis in patients with cancer.  75% of patients’ treatment was interrupted, usually because of 
thrombocytopenia. 
 
Related Studies 
1. Cancer Patients:  LMWH - Primary Prophylaxis 
Reichardt P, Kertzshmar A, Biakhov M et all:  A phase III randomised, double-blind placebo controlled 
study evaluation the efficacy and safety of daily low-molecular-weight –heparin (dalteparin sodium) in 
prevention catheter-related complications (CRCs) in cancer patients with central venous catheters 
(CVCs).  Proc Am Soc Clin Oncol 21: 369a, 2002 (abstract 1474) 
The endpoint of this study was ‘clinically overt’ CRCs including thrombotic events requiring anticoagulant or 
thrombolysis, clinically overt PE and CVC obstruction requiring CVC removal.  425 patients were randomised to 
5000iu dalteparin or placebo for 16 weeks within 5 days of CVC insertion.  There was no benefit in the reduction 
of CRCs in the treatment arm as compared with placebo (3.7% vs 3.4%; p=0.9)  A venographically determined 
endpoint may like WARP, may have resulted in a higher rate of venous thromboembolic events.  
Largo SW, Verdonck LF, Borel Rinkes IH, et al: No effect of nadroparin prophylaxis in the prevention 
of CVC-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 
26:1103-1106, 2000 
 
2. Heparin vs warfarin 
Low – molecular-weight heparins or oral anticoagulation for the secondary prevention of deep vein thrombosis 
in cancer patients 
Lee AY, Levine MN, Baker RI, BowdenC, Kakkar AK, Prins M, Julian JA, Haley S, Kovacs MJ and 
Gent M.  Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous 
Thromboembolism in Patients with Cancer N. Eng. J Med 2003 349 (2): 146-153 
In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral antico-
agulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding. 
 
3. Interaction between warfarin and chemotherapy 
Given the high percentage (~65 %) of patients in WARP are on fluorouracil-based chemotherapy, the following 
observations are of interest and strengthen the case for regular INR monitoring in patients on both warfarin 
arms of WARP and also make us consider the way our SAE collection (we request that no chemo-related SAEs 
be sent).  
Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M and 
Santoro A. Minidose warfarin for catheter-associated thrombosis in cancer patients: can it be safely 
associated with fluorouracil-based chemotherapy? Journal of Clinical Oncology 21(4):736-739; 2003 
A high incidence of INR abnormalities was observed in this cohort of patients 
 
Review 
Venous Thromboembolism Associated with Long Central Venous Catheters in Cancer Patients JCO 
21(1): 3665-3675; 2003.   
Excellent review 
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Recruitment Rates per Centre 
 
Centre Frequency % 
Cheltenham General Hospital 214 13.5 
St.Mary's, Portsmouth 93 5.8 
Newcastle General Hospital 76 4.8 
Belfast City Hospital Trust 75 4.7 
Royal Berkshire Hospital 70 4.4 
Western General Hospital 70 4.4 
Queen Elizabeth Hospital, Birmingham 59 3.7 
Exeter Oncology Centre 58 3.6 
Diana Princess of Wales Hospital 57 3.6 
Birmingham Heartlands Hospital 56 3.5 
Huddersfield Royal Infirmary 54 3.4 
Russells Hall Hospital 53 3.3 
Cumberland Infirmary 46 2.9 
St Luke's Cancer Centre 42 2.6 
Singleton Hospital 39 2.5 
St James's Hospital 32 2.0 
Great Western Hospital 28 1.8 
New Cross Hospital 26 1.6 
Royal Sussex County Hospital 25 1.6 
Churchill Hospital 24 1.5 
Velindre Hospital NHS Trust 24 1.5 
Charing Cross Hospital 20 1.3 
The Essex County Hospital 20 1.3 
Princess Royal Hospital 16 1.0 
Royal Free Hospital 15 0.9 
Royal South Hants Hospital 15 0.9 
St George's Hospital 15 0.9 
Wycombe Hospital 15 0.9 
Walsall Manor Hospital 14 0.9 
Cookridge Hospital 13 0.8 
Princess Alexandra Hospital 13 0.8 
South Tyneside District Hospital 13 0.8 
The Alexandra Hospital 13 0.8 
St Marys Hospital 12 0.8 
Whiston Hospital 12 0.8 
Plymouth Oncology Centre 11 0.7 
Walsgrave Hospital 11 0.7 
University College Hospital 10 0.6 
Broomfield Hospital 9 0.6 
Oldchurch Hospital 9 0.6 
Addenbrookes Hospital 8 0.5 
Pinderfields Hospital 8 0.5 
Queen Elizabeth Hospital London 8 0.5 
City Hospital NHS Trust 7 0.4 
323 
 
Royal Lancaster Infirmary 7 0.4 
Stoke Mandeville Hospital 7 0.4 
Guy's Hospital 6 0.4 
Mount Vernon Hospital 6 0.4 
Ninewells Hospital 6 0.4 
Hammersmith Hospital 5 0.3 
North Hampshire hospital 5 0.3 
Derbyshire Royal Infirmary 4 0.3 
Eastbourne District General Hospital 4 0.3 
South Cleveland Hospital 4 0.3 
Wexham Park Hospital 4 0.3 
Worcestershire Royal Hospital 4 0.3 
Aberdeen Royal Infrimary 3 0.2 
Glasgow Royal Infirmary 3 0.2 
Ipswich Hospital NHS Trust 3 0.2 
Royal Gwent Hospital 3 0.2 
Good Hope Hospital 1 0.1 
North Devon District Hospital 1 0.1 
Princess Royal University Hospital 1 0.1 
Royal Hampshire County Hospital 1 0.1 
Royal Preston Hospital 1 0.1 
Sandwell Hospital 1 0.1 
Warwick Hospital 1 0.1 
West Cumberland Hospital 1 0.1 
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Publications 
 
Central Venous Catheters (CVCs) present a stress test to the coagulation system in cancer
patients. The major thrombotic complication of CVCs is venous thromboembolism (VTE) and in
the majority of cases, is asymptomatic.
However, catheter-related thrombosis (CRT) is a source of considerable morbidity, the most
severe of which is pulmonary embolism. The last decade has seen an enormous increase in the
use of CVCs to deliver infusional chemotherapy for a range of malignancies. Novel catheter
designs are revolutionising patient care with attendant improvements in catheter care and
placement.
The aetiology of CRT is multifactorial - trauma of catheter insertion, endothelial damage from
chemotherapy, size and rigidity of catheter, stasis of blood flow around the catheter are factors
which have been proposed but few randomised studies have been executed. Two significant risk
factors for CRT, identified from a cohort study, were i) having had a previous catheterisation and
ii) more than one attempt at insertion1 – ‘see Risk Factors’.
As part of the largest randomised trial of thromboprophylaxis with warfarin, in cancer patients
with CVCs, named WARP, we examined catheter-specific risk factors for thrombosis.
Intraluminal: within the catheter and often under-
reported
Fibrin Tail: fibrin, blood cells and platelets adhere
to the top of the catheter (often acting as a ball valve)
Fibrin Sheath: an extraluminal fibrin sheath is
formed normally around the top of the catheter and
may extend back along the catheter
Mural Thrombosis: fibrin from the vessel wall
attaches to the catheter surface and is often a total
occlusion
Background
References
Central Venous Catheters and Thrombosis  
in Cancer Patients
Annie Young1, Gulnaz Begum2, Anita Ashton1, Sue Anderson1, Lucinda Billingham3, Ana Hughes3, Debbie Hunter1, Keith Wheatley 3            
1 3 Counties Cancer Network,   2 University of Warwick,  3 University of Birmingham
Results
Conclusion
WARP Trial – Catheter Complications
Of the 1590 patients randomised from 68 UK centres, the overall CRT rate was
5.3%. Warfarin demonstrated no apparent benefit over no warfarin (5.9% vs
5.9%, p=0.98). 916 (58%) of catheters inserted, were PICCs. 78% had single
lumens; 92% were silicone; 40% >4F; 56% had non-return valves and 32% of
catheters required heparin flushes. 21% of patients had catheter complications,
37% of whom had CVC infections. Median time to thrombosis was 37 days;
IQR 13-80 days. Logistic regression identified CVC lumen as a potential
predictor of a CVC-related thrombosis, with patients with double or triple lumen
CVCs more likely to suffer a thrombosis than those with a single lumen. CVC
material appeared to have some importance, showing CVCs made of silicone
less likely to have a CRT than those made of polyurethane or other material.
CVC infection, CVC insertion site, CVC type and CVC size were unrelated to
the occurrence of CRT.
Overall, CRT rates are low, with warfarin adding no apparent benefit. This
multivariate analysis demonstrates the only catheter-specific risk factor for
thrombosis is a double or triple lumen catheter compared to single lumen, with
non-silicone catheters showing a trend towards higher thrombotic potential.
Clinical Features of Thrombosis
Types of Catheter Thrombosis
Clinical features of thrombosis are variable and may not become apparent until total occlusion of
the vessel occurs. Early symptoms include skin erythema overlying at catheter, oedema,
discomfort, pyrexia and pain in arm on the catheter placement side. Later symptoms include facial
swelling, neck distension and arm swelling. CRT is still an important clinical problem.
Methods Risk factors of Catheter Related Thrombosis
Very few prospective randomised studies have been undertaken to compare
different types of catheters, ports, surface coatings etc. A number of potential
risk factors for development of CRT have been suggested including CVC
bioavailability (chemical and surface structure, rigidity, diameter, additive
agents), number of lumens (3, 2 or 1), catheter tip, position, previous CVC
insertions and site of insertion, insertion technique, CVC related infection and
high platelet count. In the prospective single centre cohort study of Lee et al
(2006)2 significant baseline factors for CRT were: more than one insertion
attempt, (p=0.03), ovarian cancer (p=0.01) and previous CVC insertion
(p=0.03).
A logistic regression analysis was performed to identify potential predictors
of a CVC-related thrombosis. Explanatory variables included stratification
variables, catheter placement (central vs peripheral, treatment length (<24
vs 24 hours), sclerosant potential of chemotherapy (sclerosant vs non-
sclerosant). CVC information was also considered, CVC lumen (single vs
double/triple), CVC material (silicone vs other), Type of CVC (valved vs non-
valved), CVC size (F). Forward, backward and step-wise regression
techniques were applied, a 10% significance level was used for entering
and removing from the model. A total number of 1547/1590 patients had
complete CVC data and were included in analysis, of these 83 patients had
suffered a CRT. Due to the small number of events this analysis was viewed
as an exploratory exercise only and results are to be treated with caution. All
analyses were performed using SAS statistical software (SAS Institute, SAS
Circle, Cary, North Carolina, USA).
Positioning of the catheter tip in the upper portion of 
the lower third of the Superior Vena Cava is crucial. 
Other positions may increase the risk of thrombosis2
For contact details contact Annie Young on e-mail: a.young@bham.ac.uk
1. Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer
Agnes Y.Y. Lee, Mark N. Levine, Gregory Butler, Carolyn Webb, Lorrie Costantini, Chushu Gu, Jim A. Julian 
JCO Mar 20 2006: 1404-1408 
2. Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients
Melina Verso, Giancarlo Agnelli 
JCO Oct 1 2003: 3665-3675 
INTRODUCTION
Venous thromboembolism (VTE) is a common clinical problem in cancer patients.
Uncertainty remains as to whether treatment with oral anticoagulants (OA - mainly 
warfarin) or low molecular weight heparin (LMWH), given by subcutaneous 
injection, is beneficial in primary and secondary thromboprophylaxis and practice 
varies widely. It has been proposed that anticoagulant therapy may also improve 
survival in cancer patients. Several randomised trials have investigated warfarin 
for VTE in cancer patients; other trials have looked at LMWH.
The largest trial of VTE prophylaxis in cancer patients with central venous 
catheters (CVCs), WARP, has just been completed and showed no apparent 
benefit for low dose warfarin. Among 811 patients randomised to low dose
warfarin versus not, the VTE rate was 5% in both arms (OR = 1.04, 95% CI = 0.56-
1.92, p=1.0) and mortality was not reduced (OR=1.02, CI=0.74-1.4, p=0.8) (Young et 
al., ASCO, 2005, LBA8004). With this result needing to be put in the context of 
other RCTs of anticoagulants, we performed meta-analyses to evaluate the effect 
of warfarin and LMWH on primary and secondary VTE rates and mortality.
Meta-Analyses of Randomised Controlled Trials (RCTs) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients
Wheatley K1, Gross LE1, Hills RK1 and Young AM2
Birmingham Clinical Trials Unit, University of Birmingham, UK1 CRUK Trials Unit, University of Birmingham, UK2
METHODS
TRIAL IDENTIFICATION AND ELIGIBILITY
A comprehensive computerised literature search was undertaken to identify 
relevant trials. This included searching abstracts on MedLine, Embase, NCI trials
register and ACSO, ISTA and ASH meeting websites. Studies were eligible for 
inclusion if they were randomised trials of cancer patients comparing either 
treatment (warfarin or LMWH) with no treatment or one treatment with another (OA 
v LMWH) in the management of primary or secondary prophylaxis. These included 
studies using central venous catheters. 
OUTCOME MEASURES
Data extracted by two independent reviewers included the type of, the dose and
duration of treatment (warfarin or LMWH), whether it was primary or secondary
VTE prophylaxis, the number of VTEs and deaths during the trial and whether 
the endpoint was symptomatic or asymptomatic (venographically determined)
VTE.
ANALYSIS
Results were combined using standard meta-analytic techniques to estimate
overall treatment effects for both VTE and mortality rates for the following 
treatment subgroup comparisons:
- warfarin vs no warfarin
- LMWH vs no LMWH
- LMWH vs OA
Differences in treatment effects between trials and subgroups were assessed 
using tests of heterogeneity. We also used a test for trend over trials to 
investigate whether results have changed over time in the warfarin v no-warfarin
comparison.
TRIALS
14 eligible trials were identified with data on VTEs (total of 4154 patients) and 14 
were identified with mortality data (total of 3790 patients). Trials were classified 
according to treatment comparison.
Table 1: Warfarin v No Warfarin Trials
Table 2: LMWH v No LMWH Trials
Table 3: LMWH v OA Trials
RESULTS
WARFARIN VERSUS NO WARFARIN
Data was available on VTEs in 5 trials (1355 patients). There was no significant 
difference between warfarin and no-warfarin treated patients in the incidence of 
VTEs (Odds Ratio (OR) = 0.75, 95% Confidence Interval (CI)=0.5 to 1.13; p=0.2)
(Figure 1). There was some evidence of heterogeneity between the treatment 
comparisons (p=0.05) and of a trend over time in trial outcomes (p=0.01).
Figure 1: VTEs in Warfarin v No Warfarin Trials
An additional 3 trials had survival data (2033 patients in 7 trials in total).  There was 
no clear evidence of a difference in mortality rates for warfarin compared
to no-warfarin treated patients (OR = 0.2, CI = 0.81 to 1.01; p = 0.07) (Figure 2).
Figure 2:Mortality Rates in Warfarin v No-Warfarin Trials
LMWH VERSUS NO LMWH
4 eligible trials comparing LMWH with no treatment for VTEs were found with a total 
of 1667 patients. There is evidence that VTE rate is reduced in patients treated with
LMWH as compared to no treatment (OR = 0.64, CI = 0.44 to 0.94; p = 0.02) 
(Figure 3). 
Figure 3: VTEs in LMWH v No LMWH Trial
One of the VTE studies and an additional 3 other trials had mortality data available (772
patients). Mortality rates in LMWH patients were reduced by 23% (OR = 0.77, CI = 0.66 to 
0.90; p=0.001) (Figure 4).
Figure 4: Mortality in LMWH v No-LMWH Trials
LMWH VERSUS ORAL ANTICOAGULANTS (OA)
5 trials (1132 patients) were found to be eligible for investigating VTE rates in 
patients treated with LMWH compared to oral anticoagulants. VTE rates 
decrease significantly more in patients treated with LMWH with 9% occurring 
on LMWH compared to 16% occurring on OA (OR = 0.50, CI = 0.35 to 0.72; 
p=0.0001) (Figure 5).
Figure 5: VTEs in LMWH v OA Trials
With 3 of the 5 VTE trials also containing mortality data (985 patients in total), no 
significant difference was found in mortality rates between LMWH and OA treated 
patients (OR = 0.89, CI = 0.74 to 1.10; p = 0.3) (Figure 6).
Figure 6: Mortality Rates in LMWH v OA Patients
CONCLUSION
The results of these preliminary meta-analyses suggest that LMWH is the preferred 
form of prophylaxis for VTE in cancer patients since it was shown to be superior to 
both no treatment and to oral anticoagulants (mainly warfarin). There
may also be an anti-tumour effect, leading to a survival benefit, but further 
research is needed to confirm or refute this.
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